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Abstract
HIV-1 Nef is a key pathogenic protein, allowing HIV-1 to evade the host immune
system by downregulating MHC-I and CD4. Furthermore, it was recently discovered
that Nef counteracts the host factor SERINC5 to increase HIV-1 infectivity, but the
mechanistic details of the Nef:SERINC5 interaction still need to be explored.
Throughout this dissertation, I will explore the hypothesis that the genetic diversity
that defines HIV-1 has a pronounced effect on the HIV-1 protein Nef, altering its
function between and within group M subtypes. To address this hypothesis I
investigated how MHC-I and CD4 downregulation differ among all non-recombinant
group M subtypes. These studies revealed subtype-specific differences in Nef
function that were associated with differences in Nef expression between subtypes.
Further investigation revealed unique subcellular distribution of Nef within the rarely
studied subtypes G and H. A low expressing Nef isolate of the globally predominant
subtype C was then analyzed using mutational and stability studies, identifying a
previously undefined region in an alpha helix of Nef that is essential for protein
expression and function. Moreover, the molecular details of the recently defined Nefmediated SERINC5 downregulation are elucidated. The microscopy technique of
bimolecular fluorescence complementation was used to demonstrate an in
cellulo Nef:SERINC5 interaction, implicating key Nef protein interaction motifs. The
Nef:SERINC5 complex was then mapped throughout the cell, highlighting the ability
of Nef to hijack protein trafficking machinery, shuttling SERINC5 to degradative
compartments to favour HIV-1 replication. Mutational analysis of SERINC5 shed
light on the genetic determinants of the anti-infectivity of this poorly understood HIV1 restriction factor. From there, these findings were placed in the context of the HIV1 epidemic, investigating the conservation and variation in SERINC5 downregulation
among Nef isolates from subtype C and A endemic regions.
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Chapter 1

1

Introduction

1.1 Viruses; masters of adaptation
Across all domains of life, there are countless examples of life forms that are
exquisitely adapted to their environment, thriving in niches upon their emergence.
Indeed, the ability to adapt is often included in the definition of life itself (1).
However, some of the most remarkable examples of adaptation come from
viruses, that segment of biology that is often left out of the conversation of life (2).
While there is no universal definition of life, viruses meet many of the commonly
cited requirements for something to be considered living (3). Namely, they are
able to utilize energy to adapt and respond to stimuli in their environment.
However, viruses lack a cellular architecture and depend on other forms of life to
replicate their genetic material (2, 4). This dependence on cellular life
necessitates that viruses be able to rapidly adapt to new environments.
The functional capability of viruses varies dramatically, but a defining feature of
all viruses is their inability to generate energy or produce proteins on their own,
preventing their replication outside of cellular hosts (5, 6). The largest known
viruses encode more proteins than some bacteria and are even able to repair
DNA damage (7-9). Some of the smallest known viruses encode only four
proteins, just enough to replicate their RNA genomes and form a capsid (10).
The functional limitations of these small viruses are due to their restricted

2

genomes, which are free of much of the redundancy that usually protects cellular
life.
Bacteria, archaea, and eukarya all require genetic mutations to adapt to
changing environments, but their complicated genomic architecture is vulnerable
to high mutation rates (11-13). Disruption of the structure or function of key
metabolic proteins can prove fatal, which has led to the evolution of high fidelity
DNA repair mechanisms and duplication or convergent evolution of proteins
serving similar functions (14, 15). Viruses hijack these highly conserved
metabolic pathways, pairing them with their genetic plasticity to rapidly evolve
and establish themselves across the three domains of life.
Although viruses are not included in the classical three domains of life, the
importance of these obligate intracellular symbionts cannot be understated.
Viruses are ubiquitous in nature (16) and when their symbiotic relationship is
parasitic, infected species evolve to control or eliminate the virus from the
population (17, 18). Furthermore, the ability of viruses to move within and
between species provides a form of gene transfer as viral particles incorporate
genetic material from their hosts and carry it within virions to new hosts (19, 20).
This allows viruses to act as both an impetus for, and mechanism of natural
selection.

1.2 Retroviruses and their influence on human life
The ubiquity of viruses is exemplified by estimates that up to 8% of the human
genome is composed of viral remnants, genome fragments from viruses that had

3

infected and integrated into germline cells of distant human ancestors (21, 22).
These fragments are termed human endogenous retroviruses (HERVs) and the
vast majority have been mutated extensively since their chromosomal
integration, losing the ability to produce functional proteins (23, 24). However,
certain endogenous retrovirus (ERV) sequences are highly conserved over the
millions of years since they first integrated into ancient primate chromosomes
and may still encode functional proteins (25-27). Syncytin is an example of a
protein derived from a retrovirus that infected ancient primate germline cells.
Specifically, syncytin is a viral envelope surface protein that enabled these
retroviruses to attach and infect permissive host cells (27). Interestingly, cells
expressing syncytin from HERV gene remnants in humans and other mammalian
species have acquired the ability to attach to and fuse with cells that express the
cognate syncytin receptor (27-29). This observation suggests that these proteins,
introduced into the human genome by viral infection of ancient primate germline
cells millions of years ago, have retained their function. Furthermore, it is
hypothesized that this acquired function plays a fundamental role in placentation
in mammals (27). Indeed, syncytin expression in trophoblasts during fetal
development allows for cell-to-cell fusion that is essential for proper development
of the maternal-fetal interface in utero (27-29). If this hypothesis is correct, it is
yet another example of the complicated and serendipitous methods by which
evolution produces novel phenotypes and underscores the role viruses have
played in shaping human biology.

4

1.3 Human Immunodeficiency Virus type-1
Prior to their integration into ancient primate genomes, the HERVs responsible
for syncytin protein production were freely circulating retroviruses, closely related
to present gammaretroviruses from the Retroviridae family (24, 30).

These

viruses are referred to as retroviruses because following infection they generate
a DNA copy of their RNA genome using an enzyme known as reverse
transcriptase, thereby reversing the linear “DNA to RNA dogma” long held in
molecular biology. The independent discovery of reverse transcriptase in the
1970s by David Baltimore and Howard Temin expanded our understanding of
how genetic information could be transmitted (31, 32). The research that led to
these discoveries was conducted with Rous sarcoma virus, a retrovirus that
causes cancer in chickens; however, retroviruses have also had a dramatic
impact on humans, revealing once again our vulnerability as a species.
The identification of human immunodeficiency virus (HIV) in 1983 began what
has been a long and painful struggle, with close to 40 million deaths globally
since its discovery and countless more prior (33-35). HIV is an enveloped, singlestranded positive-sense RNA virus in the genus Lentiviridae and the Retroviridae
family (36). The HIV RNA genome is just over 9.7 kb and encodes 15 proteins
flanked by two long terminal repeats (LTR). Nine of these proteins are derived
from the 3 polyproteins encoded by the gag, pol and env genes, and the
remaining six proteins, Vif, Vpu, Vpr, Rev, Tat and Nef, are encoded by individual
genes (Figure 1.1). We now know that there are two types of HIV, HIV type 1
(HIV-1) and type 2 (HIV-2), which originated from zoonotic transmissions from
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distinct primate species in central Africa (37). It has been reported that HIV-1
began as a zoonotic transmission from chimpanzees (Pan troglodytes) (38, 39)
or gorillas (Gorilla gorilla) (40) infected with simian immunodeficiency virus (SIV)
in central Africa, whereas HIV-2 was due to zoonotic transmission from sooty
mangabeys (Cercocebus atys) (41, 42). Despite similar origins, HIV-1 and HIV-2
vary greatly in prevalence and pathogenesis. HIV-1 has infected tens of millions
more humans than HIV-2 and results in an accelerated pathogenesis compared
to HIV-2 (35, 43, 44). As a result, the vast majority of HIV biomedical research
has focused on HIV-1.
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Figure 1.1 Genomic Structure of Human Immunodeficiency Virus type 1
(HIV-1).
(A) HIV-1 is an enveloped, single-stranded positive-sense RNA virus from the
genus Lentivirdae and family Retroviridae. (B) The RNA genome is
approximately 9.7 kb and encodes 15 proteins on 3 reading frames flanked by 5’
and 3’ long terminal repeats (LTR). The genes gag, pol and env encode
polyproteins that are post-translationally cleaved and responsible for the
structural (gag and env) and enzymatic (pol) functions of HIV-1. HIV-1 also
encodes a set of accessory proteins (green; Vif, Vpr, Tat, Rev, Vpu and Nef) that
are required for optimal in vivo replication. (C) The HIV-1 accessory protein Nef
is encoded by an open reading frame at the 3’ end of the HIV-1 RNA genome.
Nef is a small (~27 kDa) non-enzymatic and non-structural protein that is
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expressed early in HIV-1 infection and packaged in HIV-1 virions. The Nterminus of Nef is co-translationally modified through the attachment of a
myristoyl lipid moiety (light blue).
Although discovered in 1983, HIV-1 is believed to have been circulating in human
populations on the African continent since the early 1900s (45, 46). However, it
was not until the second half of the century that HIV-1 reached the pandemic
proportions we now experience (47-49). We may never get a completely
accurate picture on the natural history of the virus, but multiple factors are
thought to have promoted the spread of HIV-1 within and out of central Africa.
These include the socio-political state of the world during the emergence of HIV1 (50) and specific virus characteristics and functions (51). As with many human
pathologies, the extent of the spread and control of HIV-1 has been greatly
influenced by human behaviour. The pandemic nature of HIV-1, and most other
infectious diseases, is only possible in the current interconnected world enabled
by intra- and intercontinental travel, which has drastically modified the global
transmission patterns of many viruses (52-54). Furthermore, when one looks at
the epidemiology of HIV-1 in the 21st century, it is impossible to ignore the fact
that the populations most heavily affected by HIV-1 are marginalized,
impoverished and underserved (35). Years of colonialism and resource
extraction left central Africa with a fractured society unable to adequately monitor
and respond to an emerging epidemic (55-57). Moreover, the stigmatization of
homosexuality delayed and diminished the initial response to HIV-1 once the
virus reached high-income nations. Indeed, when the clinical manifestations of
HIV-1 infection were first seen in the United States, patients were diagnosed with
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gay related immune deficiency (GRID) as many erroneously believed the
infection was restricted to men having sex with men (MSM) (58). Furthermore,
generations of institutionalized racism have left populations across the world
more susceptible to infection and less likely to receive effective antiretroviral
treatment. Accordingly, HIV-1 rates in the African American and indigenous
populations in the United States and Canada, respectively, are among the
highest (59-62) in those countries. Finally, stigma towards those affected by
addiction currently risks our ability to control new outbreaks as people who inject
drugs currently represent the populations with the greatest increase in incidence
rates (35, 62). Thus, as its name suggests, HIV-1 is very much a human disease,
unquestionably shaped by our anthropology and precisely adapted to our
biology.
The devastating impact HIV-1 has had on the human species is due to the ability
of the virus to deplete certain aspects of the immune system. As an obligate
intracellular parasite, HIV-1 must find a way into its target cells. The primary
receptor that HIV-1 uses to infect cells is the cell surface protein cluster of
differentiation 4 (CD4) (63, 64). CD4 is a marker for a subset of immune cells,
CD4+ T helper cells, among other CD4+ cells such as monocytes, macrophages,
dendritic cells and natural killer T cells (65). All these additional cell types can be
infected with HIV-1, however the extent to which they are involved in HIV-1
pathogenicity is not fully understood. CD4+ T helper cells play a key role in
orchestrating adaptive immune responses (66). As a result, as HIV-1 replicates
and spreads within its host, it targets and kills these immune cells that are
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essential for eliminating the virus (67). This depletion of CD4+ T cells is why HIV1 infection progresses to acquired immunodeficiency syndrome (AIDS), a
weakened immune state in which CD4+ T helper cells drop to levels so low that
the immune system is overcome by otherwise well-controlled infections (68).
Indeed, unexplained infections of patients with the fungus Pneumocystis jirovecii
(69) and the rarely seen human herpesvirus 8 (70) were what prompted the initial
investigations that led to the discovery of HIV-1. These immune system-altering
characteristics help explain the lethal consequences of an untreated HIV-1
infection and why the development of a cure or vaccine is so important.
Historically, when scientists have sought protective measures against infectious
diseases, they have attempted to induce or mimic the natural immune response
that is mounted against the pathogen. However, as HIV-1 selectively targets and
depletes key immune cells, there are no known effective responses to replicate
or mimic for HIV-1. This characteristic changes the methods required to target
this devastating virus. In addition, as a retrovirus, HIV-1 integrates its genome
into the genome of the cells it infects. As a result, once HIV-1 establishes an
infection in a host organism, the host is infected for life (71). Furthermore, the
reverse transcriptase that HIV-1 encodes and uses to transcribe its RNA genome
into a DNA template is a low fidelity enzyme that lacks any proofreading
capability (72, 73). Thus, this error-prone reverse transcription results in a
mutation rate that far exceeds what would be viable in cellular life and increases
the pace at which HIV-1 can evolve (74). Ultimately, this results in infected hosts
being infected with not a single HIV-1 virus, but a quasispecies composed of
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millions of unique viruses, upon which the forces of natural selection can act (75,
76).

1.4 Genetic diversity is a defining characteristic of HIV-1
As a consequence of the high mutation rate engendered by its reverse
transcriptase, HIV-1 has developed a vast degree of genetic diversity (77). In an
attempt to understand the evolution of HIV-1, the virus has been categorized into
4 groups: Group M or the Major group, group N for non-M or O, group O for
outlier and group P, named so to conform with previous nomenclature (36, 37).
Each group is believed to represent a distinct zoonotic transmission event of SIV
into humans, with groups M and N originating from SIV-infected chimpanzees
(Pan troglodytes) (38, 39) and groups O and P originating from SIV-infected
gorillas (Gorilla gorilla) (40). For reasons that are not entirely understood, group
M is the only group to have spread widely out of central Africa and is responsible
for over 95% of the infections globally, representing roughly 34 million infections
(77, 78). Group M is further divided into a number of subtypes labeled A through
K (with the exceptions of E and I), some of which can be divided further into subsubtypes (36, 37). Subtypes are designated based on genetic similarity, with
inter-subtype diversity of up to 30% and intra-subtype diversity of up to 12% (77)
(Figure 1.2A and B).
In addition to these subtypes, which are believed to have diverged from a
common zoonotic transmission event, HIV-1 also has the ability to genetically
recombine, introducing even more genetic diversity (79). The recombination
ability of HIV-1 is due to the fact that as HIV-1 virions assemble in infected cells,
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2 copies of the RNA genome are packaged into the viral capsid (80, 81).
Interestingly, in regions endemic for more than one subtype of HIV-1, individuals
can be infected with multiple subtypes. In this situation, the same cell can be
infected and express the viral genomes of two subtypes, thereby resulting in
virions that have packaged one RNA genome from each subtype. Consequently,
when these virions infect cells and undergo reverse transcription, the polymerase
can jump from one genome to another producing recombinant viruses (80). If
these viruses are viable and spread to new hosts, they are termed circulating
recombinant forms (CRFs); however, if these recombinants are only isolated
from a single individual they are known as unique recombinant forms (URFs)
(Figure 1.2B). There are currently over 96 CRFs that have been classified and
this number is expected to increase (37). Global migration continues to introduce
new subtypes into diverse populations and changing transmission patterns are
connecting previously isolated populations. Importantly, recombination allows for
a rapid exchange of large amounts of genetic information (82). The potential for
genetic exchange may pose a threat to controlling drug resistance in the age of
widespread anti-retroviral therapy (83, 84). Indeed, if drug resistant viruses coinfect HIV-1 positive individuals, there may be selective pressure for
recombination events to transfer drug-resistant mutations, generating novel
recombinant viruses.

1.5 Pandemic spread of HIV-1
In addition to the genetic diversity described above, HIV-1 Group M also displays
a great deal of geographic diversity. As expected, central Africa, the region of the
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original zoonotic transmission from chimpanzees to humans, has the greatest
diversity of infecting subtypes (78) (Figure 1.3C). The spread of HIV-1 outside of
central Africa is hypothesized to have been shaped by the founder effect (85-87).
This phenomena is common in evolution and occurs when a relatively small
group of organisms is introduced into a region they previously did not inhabit and
subsequently shape the genetic characteristics of all following generations (88).
As an aside, a similar phenomenon occurs with each new HIV-1 infection.
Indeed, the quasispecies that is established in HIV-1 positive individuals is
largely determined by a relatively small number of transmitted founder viruses
(89, 90).
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Figure 1.2 Extensive genetic and geographic diversity of HIV-1.
(A) Phylogenic tree showing the distinct genetic clustering of HIV-1 groups M, N,
O and P with different SIV strain from chimpanzees (SIVcpz) or gorillas (SIVgor).
(B) Taxonomic structure and nomenclature of HIV. (C) Global map illustrating the
geographic diversity of HIV-1 group M infections. Regions of the world are
coloured based on the predominant infecting subtype or recombinant. Size of pie
charts corresponds to the number of infections. (A modified from (77), B created
using information from (91), and C modified from (78)). CRFs; circulating
recombinant forms, URFs; unique recombinant forms.
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Up until recently, HIV-1 infections in North America were almost exclusively due
to subtype B viruses. Interestingly, subtype B is found at low frequencies in
regions outside of the Americas and Western Europe that otherwise have high
HIV-1 prevalence (78) (Figure 1.3C). In the United States, this is believed to be
due to the initial introduction, via Haiti, of a subtype B virus into the MSM
population early in the epidemic (85). As the HIV-1 epidemic grew in the United
States, it is thought to have seeded epidemics throughout the Americas and
Western Europe (92-94). This original subtype distribution has been changing
over time, as immigration from HIV-1 endemic countries has introduced a
diversity of subtypes (78, 95). Indeed, as of 2011, these immigrant populations
make up over 20% of new HIV-1 infections in Ontario and close to 17% of new
infections in Canada as a whole (62) (Figure 1.3B). In contrast to subtype B, HIV1 subtype C, which occurs at low rates in North America, is the predominant
subtype found in southern Africa and India, regions with very high incidence rates
and large populations, respectively. As a result, HIV-1 subtype C is responsible
for just under half of all HIV-1 infections globally (77, 78). A similar geographic
discrepancy with respect to subtypes is observed in Southeast Asia where the
circulating recombinant form 01_AE (CRF01_AE) makes up the vast majority of
HIV-1 infections and has significantly contributed to the increasing proportion of
global HIV-1 infections due to CRFs (78) (Figure 1.3C).
The geographic distribution of subtypes is highly influenced by the route of HIV-1
transmission. Within a given population, there may be separate subpopulations
that are at higher risk for HIV-1 infection, but these subpopulations can exist

15

largely independent of each other. For example, in South Africa, there is a high
rate of heterosexual HIV-1 transmission that has largely consisted of subtype C
infections. Indeed, the near ubiquitous nature of subtype C infections in South
Africa (98% of HIV-1 infections in South Africa in 2007 were subtype C) has led
to it being the most prevalent subtype globally (78). However, within the MSM
population in South Africa and in particular the white MSM population, a
disproportionate number of infections are due to subtype B (96, 97). These
differences reflect the epidemiological and social separation of these populations
and further highlight the complicated evolutionary history of HIV-1. Although
these independent epidemics are becoming more integrated over time, they
illustrate the dramatic diversity of HIV-1 between and within nations (Figure 1.3).
Knowledge of these intricate differences in subtype distribution is critical for
monitoring outbreaks of HIV-1 and enables officials to track and predict future
infections, a mainstay in the control of infectious diseases.
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Figure 1.3 Breakdown of new HIV-1 infections in key populations.
The percentage of new HIV-1 infections in different subsets of the population
from selected WHO geographic regions (A) or provinces in Canada (B). Regions
and provinces were chosen to demonstrate the differences in the populations
that HIV-1 infects in different geographic regions. (A modified from (35) and (98),
B modified from (62))
In addition to being valuable for epidemiological monitoring of HIV-1, subtypes
may impact how individual patients experience an HIV-1 infection. Following the
initial infection, HIV-1 replicates unchecked by the adaptive immune response.
This results in a period known as peak viremia, where viral loads in the blood are
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elevated. As a consequence, there is a transient drop in CD4+ T cells and the
patient experiences flu-like symptoms, typically 2-4 weeks following infection.
Once the adaptive immune system can mount a response, viremia is controlled
to a viral set-point, and CD4+ T cells rebound close to pre-infection levels (99101). However, HIV-1 is still actively replicating in the body, just at low levels.
This period is known as the asymptomatic phase and varies between individuals,
generally lasting 8-10 years (102, 103). Throughout this phase, the low level of
HIV-1 replication in CD4+ T cells leads to their slow decline. Eventually, this
decline in CD4+ T cells compromises the immune system to a point where it can
no longer function adequately. At this state, individuals are diagnosed with AIDS
(104). At the AIDS stage, HIV-1 replication is no longer controlled, viral loads
increase and the body is susceptible to a number of opportunistic infections that
would otherwise be cleared by a healthy immune system (68). It is these
opportunistic infections that result in death in HIV-1 infected patients, not the
virus itself, but the debilitating effect the virus has on the body’s immune system.
As a result, if HIV-1 infected individuals do not receive treatment, they can
present with serious complications from infections with Pneumocystis jirovecii,
Candida and human herpesvirus 8, which are usually not observed in nonimmune compromised individuals. In addition, AIDS results in an increased risk
of developing multiple forms of cancers and increases the risk of serious
complications from microorganisms that otherwise cause mild symptoms (68,
104) (Figure 1.4).
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Figure 1.4 The clinical course of HIV-1 from primary infection to death.
The clinical course of HIV-1 is most commonly described based on CD4+
lymphocyte levels (blue, left axis) and viral load (red, right axis). Following
primary infection, HIV-1 viral loads peak, corresponding with a transient drop in
CD4+ lymphocytes. This initial phase represents acute HIV-1 infection and is
associated with flu-like symptoms. As CD4+ lymphocytes rebound, viral load
reaches a nadir, known as the viral set-point and symptoms resolve, signifying
the beginning of the asymptomatic phase. Throughout the asymptomatic phase,
viral load increases and CD4+ lymphocytes decline. The rate of these changes
varies from patient to patient based on viral and host characteristics, lasting a
median of 8-10 years. Patients are diagnosed with acquired immunodeficiency
syndrome (AIDS) once CD4+ lymphocytes drop below 200 cells/mm3 and/or they
develop one of many AIDS-defining conditions. In the absence of treatment,
patients succumb to opportunistic infections or another AIDS-defining condition.
(Figure modified from (105)).
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1.6 HIV-1 disease progression
The rate at which CD4+ T cells decline throughout an HIV-1 infection is one
measure that is often used to categorize HIV-1 disease progression (105). In an
effort to determine how disease progression can be halted or reversed, there is
much interest in understanding what is responsible for the differences observed
in disease progression. The progression of HIV-1 infection to AIDS is influenced
by host and viral factors, as well as the complex interactions between the virus
and the host. Some of the most studied host factors affecting HIV-1 disease
progression are human leukocyte antigen (HLA) alleles (106-109). Certain HLA
alleles have been repeatedly shown to be associated with decreased HIV-1
disease progression or decreased susceptibility to HIV-1 infection (107, 108, 110,
111). Furthermore, studies have linked these associations with a more efficient
adaptive immune response. Many other naturally occurring polymorphisms have
been suggested to play a role in HIV-1 diseases progression. Not surprisingly,
these polymorphisms are often located in genes for immune-related proteins.
These include host restriction factors that have been shown to have anti-HIV
activity, but are counteracted by HIV-1 proteins (112), cytokines that regulate the
adaptive immune response (113, 114) and pattern recognition receptors (PRRs)
of the innate arm of immunity (115). However, these findings have not been fully
substantiated and large genome-wide association studies have failed to identify a
correlation between many of these polymorphisms and HIV-1 disease
progression (116). That being said, a study of 2554 HIV-1-infected Caucasians
did find that mutations in the chemokine receptors CCR5 and CCR2 had
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protective effects on HIV-1 disease progression (117). These findings are in line
with the role of CCR5 and CCR2 as main and minor co-receptors for HIV-1,
respectively (118, 119). Studies such as this do not exclude the possibility of
other polymorphisms affecting HIV-1 disease progression, but rather underscore
the complex interplay between host genomic factors and the difficulty in isolating
the effect of a single genetic mutation at the population level. Taken together,
these findings suggest that there may be a HIV-1 protective immune phenotype
that may prevent infection or decrease the rate of HIV-1 disease progression.
Given the differences in subtype distribution across nations and populations,
there have also been attempts to determine if the infecting subtype plays a role in
HIV-1 disease progression. These studies are difficult to conduct, as they require
demographically similar populations where two or more subtypes are endemic.
However, despite the difficulty in setting up these studies, evidence suggests that
the infecting subtype does influence disease progression. Multiple studies have
been conducted in cohorts of HIV-1-infected individuals in eastern Africa where
subtypes D and A both circulate. These cohorts are composed of pregnant
women, sex workers, or members of the adult population that do not identify to
these to groups. The cohorts have ranged in size from 145 to 1045 individuals.
All these studies have shown that individuals infected with subtype D viruses
progress more rapidly to AIDS compared to those infected with subtype A viruses
(120-122). Studies have also demonstrated that there is a higher risk of dying
from AIDS in patients infected with subtype D (123, 124).
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Interestingly, a recent analysis of 303 HIV-1-infected women from Uganda and
Zimbabwe infected with subtypes A, C or D confirmed the findings of the studies
mentioned above, but also demonstrated that patients infected with subtype C
viruses progress more slowly to AIDS (125). These findings may have
implications for control of the global epidemic and suggest a possible explanation
behind the high global prevalence of subtype C, as a subtype with a slower
progressing disease provides more opportunity for transmission.
The aforementioned studies have all been conducted in sub-Saharan Africa
where there is a high prevalence of multiple HIV-1 group M subtypes in close
geographic and epidemiologic proximity. As discussed earlier, the spread of HIV1 outside of central Africa resulted in distinct viral populations emerging
throughout the world (78). Due to these relatively more heterogeneous
populations, studies investigating differences in disease progression between
subtypes outside of Africa have been difficult. In particular, comparing subtype B
disease progression to other subtypes is difficult due to the isolated nature of
subtype B infections in higher-income countries (126-128). This renders it hard to
control for confounding factors such as income and access to healthcare when
comparing to subtypes found predominantly in middle to low-income countries.
Overall, the mechanisms governing the above differences in disease progression
are poorly understood. This is partly due to the fact that much of the research
that has been conducted on the molecular mechanisms of the viral-host
interactions that occur during an HIV-1 infection have been studied in the context
of a subtype B infection (129). In the years that followed the recognition of AIDS
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as a clinical entity, there was intense research into determining the causative
agent. HIV-1 was identified as the virus responsible for AIDS when researchers
isolated full-length molecular clones from AIDS patients (33, 34). The original
HIV-1 molecular clone was known as IIIB/LAI (formerly known as BRU) and was
isolated in 1983 in France (130). This clone gave rise to the molecular clone
HXB2, which is still widely used, but has been altered through laboratory
adaptations. In addition, IIIB/LAI was intentionally recombined with another HIV-1
isolate, NY5, to generate the laboratory clone pNL4-3 (131). Laboratories in the
United States also isolated HIV-1 molecular clones, notably the clone SF2, which
is widely used in HIV-1 research (132). These isolated viruses, among a handful
of others, became the clones used by thousands of researchers in the following
decades. Importantly, as this pioneering research was conducted in France and
the United States, the AIDS patients these clones were isolated from were
infected with HIV-1 subtype B. As a result, despite almost 90% of global HIV-1
infections being non-subtype B, our understanding of how HIV-1 affects the
molecular processes of the cells it infects is from research predominantly using
subtype B viruses. This same discrepancy is true for the research on the drugs
that have been developed to treat HIV-1 (133, 134). The long-term impact of this
disconnect between research and reality, and its effect on our ability to control
HIV-1 globally is yet to be determined.

1.7 HIV-1 Nef: a key pathogenic factor
Evidence for one of the most compelling viral factors shown to influence disease
progression comes from the clinical observation of an Australian cohort of eight
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patients that were infected with HIV-1 after receiving a contaminated blood
transfusion. Known as the Sydney Blood Bank Cohort, these eight individuals
were transfused with blood or blood products from an HIV-1-infected donor
between 1980 and 1984. The recipients ranged in age from 18 to 71 and varied
in their indications for transfusion. Three of the recipients died of non-HIV-1
related causes, while the remaining five recipients, as well as the original donor,
survived without antiretroviral therapy for 14-18 years post-infection (135-137).
The donor eventually commenced antiretroviral therapy, but significantly later
than the 8-10 years seen in normal HIV-1 infections. Two of the recipients also
commenced antiretroviral therapy, but passed away from non-HIV-1 related
causes shortly thereafter. Strikingly, three of the HIV-1 infected recipients have
continued to have undetectable viral loads over 25 years since infection and do
not show clinical signs of HIV-1 infection (138). Upon the isolation and
sequencing of the HIV-1 viruses from the patients of the Sydney Blood Bank
Cohort, it was found that the viral genome contained a large deletion in the HIV-1
nef gene that resulted in a non-functional Nef protein (139, 140). A small nonenzymatic and non-structural protein, Nef has subsequently been shown to be
essential to HIV-1 pathogenesis. Studies in both transgenic mouse models (141)
and SIV-infected macaques (140) have clearly demonstrated the requirement of
Nef for CD4 decline and the progression to AIDS.
Initially thought to decrease the infectivity of HIV-1 virions, this 27-35 kDa protein
was originally termed a negative factor, from which the name Nef is derived (142,
143). However, it was quickly shown that Nef in fact increases infectivity of
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virions (144-146) along with a number of other functions, just a few of which will
be expanded on below.
As it is not required for in vitro HIV-1 replication, Nef, along with a number of
other proteins encoded by HIV-1, is termed an accessory protein. To
compensate for its lack of enzymatic or structural properties, Nef interacts with a
plethora of host proteins to carry out the functions that make it necessary for in
vivo replication (145, 147-150). Through these interactions, Nef hijacks the host
cell trafficking machinery and alters the molecular architecture of infected cells
(151-153). The effect of Nef on the organization of infected cells is most apparent
when looking at how the composition of cell surface proteins changes in its
presence or absence. The degree to which Nef is able to alter the levels of cell
surface proteins is astounding, with reports demonstrating that Nef increases or
decreases the cell surface levels of at least 37 proteins (154). These
downregulated proteins include key proteins involved in cytokine signaling, T cell
maturation and immune regulation. The impact of this large-scale reorganization
is not completely understood, but there are a handful of well-studied Nefmediated modifications in infected cells that can help explain its essential role in
HIV-1 pathogenesis.

1.8 The multiple functions of HIV-1 Nef
One of the first described effects of Nef expression was its ability to
downregulate CD4 from the surface of infected cells (155). This finding was of
particular significance for HIV-1 infection, as CD4 is the main receptor used by
HIV-1 to enter host cells (119). Indeed, CD4 is one of the main co-receptors for
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the T cell receptor (TCR) and is involved in stabilizing the interaction of the TCR
with major histocompatibility complex class II (MHC-II) (66). As Nef-mediated
CD4 downregulation was further explored, it was also shown to involve key hostvirus protein interactions with the intracellular trafficking machinery. These
interactions result in CD4 molecules from the cell surface being shuttled into a
retrograde

transport

pathway.

The

culmination

of

this

Nef-mediated

downregulation is the trafficking of CD4 molecules to a lysosomal compartment
where CD4 is degraded. Specifically, Nef functions to facilitate the internalization
of CD4 through interactions with adaptor protein 2 (AP-2) (151, 156, 157) and
then targets CD4 containing endosomes to lysosomes through interaction with
the beta subunit of the coatomer COPI (158, 159). In addition to identifying the
host proteins involved, the specific residues within Nef that mediate the
interactions required for CD4 downregulation have been described and will be
elaborated on later in this chapter. Interestingly, the ability of Nef to downregulate
CD4 is conserved across HIV-1 subtypes with over 80 Nef proteins from each of
subtypes A, B, C and D all showing robust downregulation, albeit with subtype C
showing a slightly decreased ability compared to subtype B (160). In addition to
Nef, the HIV-1 proteins Env (161, 162) and Vpu (163) also contribute to
decreasing cell surface levels of CD4 on infected cells.
The conservation and redundancy of this Nef function suggests it provides a
replication advantage for HIV-1. Indeed, as mentioned above, CD4 is the primary
receptor used by HIV-1 to enter cells. Once a cell becomes infected, it is
beneficial for HIV-1 to remove the remaining CD4 from the cell surface to prevent
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reinfection with additional virions (164, 165). This repeated infection, known as
superinfection, can overwhelm the infected cell leading to apoptosis, preventing
any new HIV-1 virions from being released. Removal of CD4 from the cell
surface also increases the dissemination of HIV-1 virions by preventing newly
released virions from reinfecting the host cell from which they just budded. In
addition, it has been demonstrated that circulating antibodies can bind HIV-1 Env
proteins on the surface of infected cells more efficiently when those Env proteins
are interacting with CD4 molecules on the cell surface. The Env:CD4 interaction
leads to conformational changes in Env, revealing epitopes that antibodies can
recognize (166). These antibodies can then act as ligands for receptors on
natural killer (NK) cells, a subset of immune cells that can induce lysis of the
infected cells via the release of effector proteins that is initiated by the
antibody:receptor interaction (167). By decreasing cell surface levels of CD4,
HIV-1 Nef prevents this innate and adaptive immune process known as antibodydependent cell-mediated cytotoxicity (ADCC) (168) (Figure 1.5). As expected, the
ability of HIV-1 Vpu to downregulate CD4 also plays a role in limiting ADCC,
highlighting the complementary functionality of the HIV-1 accessory proteins
(169).
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Figure 1.5 CD4 downregulation by HIV-1 Nef protects infected cells from
ADCC and superinfection.
In the absence of Nef (Nef -), HIV-1 infected cells have increased CD4 levels on
the cell surface. Binding of CD4 with HIV-1 Env increases the binding affinity of
anti-Env antibodies and sensitizes infected cells to recognition by CD16
expressing NK cells and subsequent NK killing by antibody-dependent cellmediated cytotoxicity (ADCC). Increased CD4 levels on the cell surface also
allows for superinfection of CD4+ T lymphoctyes with multiple strains of HIV-1, as
represented by different coloured virions. In the presence of HIV-1 Nef (Nef +),
CD4 is more efficiently removed from the cell surface and shuttled to lysosomes
for degradation, as represented by fragmented CD4 in gradient shaded vesicle.
Preventing ADCC is not the only method by which Nef allows HIV-1 to evade the
host immune system. Nef is also able to downregulate major histocompatibility
complex class I (MHC-I) (170, 171). MHC-I is an immune receptor expressed
ubiquitously on all nucleated cells in the body. It functions in immune surveillance
by continuously expressing protein fragments generated from the cellular
proteasomal degradation pathway. In healthy cells, these protein fragments
originate from the natural turnover of proteins and are recognized by cytotoxic T
lymphocytes (CTLs) as self peptides (172). In the context of infection, viral

28

proteins are translated in the cytoplasm and following their proteasomal
degradation are loaded onto MHC-I molecules in the endoplasmic reticulum (ER)
and trafficked to the cell surface. Once at the cell surface, these MHC-I
molecules displaying viral peptides are recognized as non-self by CTLs, which
then induce apoptosis in infected cells (173). Nef is able to remove MHC-I from
the cell surface, preventing infected cells from signaling to CTLs, and thereby
allowing HIV-1 infected cells to go undetected (174) (Figure 1.6). In order to
remove MHC-I from the cell surface, Nef utilizes a separate intracellular
trafficking pathway from the one used to downregulate CD4 (175, 176). Nef
requires interaction with the trafficking protein phosphofurin acidic cluster sorting
protein-2 (PACS-2) to localize to the trans-Golgi network (TGN) and initiate a
signaling cascade through the activation of a Src family kinase (SFK) (170, 177,
178). The result of this signaling cascade is the clathrin-independent endocytosis
of MHC-I, mediated by the small GTPases ADP-ribosylation factor 1 and 6
(ARF1 and ARF6) (179). Nef will subsequently interact with the trafficking
proteins adaptor protein -1 (AP-1) and PACS-1 to shuttle MHC-I containing
endosomes back to the TGN where it is sequestered (170, 175, 180).
The key role MHC-I plays in immune surveillance has led to the convergent
evolution of viral strategies to alter its surface expression. Indeed, both herpes
simplex virus (HSV) and human papillomavirus (HPV) modulate the levels of
MHC-I on the cell surface. HSV interferes with peptide loading of MHC-I
molecules

(181),

whereas

HPV

decreases

MHC-I

expression

at

the

transcriptional level (182). These are just two of many viruses that target MHC-I
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(183-185). However, the human immune system has evolved a method to
counter the actions of these viruses. Circulating NK cells detect the absence of
MHC-I molecules from the surface of cells and induce apoptosis (186).
Interestingly, HIV-1 Nef specifically targets the MHC-I molecules HLA-A and B
and to some extant HLA-C while leaving most HLA-C as well as HLA-G and E on
the surface. This selective downregulation prevents recognition by NK cells,
allowing HIV-1 infected cells to evade both CTL and NK killing (187).
CD8+
T Lymphocyte
TCR
B7

Nef -

Nef +

CD8

MHC-I
Nef

CD28
MHC-I

CD4+
T Lymphocyte

Figure 1.6 Evasion of CD8+ T lymphocyte by Nef-mediated MHC-I
downregulation.
In the absence of Nef (Nef -), peptides from HIV-1 proteins (yellow circles) are
loaded onto MHC-I complexes and presented at the surface of infected cells.
Upon recognition of the viral peptide:MHC-I complex, circulating CD8+ T
lymphocytes are activated and stimulated through TCR and co-stimulatory
(B7:CD28) signaling. Once activated, CD8+ T lymphocytes induce apoptosis of
infected cells, limiting viral spread. In the presence of Nef (Nef +), MHC-I is
removed from the surface of HIV-1 infected cells and the virus is able to replicate
and disseminate.
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1.9 SERINC5: a novel HIV-1 restriction factor
As mentioned above, the initial identification and functional description of Nef in
1985 and 1986 determined this accessory protein to have a negative regulatory
effect on HIV-1 viral replication (142, 143). However, before the end of the
decade, there were conflicting reports, suggesting that Nef did not impair
replication (144). In the following eight years, the negative regulatory effects of
Nef were largely refuted and it was established that this protein was actually
required for optimal in vivo infectivity (145, 146). The original studies
demonstrating the role of Nef in infectivity were published in the early to mid
1990s, but the mechanism by which Nef increased infectivity remained poorly
understood for more than twenty years. It was not until 2015 that Nef was once
again demonstrated to downregulate a host protein from the cell surface to exert
its effects. Two simultaneous reports identified the host proteins serine
incorporator 3 and 5 (SERINC3 and SERINC5) as HIV-1 restriction factors that
Nef counteracts to optimize viral infectivity (188, 189). In both reports SERINC5
was shown to be the more potent restriction factor, and subsequent studies have
focused on SERINC5, with SERINC3 thought to play a minimal role in anti-HIV-1
activity.
The identification of SERINC5 as an intrinsic restriction factor counteracted by an
accessory protein is familiar in the HIV-1 field (190). Vif and Vpu, two other
accessory proteins, counteract the host proteins APOBEC3G (191) and tetherin
(192), respectively. HIV-1 replication and spread is greatly impaired by these
restriction factors unless the HIV-1 accessory proteins are present. A similar
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phenomenon occurs with Nef and SERINC5. In the absence of Nef, cell surface
SERINC5 is incorporated into budding virions. Once in virions, SERINC5 has an
inhibitory effect on the fusion of virions with target cells and by doing so it acts as
a viral restriction factor. However, when Nef is expressed in infected cells, it
downregulates SERINC5, reducing the amount of SERINC5 at the cell surface
and therefore the amount of SERINC5 in budding virions (188, 189, 193).
The exact mechanism by which SERINC5 impairs the fusion of HIV-1 virions with
target cells is not known, partially because the physiological function of SERINC5
in uninfected cells has not been thoroughly studied. Prior to its discovery as an
HIV-1 restriction factor, there had been very few studies on the function of
SERINC5, which has also been called C5orf12 and TPO1. The original articles
describing SERINC5 focused on the transcriptional profile of the rat orthologue
TPO1, which was highly expressed in oligodendrocytes in the rat brain (194).
Even with the discovery of the human orthologue, many of the subsequent
articles only identified SERINC5 as part of large-scale screens. The few studies
that have tried to assess the function of SERINC5 have outlined a potential role
for SERINC5 in membrane lipid biosynthesis (195, 196). Specifically, SERINC5
is thought to act as a scaffold for key enzymes involved in serine biosynthesis
and its subsequent incorporation into phosphatidylserine and sphingolipids (197).
However, with its discovery as a restriction factor, there has been a flurry of
research into SERINC5, which has increased our understanding of this protein,
but also left many questions unanswered. The study of Nef proteins from a
number of primate lentiviruses has suggested the anti-SERINC5 ability of Nef as
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one of the determinants of transmission between species (198). Mutational
analysis has revealed motifs required for Nef to counteract SERINC5 (193). A
biochemical examination showed that the lipid composition of HIV-1 virions is not
altered by SERINC5 (199). The most highly expressed and functionally active
splicing isoform of SERINC5 has been identified (200). Domain swapping studies
have implicated certain regions of SERINC5 in its anti-infectivity function (201). In
addition, HIV-1 Env has also been demonstrated to have anti-SERINC5 activity,
but at a different stage in the HIV-1 infection cycle (202). The evolution of two
viral proteins to counteract SERINC5 suggests a strong selection pressure to
overcome the anti-infectivity function of this newly identified restriction factor.

1.10 The structure-function relationship of Nef
The ability of Nef to downregulate CD4, MHC-I and SERINC5 highlights the
multifunctional nature of Nef. Indeed, this multifunctionality is quite astounding,
but also a necessity for a virus such as HIV-1, whose genome is only 9 kb and
encodes 15 proteins (33, 34). With this limited coding capacity, HIV-1 has
evolved proteins that are able to carry out multiple functions in order to
successfully infect and replicate in host cells. The structure of Nef provides some
insight into how this small protein can have such a dramatic effect on a cell. HIV1 Nef consists of two structured globular domains connected with a flexible loop
region and unstructured tails at both the amino and carboxy-termini (147, 203205). Upon the discovery of Nef, even before its function was determined,
researchers noted an N-terminal glycine at position 2, which undergoes a cotranslational modification known as myristoylation (206). This modification adds a
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myristoyl group, a fatty acid derivative, to the amino-terminus of Nef, which
subsequently acts to localize it to lipid membranes. This membrane localization is
required for Nef to carry out essentially all its functions. As such, a Nef G2A
mutant is often used as a negative control in studies of Nef function (207, 208).
Furthermore, a glycine at position 2 is highly conserved across all HIV-1 groups
(91, 209). Molecular pathways that rely on the assembly of multi-protein
complexes often use lipid membranes as an anchor or scaffold, from which they
can initiate downstream signaling cascades (210). This is exemplified by
signaling through the ubiquitous G-coupled protein receptors (211) or through T
cell receptor (212, 213). The N-myristoylation of Nef facilitates its interaction with
host proteins at the cell surface and allows Nef to subvert their function to favour
HIV-1 replication.
Throughout its structure, Nef has binding motifs it uses to interact with a variety
of host proteins that play key roles in intracellular trafficking and signaling. These
host proteins have a large number of interaction partners, amplifying the host
pathways that Nef can subvert. One such example is the PxxP75 motif in the
central globular domain of Nef that interacts with the SRC homology 3 (SH3)
domain found in the RT loop of SFKs (205, 214). The interaction of Nef with the
SFK Hck leads to its activation and has been implicated in viral replication.
Indeed, suppression of Hck activation through the use of antagonists or dominant
negative mutants decreases HIV-1 replication (215-218). The ability of Nef to
downregulate such a large number of cell surface proteins can also be attributed
to specific motifs. As mentioned earlier in this chapter, Nef is able to interact with
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the cell sorting proteins PACS-1 and -2, thereby shuttling MHC-I away from the
cell surface (177, 219). An acidic cluster motif from position 62 to 65, EEEE65
mediates this interaction. Mutation of this acidic cluster (E4A) impairs the
Nef:PACS interaction and significantly decreases the ability of Nef to remove
MHC-I from the cell surface (170, 177, 179, 219). Distinct motifs have also been
implicated in the ability of Nef to interact directly with the cytoplasmic tail of CD4
(WL58) (220), hijack the membrane trafficking proteins AP-1 and -2 (LL165) (221,
222), and activate the serine/threonine-protein kinase Pak2 (RR106) (223). The
extensive network of interaction motifs on this 206 amino acid protein helps
explain the multitude of functions that have been ascribed to Nef (147).
The motifs above have been identified through mutational analysis to elucidate
their roles in the functions carried out by Nef. Given the genetic instability of the
HIV-1 genome explored earlier in this chapter, the conservation of these binding
motifs across the epidemic suggests the interactions they mediate play a vital
role in HIV-1 replication. The identification of these highly conserved protein
sequences may be valuable given the propensity of HIV-1 to mutate to escape
detection by the immune system (111, 224). Despite the fact that the adaptive
immune response is eventually overcome by HIV-1 with the development of
AIDS, it is continuously attempting to target and eliminate HIV-1 infected cells. As
mentioned above, HIV-1, and Nef in particular, has evolved mechanisms to
evade some of these adaptive immune responses. Potentially the most effective
method by which HIV-1 avoids detection and elimination by the immune system
is by the inherent genetic flexibility that leads to the high degree of HIV-1 genetic
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diversity (74). By mutating so frequently and with such ease, HIV-1 is a
constantly moving target. T cell-mediated adaptive immune responses largely
evolved to target specific peptide sequences from foreign organisms. This
specificity is one of the reasons why normal tissues do not normally sustain
collateral damage during an adaptive immune response (173, 225). However,
this defining characteristic also means it is inadequately prepared to clear
infections like HIV-1. By the time the body is able to activate and mature immune
cells, the peptides for which they have specificity may no longer exist in the pool
of viruses now circulating.
The changes in protein sequences that allow HIV-1 to continue to replicate are
known as escape mutations. Although these mutations may allow infected cells
to evade MHC-I meditated detection, they can have a fitness cost to the virus
(74). As such, the evolution of HIV-1 viral proteins is a balance between avoiding
clearance by CTLs, while maintaining the functional capacity to replicate (226,
227). These evolutionary forces are particularly strong in the HIV-1 proteins Gag,
Pol and Nef, which appear to be the most immunogenic viral proteins, that is,
peptides expressed on MHC-I molecules are most frequently derived from these
three HIV-1 proteins (228). This process may contribute to the protective effects
seen in individuals with specific HLA alleles described earlier in this chapter. For
example, the presence of the HLA-B*13 allele has been linked to decreased HIV1 viral loads. Indeed, the escape mutations that emerge in Gag and Nef in
individuals who carry the HLA-B*13 allele have been shown to result in impaired
function of both viral proteins (229). Different HLA alleles have different potential
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binding grooves meaning they show preference for certain viral epitopes. If the
epitopes that are displayed by the HLA molecules are derived from highly
conserved regions of their native viral protein, escape mutations are more likely
to have fitness costs to the virus. This results in a situation where mutations will
decrease pathogenesis. Conversely, a lack of mutations in these regions allows
for better control of the virus. Combined, the mutation, or not, of these epitopes
results in decreased disease progression (74, 226, 227). The ability to identify
highly immunogenic epitopes with limited mutational flexibility may be useful in
future vaccination attempts as eliciting CTL responses to these epitopes may
provide more broad and sustained protection against HIV-1 (230-232). Indeed, a
similar approach is being used to target the stalk region of influenza A and B
viruses, in hopes of developing a “universal” influenza vaccine (233, 234).

1.11 Treatment and control of HIV-1
As with all infectious diseases, there is great interest in generating a vaccine that
induces protection against HIV-1. Although there have been numerous clinical
trials of potential HIV-1 vaccines using a variety of different strategies, there is no
HIV-1 vaccine presently available (235). While none of the tested vaccines have
been clinically successful, these attempts have enhanced our understanding of
the correlates of immune protection. The only vaccine to demonstrate significant
protection was the RV144 vaccine trial, which displayed 31.2% efficacy at two
years (236). The results of this trial have been extensively analyzed since they
were reported in 2009. It is believed that the protection seen in the RV144 trial
was due to a combination of non-neutralizing Env targeting antibodies (236-238),
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HLA A*02 restricted epitopes (239) and ADCC from vaccine-induced antibodies
(238, 240, 241). There are numerous vaccine trials currently underway, at
various clinical phases. The furthest along is the HVTN702 trial, which is at
phase IIb/III. Based on the promise of the RV144 trial, the vaccine trial HVTN702
is being conducted in South Africa using a modified version of the vaccine used
in RV144. Upon its completion in 2021, HVTN702 will be the largest HIV-1
vaccine trial ever and offers hope for improved efficacy (235).
The value of an effective HIV-1 vaccine is increased by the fact that there is
currently no mechanism to cure an HIV-1 infection, as present treatment requires
life-long pharmacotherapy (242). If HIV-1 positive individuals have access to
current antiretrovirals, they can expect to have a normal life span (102). As a
result, HIV-1 has effectively become a chronic disease that is medically managed
throughout a patient’s life, more akin to diabetes or hypertension when compared
to other viral infections. Current HIV-1 therapy is a combination of three
antiretrovirals that are usually taken orally once a day. In total, there are twentyeight

United

States

Food

and

Drug

Administration

(USFDA)-approved

antiretrovirals from seven drug classes, which are differentiated by their
mechanism of action. That being said, clinical treatment of HIV-1 largely uses
drugs from just four classes. Two classes target reverse transcription, the
nucleoside analogues nucleoside reverse transcriptase inhibitors (NRTIs) and
the

allosterically

binding

non-nucleoside

reverse

transcriptase

inhibitors

(NNRTIs). The other two classes are protease inhibitors (PIs), which block the
proteolytic cleavage of viral proteins that is required for viral maturation and
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integrase inhibitors (INIs), which prevent the integration of viral DNA into the host
chromosome (242). As of 2016, the preferred first-line regimen according to the
World Health Organization (WHO) consists of a backbone of two NRTIs and an
additional NNRTI or INI with a PI used in special circumstances (243).
In addition to these commonly used antiretrovirals, there are also three classes of
drugs that target the entry of the virus into cells (242). These three classes are
fusion inhibitors, co-receptor antagonists and CD4 attachment inhibitors, each
with only one USFDA-approved drug. The fusion inhibitor enfuvirtide binds the
viral envelope protein gp41, preventing fusion of the viral and host membranes,
however, enfuvirtide has a low potency and short half-life and is rarely used
clinically (244). The co-receptor antagonist maraviroc binds the HIV-1 coreceptor CCR5, inducing a conformational change that prevents binding of the
viral envelope protein (245). The recently approved monoclonal antibody
ibalizumab is a CD4 attachment inhibitor and is the first biologic approved for the
treatment of HIV-1. It binds to CD4, preventing HIV-1 entry, but does not alter the
immunological function of CD4 (246). Both maraviroc and ibalizumab are used as
salvage treatment, with ibalizumab just being approved for use in patients with
multi-drug resistant HIV-1 in 2018. Thus, although patients cannot be cured at
this point, the vast array of drugs is a testament to the past three decades of
basic and clinical HIV-1 research.
As is the case with the management of all chronic diseases, optimal outcomes
only occur with consistent access to health care resources and high levels of
adherence to treatment regimens. The benchmark used for antiretroviral
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treatment is an adherence level of 95%, measured using self-reported data or
data from drug dispensing records. Results from studies of drug adherence are
highly variable and generally range from around 20% to close to 90% depending
on population demographics and location (247-250). A systematic review from
2006 made a pooled estimate that adequate adherence was only achieved in
55% of patients in North America (data from 17 573 patients) and 77% in SubSaharan Africa (data from 12 116) (251), while a 2018 study of adherence in 8
501 patients in Korea observed an adherence rate of 70% (252). In many of the
high-risk HIV-1 positive populations, there are a number of barriers to achieving
95% adherence. Homelessness, daily alcohol or illicit drug use, and less than a
high school education have all been independently shown to negatively correlate
with medication adherence (251, 253, 254). Qualitative research has also
demonstrated that HIV-1 stigma, medication cost and a desire to be “drug free”
are commonly cited as reasons why patients stop taking antiretrovirals (250, 255,
256). Addressing these barriers will be essential as we attempt control of the
HIV/AIDS pandemic.
The long-term use of antiretrovirals raises additional concerns. We are entering
an unknown territory with patients expected to take daily treatment for up to 50
years, but we are just beginning to investigate the health impacts of long-term
antiretroviral therapy. The epidemiological studies on the complications of
chronic antiretroviral exposure are mixed, but systematic reviews have
suggested that antiretroviral use is correlated with diabetes, chronic kidney
disease and cardiovascular disease (257-264). These studies in no way
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undermine the success of antiretroviral treatments, but rather highlight the
complexities involved in the long-term care of HIV-1-infected patients.
Although managed like other chronic diseases, the infectious nature of HIV-1
makes the risk of resistance to current treatments a serious concern. The same
genetic instability that allows HIV-1 to evade immune responses can result in
mutations that impair or eliminate the binding of drugs used to treat HIV-1. The
history of antiretroviral drug development is shaped by drug-resistant mutations.
From 1986 to 1996 antiretroviral therapy consisted of mono or dual therapy.
These treatments significantly decreased viral loads, but this viral suppression
was short-lived as viruses evolved mutations that rendered them resistant to
binding by the drugs. It was not until patients were treated with three drugs that
they achieved sustained viral suppression. The use of triple therapy dramatically
reduced the chances that a virus will evolve resistant mutations to all three drugs
(242). This remains true, but many people who fail antiretroviral treatment do so
because of acquired or transmitted drug-resistant mutations. Acquired drug
resistance refers to de novo mutations that evolve throughout antiretroviral
treatment and are a major cause of increased viral loads in patients on treatment,
known as virological failure (247, 265-267). Patients with elevated viral loads are
more likely to transmit these drug-resistant viruses to other individuals. The
presence of antiretroviral-resistant mutations in newly infected, treatment-naive
patients is known as transmitted drug resistance and is a major public health
concern (268). Transmitted drug resistance is most prevalent in regions of the
world that have had access to antiretrovirals for the longest period of time. As a
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result, the prevalence of transmitted drug resistance is around 12% in North
America and 10% in Europe, whereas prevalence in sub-Saharan Africa and
Southeast Asia is closer to 3% (269-272). It is possible to overcome this
resistance by using drugs that target a different mechanism of HIV-1 replication.
However, resistance is of particular concern in low- and middle-income countries
(LMICs) where access to these second and third-line antiretroviral treatments
can be limited, drug supplies can be interrupted more frequently and there are
decreased resources for pre-treatment screening to identify resistance mutations
(271). Current guidelines in high-income nations are to screen patients at
diagnosis in order to guide treatment (273, 274), however, in LMICs screening is
prohibitively expensive and resource-intensive (272, 275, 276). Even patients in
LMICs who fail first-line treatment are not routinely screened for drug-resistant
mutations and instead are treated empirically with a second-line therapy (272).
Antiretroviral resistance increases the risk of HIV-1-related morbidity and
mortality, increases the cost of future treatment and increases the risk of further
transmission of HIV-1 (277-279). Transmitted drug resistance to NNRTIs is of
particular concern as it is the first-line treatment for prevention of mother-to-child
transmission (243, 272).
Both vaccine and cure approaches to controlling HIV-1 have their obstacles. For
cure approaches, these include achieving complete eradication of HIV-1 infected
cells from the body (280). As of yet this has not been feasible due to what is
known as the viral reservoir. During the acute phase of HIV-1 infection, the virus
predominantly infects effector CD4+ T cells. Following the acute phase, most of
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these virally infected cells die off either from the cytopathic effects of HIV-1
infection or by the antiviral immune response (105, 281). However, a minority of
these cells transition into CD4+ memory T cells and form a long-lived population
of cells that contain integrated HIV-1 genomes (281). These cells are referred to
as latently infected as they are not actively replicating and producing a large
number of HIV-1 virions. Instead, these cells maintain a low-level of HIV-1
transcription and protein production allowing them to remain undetected by the
immune system and mostly unaffected by antiretroviral therapy (282). If
antiretroviral therapy is interrupted, these latently infected cells are responsible
for the viremic rebound that occurs in the following two weeks to two months
(280, 283). One current cure strategy being investigated attempts to
pharmacologically reactivate these latently infected cells, making them
increasingly susceptible to antiretroviral therapy and subsequent clearance by
the adaptive immune response (102). This strategy, referred to as “shock and
kill”, has thus far failed to completely eliminate latently infected cells, potentially
in part due to the immune evasion strategies mentioned above that HIV-1
employs (284-287). Indeed, if reactivated cells are actively producing viral
proteins, HIV-1 Nef will downregulate MHC-I and CD4 from the cell surface,
preventing clearance by CTLs or ADCC, respectively (288). In addition, the
effectiveness of shock and kill strategies is hard to assess as the exact
anatomical locations and extent of the latent reservoir remain unknown (289).
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1.12 The burden of HIV-1
With the devastating impact HIV-1 has had on human populations, and the
subsequent decades of research that it fueled, we have learned a great deal
about the virus and how we can limit its pathogenesis. This has resulted in some
significant progress in the management of HIV/AIDS. Global HIV-1 incidence
rates peaked in 1997 with 3.2 million new infections while HIV-1 mortality
reached its highest point in 2004 with 2.1 million deaths. As of 2016, there were
1.8 million new HIV-1 infections and 1.0 million deaths. The greatest burden of
HIV-1 and AIDS is found in eastern and southern Africa where there are 19.7
million people living with HIV-1, accounting for 53% of all infections globally (98).
As a result, it is in these regions where the most progress on controlling the
epidemic has been made with eastern and southern Africa experiencing a 64%
decrease in incidence and a 70% decrease in mortality since 2001. In most
regions of the world, there have been similar, but less dramatic decreases due to
the implementation of improved screening and antiretroviral therapy. There has
been an intense scale-up of antiretroviral therapy in recent years with the number
of people receiving treatment increasing from 7.5 million in 2010 to 17.0 million in
2015, representing a coverage rate of 46% (98).
However, the clinical response to HIV-1 is not uniform and may be stagnating in
certain regions. In the Middle East and northern Africa, only 24% of those
infected with HIV-1 have access to treatment and in eastern Europe and central
Asia, the HIV-1 incidence rate has increased by 60% from 2010 to 2016 (98)
(Figure 7A, B). Furthermore, even regions that are seeing overall decreases in
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infection rates have subsets of populations that are not benefitting equally. In
Canada, Indigenous peoples have a 2.7 times higher incidence of HIV and
people who inject drugs have a 59 times higher incidence than those who do not
inject drugs (62). Globally, transgender people are 49 times more likely to be
infected with HIV-1 and young women and girls are twice as likely as young men
and boys to be infected with HIV-1 (98). These stark differences in incidence
rates highlight how the HIV/AIDS pandemic is significantly influenced by the
social and political culture.
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Figure 1.7 Global trends in HIV-1 incidence and access to antiretroviral
therapy.
(A) HIV-1 incidence rates from 1990-2016 in the 8 WHO geographic regions. (B)
Antiretroviral therapy coverage in the 8 WHO geographic regions. (A and B
modified from (98))
Controlling this complicated epidemic comes at a cost. It is estimated that in
2016 there was US$19 billion spent on the AIDS response in LMICs and
maintaining an adequate response will require well over US$ 20 billion each year
in LMICs until at least 2030 (290). More efficient and effective strategies at
preventing or treating HIV-1 will be valuable assets in ending an epidemic that
has ravaged many generations. There have been very promising clinical trial
results from long-acting antiretroviral therapies that may increase adherence
rates (291, 292). Monoclonal antibodies against host proteins may offer
treatments that avoid the issue of HIV-1 resistance (293-295). Numerous HIV-1
vaccine trials are underway that are informed by the success of RV144 or are
attempting new strategies to induce immunity (235). Finally, novel antiretroviral
targets such as Nef have shown promise in vitro and could be used in
combination with reactivation agents to clear latently infected cells (215, 288,
296, 297). These strategies all take different approaches to fight HIV-1, but they
all require a comprehensive understanding of the virus, how it differs from one
region to the next and how it thwarts our immune system.
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1.13 Rationale, Hypothesis and Thesis Objectives
The HIV-1 genome is just 9 kb, but uses its limited coding capacity to carry the
genetic information required to devastate the human body (33, 34). A low-fidelity
reverse transcriptase allows HIV-1 to rapidly evolve to evade the immune
response, an exquisite example of viral adaptation (72, 73). This lack of genetic
stability also makes HIV-1 one of the most diverse viruses known (77, 298). The
impact of genetic diversity on the molecular mechanisms involved in an HIV-1
infection is not completely understood, leading to unexplained differences in
disease progression between viral subtypes (120, 121, 124). Throughout this
dissertation, I will explore the hypothesis that the genetic diversity that defines
HIV-1 has a pronounced effect on the HIV-1 protein Nef, altering its function
between and within group M subtypes.
Nef is a key pathogenic protein, allowing HIV-1 to evade the immune system by
downregulating MHC-I (171) and CD4 (155). Furthermore, it was recently
discovered that Nef counteracts the host factor SERINC5 to increase HIV-1
infectivity (188, 189), but the mechanistic details of the Nef:SERINC5 interaction
still need to be explored. To address this hypothesis I investigated how MHC-I
and CD4 downregulation differ among all non-recombinant group M subtypes.
These studies revealed subtype-specific differences in Nef function that were
associated with differences in Nef stability between subtypes. Further
investigation revealed unique subcellular distribution of the rarely studied
subtypes G and H. A low expressing Nef isolate of the globally predominant
subtype C was then analyzed using mutational and stability studies, identifying a
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previously undefined region in an alpha helix of Nef that is essential for protein
expression and function (299). These findings are found in chapter 2. In chapter
3, the molecular details of the recently defined Nef-meditated SERINC5
downregulation are elucidated. The microscopy technique BiFC was used to
demonstrate an in cellulo Nef:SERINC5 interaction, implicating key Nef protein
interaction motifs. The Nef:SERINC5 complex was then mapped throughout the
cell, highlighting the ability of Nef to hijack protein trafficking machinery, shuttling
SERINC5 to degradative compartments to favour HIV-1 replication. Mutational
analysis of SERINC5 shed light on the genetic determinants of the anti-infectivity
activity of this poorly understood HIV-1 restriction factor. From there, these
findings were placed in the context of the HIV-1 epidemic, investigating the
conservation and variation in SERINC5 downregulation among Nef isolates from
subtype C and A endemic regions.

1.14 Importance
HIV-1 Nef acts as a key pathogenic factor in disease progression. As such, it is
essential that we have a detailed understanding of the functions of Nef and how
they are influenced by genetic diversity. As HIV/AIDS decreases in prevalence
and incidence in North America, it is important that our understanding of the virus
takes into account the diversity of the epidemic and how it differs from the
subtype B-dominated infections in high-income countries. Furthermore, the
recent discovery of SERINC5 as an HIV-1 restriction factor and the role of Nef in
its antagonism opens novel avenues of research that need to be explored to fully
understand the pathogenic properties of Nef.
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Chapter 2

2

Impact of HIV-1 genetic diversity on Nef function and
expression from group M subtypes

2.1 Introduction
Despite vast improvements in our ability to prevent, detect and treat HIV/AIDS,
this chronic disease remains a major global health concern with over 36 million
infected individuals globally by the end of 2016 (1). One of the reasons a vaccine
and/or cure for HIV-1 has been so elusive is the extensive genetic diversity of the
virus (2, 3). Specifically, HIV-1 is divided into 4 groups that represent
independent zoonotic transmission of simian immunodeficiency virus (SIV) to
humans and share >70% nucleotide homology (4). The most globally prevalent
group is the HIV-1 Major group or group M, which accounts for approximately
90% of global infections. The three other groups, Non-M and Non-O or group N,
outlier group or group O and group P, which was named to conform to the
alphabetical nomenclature used previously, are responsible for the remaining
10% of HIV-1 infections, almost exclusively in central Africa. HIV-1 group M can
be further subdivided into subtypes named alphabetically A through K, with the
exception of E and I (5). Intersubtype variation can range up to 10-15%
difference in amino acid sequence when measured at the 3’ end of the HIV-1
genome (4). The prevalence rates of HIV-1 group M subtypes also vary, with
subtype B responsible for approximately 10% of the epidemic, whereas subtype
C was responsible for close to 50% or global infections in 2007 (6).
The identification of HIV-1 as the causative agent of AIDS in 1983 was confirmed
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by isolation of the virus from AIDS patients from France and the United States.
The virus isolated from these patients belonged to HIV-1 group M subtype B,
which is most prevalent in North America and Western Europe (7, 8). This virus,
or variants of it, has served as the model virus in much of the subsequent HIV-1
research, and as a result, there remains a gap in our understanding of how HIV-1
genetic diversity affects its biology. This gap in our understanding is particularly
evident in regards to subtypes that are found almost exclusively in central Africa.
As the epicenter of the HIV-1 pandemic, central Africa has the greatest diversity
in subtypes (6); however, there has been very little molecular research
conducted using these subtypes. Determining if genetic differences influence the
function of HIV-1 proteins may shed light on the differences in HIV-1 disease
progression in individuals infected with different subtypes.
The prominent role HIV-1 Nef plays in disease progression is striking given its
apparent lack of enzymatic activity (9). However, Nef is a multifunctional protein
capable of interacting with numerous cellular host proteins (10). Such a wide
array of protein-protein interactions enables Nef to alter T cell activation (11, 12),
increase

virion

infectivity

(13,

14),

modulate

membrane

trafficking

to

downregulate cell surface receptors (15), among other functions. The most well
studied functions of Nef are the downregulation of major histocompatibility
complex class I (MHC-I) (16-19) and CD4 receptors from the cell surface (20).
Downregulation of MHC-I by Nef prevents the detection of virally infected cells by
cytotoxic T-lymphocytes (CTLs) (21), whereas the removal of CD4 from the cell
surface by Nef limits killing of infected CD4+ T cells by antibody-dependent cell-
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mediated cytotoxicity (ADCC) (22, 23) and unfavorable superinfection, thereby
increasing viral dissemination (24).
In order to determine the impact of HIV-1 genetic diversity on the function of Nef,
we performed a functional analysis of representative reference strains from each
non-recombinant group M subtype. These proteins were analyzed for MHC-I and
CD4 downregulation. In addition, the cellular localization of these proteins was
investigated, as the multifunctional activity of Nef relies on its distinct subcellular
distribution allowing Nef to partake in protein-protein interactions.
Taken together, our studies revealed a striking variability in functionality between
Nef proteins from group M subtypes. Furthermore, defects in expression and
function appear to be related to aberrant subcellular distribution of Nef proteins.
These observations led us to focus subsequent investigations on the differences
in function between a subtype B and a subtype C Nef protein. Extensive
mutational analysis allowed us to identify three point mutations in the subtype C
Nef protein at otherwise highly conserved residues. These rare point mutations
were analyzed for their effects on Nef-mediated MHC-I and CD4 downregulation.
Interestingly, we were able to attribute a defect in Nef function to the stability of
Nef protein expression, highlighting the importance of these residues in proper
function of this key HIV-1 pathogenic factor.
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2.2 Methods
2.2.1

Cell Culture

CD4+ HeLa (ATCC, Manassas, VA) and HEK 293T cells (Life Technologies,
Carlsbad, CA) were grown in complete DMEM containing 10% FBS (Wisent,
Quebec, Canada), 100 U/ml penicillin and 100 µg/ml streptomycin (Hyclone,
Logan, UT). Jurkat E6.1 T cells (Catalog number 177; National Institutes of
Health, AIDS Research and Reference Reagent Program) were cultured in RPMI
1640 supplemented as above with the addition of 1% sodium pyruvate, 1% nonessential amino acids and 2 mM L-glutamine (Hyclone). All cell lines were grown
at 37°C in the presence of 5% CO2 and sub-cultured in accordance with
supplier’s recommendations.

2.2.2

Proviral plasmids and cloning strategy

The pNL4.3 ΔGag/Pol EGFP replication-incompetent HIV-1 proviral vector (25,
26) was used as the base template for modification into the viral expression
vector system. Primer overlap extension mutagenesis (27) was used to amplify
two fragments flanking the nef coding sequence in order to remove nef and insert
XmaI and NotI restriction sites, as described previously (26). Various nef coding
sequences were amplified from expression plasmids generously provided by Dr.
Thomas Smithgall (University of Pittsburgh School of Medicine) or synthetically
generated using Invitrogen GeneArt™ Synthesis (Thermo Fisher Scientific,
Waltham, MA). Subtype specific primers were used to introduce XmaI and NotI
sites on the 5’ and 3’ end of nef, respectively, enabling the insertion of nef
sequences into the pNL4.3 ΔGag/Pol EGFP vector. Nef Silent B was designed
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by introducing all synonymous mutations from Nef C.BR92025 into Nef B.JRFL
and matching the codon usage for all non-synonymous mutations between the
two proteins. Nef Silent C was designed similarly, but by introducing all
synonymous mutations from Nef B.JRFL into Nef C.BR92025 and matching
codon usage for all non-synonymous mutations.
The pNL4.3 ΔGag/Pol EGFP dVpu plasmids were constructed by inserting a vpu
gene that was mutated to contain a premature stop codon into the pNL4.3
ΔGag/Pol EGFP proviral vectors containing various nef sequences. Preexisting
EcoRI and BamHI restriction sites were used to transfer the mutated vpu
sequence from HIV-1NL4-3 vpu/nef/UD Deletion mutant (p230; NIH-AIDS reagents
catalog number 2535) vector into pNL4.3 ΔGag/Pol EGFP.
Nef-EGFP fusion protein plasmids were generated by inserting various nef
sequences into the pN1-EGFP (Takara, Mountain View, CA) expression plasmid.
pN1-EGFP was digested with AgeI and NotI and nef coding sequences were
introduced using subtype specific primers that added AgeI and NotI sites to the 5’
and 3’ ends of nef, respectively. pN1 RFP-KDEL was designed using PCR
subcloning to replace EGFP with RFP in a pN1 EGFP-KDEL plasmid kindly
provided by Dr. Ron Flannagan (Western University, London, ON).
Site-directed mutagenesis (28) was performed to generate point mutations in nef.
Mutagenic primers were designed using Agilent Technologies Primer Design
software and Agilent Technologies protocols (29) were used to introduce point
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mutations. Sequencing was performed at the Robarts Research Institute
Genomics Center to confirm all point mutations.

2.2.3

Nef Chimeras

Chimeric Nef proteins were constructed using a yeast recombination system
described previously (30). Briefly, PCR products from Nef B.JRFL and
C.BR92025 were amplified using one forward or reverse primer that bound
externally to the Nef open reading frame and an additional forward or reverse
primer that bound within the Nef open reading frame. Internal primers were
designed within the Nef coding sequence based on regions of high homology
between Nef from subtype B.JRFL and C.BR92025 to allow for recombination in
yeast. External primers remained unchanged, however, multiple sets of primers
within Nef were designed to allow for multiple junction points between the Nef
sequences form subtype B.JRFL and C.BR92025. These sets of primers were
used to produce various pairs of PCR products, one N-terminal fragment from
Nef B.JRFL and a corresponding C-terminal fragment form Nef C.BR92025, or
vice versa. A modified HIV-1 vector that had the Nef open reading frame
replaced with the selectable marker URA3 was used as the receiving vector.
Following transformation and recombination, yeast colonies were selected based
on growth on 5-Fluoroorotic acid containing media. Yeast DNA was purified and
used to electroporate competent bacteria to harvest DNA for downstream cloning
and assays. Triple and quadruple chimeric proteins (eg. Nef BCB and Nef CBCB)
were constructed using the same methodology, but with chimeric proteins used
as the template for PCR reactions.

79

2.2.4

Lentiviral production and processing

Lentiviral vectors were produced in HEK 293T cells. Cells were triple transfected
using PolyJet (FroggaBio, Toronto, ON) with pNL4.3 ΔGag/Pol EGFP Nef NL4.3
or the modified plasmids, as well as pdR8.2 and pMD2.G (pdR8.2 and pMD2.G
were provided by Didier Trono (Addgene plasmid #12263 and #12259,
respectively)) as previously described (31). Lentiviral vectors were harvested 48
hours post-transfection. Briefly, virus-containing media was centrifuged at 3 000
×g for 5 min to remove cellular debris and subsequently passed through a 0.2 µm
filter. Filtered supernatant was supplemented with an additional 20% FBS prior to
storage at -80°C.

2.2.5

Flow Cytometry

To quantify cell surface expression levels of MHC-I, Jurkat E6.1 cells were
infected with indicated viruses and fixed 48 hours later in 2% paraformaldehyde
(PFA). Cells were surface-stained for MHC-I using W6/32 (anti-MHC-I; panselective, provided by D. Johnson, Oregon Health and Sciences University).
Background fluorescence was verified using a no primary control, which revealed
a nil value. Cell surface MHC-I expression was quantified by flow cytometry (BD
FACSCanto II) and the data analyzed using FlowJo software (version 9.6.4,
Treestar, Ashland, OR). Infected cells were first gated by selecting for EGFP
positive cells and then MHC-I downregulation efficiency was calculated as
follows:
# MFI " MFI
&
exp
dNef
(( ) 100%
MHC " I downregulation efficiency (% of NL4.3) = %%
$ MFINL 4.3 " MFIdNef '

!

80

MHC-I downregulation efficiency was reported as a percent relative to NL4.3,
where 100% represents MHC-I downregulation efficiency equivalent to NL4.3
and 0% is equivalent to infection with a virus lacking Nef (dNef). MFIexp
represents the mean fluorescence intensity (MFI) of surface MHC-I in cells
infected with our experimental samples; MFIdNef represents surface MHC-I MFI in
cells infected with a virus that does not express Nef; and MFINL4.3 represents the
MFI of cells infected with our virus expressing NL4.3 Nef. For reference, NL4.3
Nef removed a median of 62±7% of MHC-I found on the cell surface when
compared to dNef.
Cell surface CD4 on Jurkat E6.1 cells was detected using the same protocol and
an allophycocyanin (APC)-conjugated anti-CD4 monoclonal antibody (clone,
OKT4, BioLegend, San Diego, CA). For reference, NL4.3 Nef removed a median
of 51±9% of CD4 found on the cell surface when compared to dVpu dNef.
To quantify cell surface CD4 on CD4+ HeLa cells, cells were collected 24 hours
post-transfection by washing with PBS and trypsinizing followed by fixation in 2%
PFA. Fixed cells were stained with an APC-conjugated OKT4 and analyzed by
flow cytometry (BD FACSCanto II) and the FlowJo software. Transfected cells
were first gated on EGFP positive cells and then CD4 downregulation efficiency
was calculated as follows:
# MFIexp " MFIEGFP &
CD4 downregulation efficiency (% of NL4.3) = %
( ) 100%
$ MFINL 4.3 " MFIEGFP '

!
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CD4 downregulation efficiency is reported as a percent relative to NL4.3, where
100% represents CD4 downregulation efficiency equivalent to NL4.3 and 0% is
equivalent to transfection with a plasmid expressing EGFP alone. MFIexp
represents the mean fluorescence intensity of surface CD4 in cells transfected
with our experimental samples. MFIEGFP represents mean fluorescence intensity
of surface CD4 in cells transfected with a plasmid expressing EGFP alone.
MFINL4.3 represents the mean fluorescence intensity of cells transfected with a
plasmid expressing Nef NL4.3-EGFP. For reference, NL4.3 Nef-EGFP removed
89±2% of CD4 found on the cell surface when compared to EGFP alone.

2.2.6

Western Blots

Infected Jurkat E6.1 cells or transfected CD4+ HeLa cells were collected at 48 or
24 hours, respectively, and lysed in lysis buffer (25 mM HEPES, 300 mM NaCl,
1.5 mM MgCl2, 0.2 mM EDTA, 0.1% Triton X-100 and 1× complete Protease
inhibitor Tablets (Roche, Indianapolis, IN)). Cells were lysed at 4°C while rotating
for 20 min before insoluble cellular debris was removed by centrifugation at 20
000 ×g for 20 min. Lysates were boiled at 98°C in 5× SDS-PAGE sample buffer
(0.312 M Tris pH 6.8, 25% 2-mercaptoethanol, 50% glycerol, 10% SDS) and
proteins were separated on 12% SDS-PAGE gels and subsequently transferred
to nitrocellulose membranes. Membranes were blocked in 5% non-fat skimmed
milk (Bioshop, Burlington, Ontario, Canada) in TBS containing 0.1% Triton X-100
for 45 min, then incubated overnight at 4°C with various primary antibodies:
rabbit anti-Nef polyclonal antibody (1:2500; catalog number 2949, NIH AIDS
Research and Reference Reagent Program, USA), rabbit anti-GFP polyclonal
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antibody (1:3000; Clontech; Takara), or mouse anti-β-actin monoclonal IgG
(1:3000; Thermo Fisher Scientific, Waltham, MA). Membranes were washed 3
times in TBS containing 0.1% Triton X-100 and incubated for 2 hours at room
temperature with the appropriate species-specific HRP-conjugated antibodies
(1:3000; Thermo Fisher Scientific, Waltham, MA). Blots were developed using
ECL substrates (Millipore Inc., Billerica, MA) and a C-DiGit chemiluminescence
western blot scanner (LI-COR Biosciences, Lincoln, NE).

2.2.7

Quantitative Reverse Transcriptase PCR (qRT-PCR)

Jurkat E6.1 cells were infected with various lentiviral vectors at equivalent
infection rates based on EGFP fluorescence. RNA was collected from infected
Jurkat E6.1 cells 48 hours post-infection using PureLink® RNA Mini Kit (Thermo
Fisher Scientific, Waltham, MA) and stored at -80°C. Purified RNA was reverse
transcribed into bulk cDNA using SuperScript® III First-Strand Synthesis System.
cDNA was used as a template for qRT-PCR with SensiFAST™ SYBR No-ROX
Kit (FroggaBio, Toronto, ON) to amplify Env and Nef specific amplicons using the
following primers: common Env and Nef fwd 5’ – GGCGGCGACTGAAGAAG,
Env

rev

5’

–

ACTATGGACCACACAACTATTGCT,

Nef

rev

5’

–

GATTGGGAGGTGGGTTGCT. qRT-PCR runs were run on a Rotor-Gene 6000
(Qiagen, Valencia, CA) with the following conditions: 1 cycle at 95°C for 2 min for
polyermase activation, 40 cycles at 95°C for 5 s for denaturation, 60°C for 10 s
for annealing, 72°C for 15 s for extension. Relative levels of Nef and Env mRNA
were calculated from standard curves generated from plasmids encoding the
respective genes at known concentrations.
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2.2.8

Transfections and Microscopy

CD4+ HeLa cells were seeded onto coverslips at 5×105 cells/coverslip 24 hours
prior to transfection. The respective plasmids were transfected into CD4+ HeLa
cells at a concentration of 400 ng/µL using PolyJet (FroggaBio, Toronto, ON).
Cells were washed three times with PBS 24 hours post-transfection before
fixation in 4% PFA for 20 minutes at room temperature. Cells were blocked in 5%
Bovine Serum Albumin/PBS containing 0.01% Triton X-100 for 1 hour prior to
immunostaining. Cells were washed twice with PBS before immunostaining (if
required). Primary antibodies were diluted in 5% Bovine Serum Albumin/PBS
containing 0.01% Triton X-100 and cells were stained with respective antibodies
for 2 hours. Primary antibodies include mouse anti-TGN46 (1:100; Sigma Aldrich.
Clone TGN46-8), mouse anti-CD63 (1:200, Developmental Studies Hybridoma
Bank. Clone H5C6), mouse anti-LAMP1 (1:200, Developmental Studies
Hybridoma Bank. Clone H4A3). Secondary antibodies were diluted (1:400) in 5%
Bovine Serum Albumin/PBS containing 0.01% Triton X-100 and cells were
stained for 2 hours. Secondary antibodies include Alexa Fluor® 647 goat-antimouse (Jackson ImmunoResearch, West Grove, PA) and Alexa Fluor® 647
donkey anti-rabbit (Jackson ImmunoResearch West Grove, PA). Mitochondria
were stained using 100 nM of MitoTracker® Deep Red FM (Thermo Fisher
Scientific, Waltham, MA) for 30 minutes prior to washing with PBS and fixation as
above. After immunostaining, coverslips were mounted on slides using
Fluormount-G or DAPI-Fluoromount-G (Southern Biotech, Birmingham, AL).
Cells were imaged on a Leica DMI6000 B at 100× objective settings using the
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Hamamatsu Orcaflash 4.0 Camera. Images were deconvolved using the Leica
Application Suite software. Co-localization analysis was conducted using the
Pearson Correlation from the Image J plugin (32).

2.2.9

Proteasome Inhibition

Proteasomal inhibition was performed on infected Jurkat E6.1 T cells. MG132
(Sigma-Aldrich, St. Louis, MO) was dissolved in DMSO to a stock concentration
of 10 mM and diluted in RPMI to the desired working concentrations. Cells were
pelleted and washed with PBS prior to resuspension and incubation with MG132containing media or media containing DMSO as the vehicle control. Cells were
incubated for the indicated times and lysed at 48 hours post-infection.

2.2.10

Pulse-chase

Jurkat E6.1 cells were infected with specific lentiviruses for 48 hours postinfection and subsequently incubated in starvation media (DMEM lacking Lcysteine and L-methionine supplemented with 5% Gibco® Dialyzed Fetal Bovine
Serum (Thermo Fisher Scientific, Waltham, MA) and Gibco® GlutaMAX™) for 30
min. Starvation media was removed and cells were pulsed with pulse media
(starvation media supplemented with EXPRE35S35 Protein Labeling Mix [35S]
(Perkin Elmer, Guelph, Ontario, Canada) at 55µCi/mL) for 30 min. Cells were
washed with complete RPMI supplemented with 20% FBS and then chased with
the same media for 0, 30, 120 or 240 min at 37ºC. After the chase period, cells
were lysed in 800 µL of RIPA-Doc buffer (140 mM NaCl, 10 mM NaH2PO4, 1%
Triton X-100, 0.05% sodium dodecyl sulfate, 0.5% sodium deoxycholate) by
rocking at 4°C for 10 min followed by centrifugation at 20 000 ×g at 4°C for 10
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min.

Following

centrifugation

the

supernatant

was

removed

and

immunoprecipitated by incubation with anti-Nef (cat: 2949; NIH AIDS Reagent
Program) conjugated Protein-A agarose beads (Sigma-Aldrich, St. Louis, MO)
overnight at 4°C while rocking. Agarose beads were then washed twice with 1
mL of RIPA-Doc and resuspended in 20 µL of 5× SDS loading buffer prior to
boiling for 5-10 min at 95°C. Proteins were separated by SDS-PAGE on a 12%
gel followed by fixation (50% methanol, 10% acetic acid in water) for 5-10 min.
Gels were dried for 2 hours onto whatman paper using a Model 583 Gel Dryer
(BioRad, Hercules, CA) and the autoradiography signal was captured by placing
the dried gel in a phosphor storage cassette for 48 hours and developing on a
Storm 820 Phosphoimager (GE Healthcare, Chicago, IL). ImageQuant 5.2 (GE
Healthcare) software was used to quantify band intensity.

2.2.11

Sequence Logo Generation

Sequence

logos

were

generated

using

WebLogo

software

(http://weblogo.berkeley.edu/logo.cgi) with the input sequences collected from
the NIH Los Alamos Database. Sequences were selected from each country that
contained a given subtype, with a maximum of 10 sequences selected from each
country. Sequences were then screened for any large deletions or incomplete
sequences. Residues in the sequence logos were colored based on Clustal
Omega (33, 34) sequence alignments; residues in blue are acidic amino acids,
residues in pink are basic amino acids, residues in red are uncharged non-polar
amino acids and those in green are uncharged polar amino acids. Frequency of
polymorphisms at positions 13, 84 and 92 were determined using the
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AnalyzeAlign tool found at the Los Alamos HIV Database to query 4553 fulllength Nef protein sequences selected using their Filtered Web Search
(http://www.hiv.lanl.gov/content/index).

2.2.12

Structural Modeling

Mac PyMOL 3 software (Schröinger, New York, NY) was used to construct
structural models depicting Nef residues W13 and A84 (PDB ID: 4EN2) (35).

2.2.13

Statistical Analysis

Statistical analysis was conducted using GraphPad Prism software (GraphPad
Software, Inc., La Jolla, CA). Downregulation and qRT-PCR data was analyzed
by one-way ANOVA, while pulse-chase data was analyzed by one-phase decay
non-linear regression.

2.3 Results
2.3.1

Known functional motifs in HIV-1 Nef are conserved across
group M subtypes.

To investigate potential differences in Nef function among group M subtypes we
compiled a set of reference strains representing subtypes A1, A2, B, C, F1, F2,
G, H and K, selected from Los Alamos National Laboratory’s HIV Sequence
compendium (36) and a subtype D consensus sequence. These proteins were
compared to the commonly used laboratory strain NL4.3, which is a laboratory
adapted HIV-1 strain that was generated from intentional recombination of the
two subtype B isolates, IIIB/LAI and NY5 (37). These subtype reference strains
were aligned with NL4.3 to identify any differences in known Nef functional motifs
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(Figure 2.1). We were primarily interested in motifs that have been
experimentally shown to be involved in the ability of HIV-1 Nef to downregulate
CD4 and MHC-I, the best described functions of Nef.
Common to essentially all Nef functions is the need for Nef to be cotranslationally modified at its amino-terminus by the addition of a myristoyl group,
a fatty acid moiety that allows for membrane association in infected cells. In Nef,
this myristolyation occurs on a glycine at residue 2 (G2), which is completely
conserved among the reference strains we analyzed (Figure 2.1). In addition,
there was a high degree of conservation in most Nef functional motifs, with those
responsible for the interaction of Nef with the cytoplasmic tail of CD4 (WL57) (38),
the interaction with SFKs (P72xxP75) (39, 40), and AP-2 interaction (LL165) (41)
being 100% conserved between the analyzed subtypes. Other motifs known to
be involved in MHC-I and CD4 downregulation were also highly conserved with
substitutions that maintain polarity and/or size. These include motifs mediating
interaction with AP-1 (M20) (35) and PACS-1/2 (EEEE65) (19, 42), which are
involved in MHC-I downregulation and motifs mediating interaction with Pak2
kinase (RR105) (43) and the vacuolar ATPase (DD177) (44, 45), which are involved
in CD4 downregulation. Notably, a tyrosine at position 120, Y120, which is
required for optimal PACS-1 binding and therefore MHC-I downregulation (19),
showed the most variability with Nef subtypes D, G and K having a phenylalanine
in lieu of tyrosine.

88

NL4.3
A1.SE94
A2.97CDKTB48
B.JRFL
C.BR92025
D (Consensus)
F1.BE93VI850
F2.CM95MP257
G.FI93HH8793
H.BE93VI997
J.SE93SE7887
K.CD97EQTB11C

MGGKWSKSSVIGWPAVRERMRRAE----------PAAD----------GVGAVSRDLEKH
MGSKWSKSSIVGWREVRERLRQTL----------AAARG----------VGAVSQDLEKY
MGGKWSKRTIVGWPEIRERMRRTPPAAEGVRPTPPAAEG----------VGAVSQDLARH
MGGKWSKRSVPGWSTVRERMRRAE----------PAADRVRRTEPAAVGVGAVSRDLEKH
MGNKWSKCSTVGRPAIRERMRRAP-----------AAEG----------VGPASQDSDKY
MGGKWSKSSIVGWPAIRERIRRTE----------PAAD----------GVGAVSRDLEKH
MGGKWSKSSIVGWPAVGERMRQTP----------TAAEG----------VGAVSRDLDRR
MGGKWSKSSIVGWPAIRERIR--------------AAEG----------VGAVSQDLDKR
MGGKWSKR---GWPAVRERIRQTP-----IRQTPPAAEG----------VGAVSQDLARH
MGGKWSKSSIVGWPAVRERIRRAQ----------PAADG----------VGAVSRDLDRR
MGNKWSKS----WPQVRERMRRAPA---------PAADG----------VGAVSQDLAKH
MGGKWSKSSIVGWSTVRERMRKTP----------PAADG----------VGAVSQDLDKH
**.****
: **:*
**
**..*:* :

40
40
50
50
39
40
40
36
42
40
37
40

NL4.3
A1.SE94
A2.97CDKTB48
B.JRFL
C.BR92025
D (Consensus)
F1.BE93VI850
F2.CM95MP257
G.FI93HH8793
H.BE93VI997
J.SE93SE7887
K.CD97EQTB11C

GAITSSNTAANNAACAWLEAQEE-EEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEG
GAVTSSN--VNHPSCAWLEAQEEEE-VGFPVRPHVPLRPMTYKGALDLSHFLKEKGGLDG
GAVTSSNTAANNPDCAWLEAQEEE-EVGFPVRPQVPLRAMTYKGAVDLSHFLKEKGGLDG
GAITSSNTAATNADCAWLEAQED-EEVGFPVRPQVPLRPMTYKGAVDLSHFLKEKGGLEG
GALTSSSTPANNADCAWLEAQQEEEEVGFPVRPQVPLRPMTYKAVVDLSFFLEEKGGLEG
GAITSSNTAATNADCAWLEAQEEDEEVGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLEG
GAITSSNTRTTNPDLAWLEAQEEEE-VGFPVRPQVPVRPMTYKAAVDLSHFLKEKGGLEG
GAITNSNTGATNADLAWLEAQEEE--VGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLEG
GAITSSNTATNNPDCAWLEAQEEDSEVGFPVRPQVPVRPMTYKAAFDLSFFLKEKGGLDG
GAVTINNTAATNPDVAWLEAQEEAEEVGFPVRPQVPLRPMTYKAALDLSHFLKEKGGLDG
GAITSSNTAATNADCAWLEAQTEE-EVGFPVKPQIPLRPMTYKGAVDLSFFLKEKGGLDG
GAVTSSNTAFNNPDCAWLEAQEDE-DVGFPVRPQVPLRPMTFKGAFDLGFFLKEKGGLDG
**:* ..
.:. ****** :
***** *::*:*.**:*...**..**:*****:*

99
97
109
109
99
100
99
94
102
100
96
99

NL4.3
A1.SE94
A2.97CDKTB48
B.JRFL
C.BR92025
D (Consensus)
F1.BE93VI850
F2.CM95MP257
G.FI93HH8793
H.BE93VI997
J.SE93SE7887
K.CD97EQTB11C

LIHSQRRQDILDLWIYHTQGYFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKG
LIYSRRRQEILDLWVYNTQGYFPDWQNYTPGPGVRYPLTFGWCFKLVPVDPDEVEQANEG
LIYSQRRQDILDLWVYNTQGYFPDWQNYTPGPGARFPLTFGWCFKLVPVDPSEVEEATEG
LIHSQKRQDILDLWVYHTQGYFPDWQNYTPGPGIRFPLTFGWCFKLVPVEPEKVEEANEG
LIYSKKRQDILDLWVYNTQGYFPDWQNYTPGPGVRFPLTFGWCFKLVPVDPREVEEANTG
LVWSQKRQEILDLWVYNTQGFFPDWQNYTPGPGIRYPLTFGWCFELVPVDPEEVEEATEG
LIYSKKRGDTLDLWVYHTQGYFPDWQNYTPGPGIRYPLTLGWCFKLVPVDPEEVEKANEG
LIYSRKRQEILDLWVYHTQGYFPDWQNYTPGPGPRFPLTFGWCFKLVPVDPEEVEKANEG
LIYSKKRQDILDLWVYNTQGFFPDWQNYTPGPGTRLPLTFGWCLKLVPVDPAVVEEATTE
LIYSKKRQEILDLWVYNTQGYFPDWQNYTPGPGEGYPLTFGWCFKLIPVDPQEVERANEG
LIYSKKRQEILDLWVHNTQGYFPDWQNYTPGPGIRYPLTFGWCYKLVPVDPSEVEEANEG
LIYSKRRQEILDLWVYHTQGFFPDWQNYTPGPGIRYPLTFGWCYKLVPVDPREVEEATEG
*: *::* : ****:::***:************
***:*** :*:**:* **.*.

159
157
169
169
159
160
159
154
162
160
156
159

NL4.3
A1.SE94
A2.97CDKTB48
B.JRFL
C.BR92025
D (Consensus)
F1.BE93VI850
F2.CM95MP257
G.FI93HH8793
H.BE93VI997
J.SE93SE7887
K.CD97EQTB11C

ENTSLLHPVSLHGMDDPEREVLEWRFDSRLAFHHVARELHPEYFKNCENNSLLHPMCQHGMDDEEKETLRWRFDSRLALRHRAQEMHPEFYKDCENNSLLHPICQHGAEDPEREVLKWKFDSRLALRHLAREQHPEFYKDCENNCLLHPMSQHGIEDPEKEVLEWRFDSKLAFHHVARELHPEYYKDCG
ENNSLLHPMSLHGMEDSHREVLQWKFDSLLARRHMARELHPEYYKDCENNCLLHPMCQHGMEDPEREVLMWRFNSRLAFEHKARVLHPEFYKDCENNCLLHPMSQHGMEDEDREVLRWKFDSSLALRHIARERHPEFYQD-ENNCLLHPMSLHGMEDDDKEVLKWQFDSRLALRHIARERHPEYYKD-ENNSLLHPIWQHGMEDEDREVLIWRFDSSLARRHLARELHPEFYKNCENNCLLYPICQHGMEDEEGEVLMWKFDSRLAFTHTAREKHPEFYKDCENNCLLHPICQHGIEDEEREVLQWKFDSSLARRHIARELHPEFYKDCENNCLLHPVNQHGMEDEHREVLKWKFDSSLARKHVAREMHPEYYKDC**..**:*: ** :* . *.* *:*:* ** * *: ***::::

206
204
216
217
206
207
205
200
209
207
203
206

Figure 2.1 Sequence alignment of Nef proteins from HIV-1 group M
reference strains.
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Clustal Omega (33, 34) was used to align protein amino acid sequences of Nef
from the laboratory strain NL4.3, or reference strains from subtypes A1, A2, B, C,
F1, F2, G, H, J, and K, as well as a consensus sequence of subtype D from the
NIH AIDS Los Alamos Database. Dotted boxes highlight motifs implicated in both
CD4 and MHC-I downregulation. Solid boxes highlight motifs implicated in MHC-I
downregulation.

Dashed

boxes

highlight

motifs

implicated

in

CD4

downregulation. “*” indicates identical residues, “:” indicates conserved residues,
“.” indicates semiconserved residues. Residues in blue are acidic amino acids,
residues in pink are basic amino acids, residues in red are uncharged non-polar
amino acids and those in green are uncharged polar amino acids.

2.3.2

Group M subtypes differ in their ability to downregulate CD4.

In order to determine if the genetic variability present between group M subtypes
impacted the function of HIV-1 Nef, we tested HIV-1 group M reference
sequences for two key Nef functions.

To test Nef-dependent CD4

downregulation, we constructed a set of mammalian expression plasmids
encoding Nef-EGFP fusion proteins to express Nef in CD4+ HeLa cells. Nef was
expressed outside the context of other HIV-1 proteins to isolate the effect of Nef
on surface CD4 levels, as other HIV-1 proteins are also able to downregulate
CD4 (Figure 2.2A). Accordingly, CD4+ HeLa cells were transfected with NefEGFP plasmids and analyzed for cell surface CD4 levels at 24 hours posttransfection. CD4 downregulation in cells expressing Nef from the various
subtypes was normalized to cells expressing the laboratory adapted NL4.3
subtype B strain. CD4 downregulation was well conserved across group M
subtypes with the exceptions of subtypes C, G and H, which had significantly
decreased CD4 downregulation efficiency. Subtype C Nef displayed a CD4
downregulation efficiency 60% of NL4.3, while subtype G and H had a
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downregulation efficiency just over 25% of NL4.3 (Figure 2.2B, C).
To explore potential causes of the decreased CD4 downregulation in subtypes C,
G and H, we investigated the expression of the various Nef proteins following
transfections in CD4+ HeLa cells. Surprisingly, subtypes C, G and H showed a
marked decrease in Nef protein expression by western blot (Figure 2.2D). This
variable expression occurred despite nef being expressed from identical
plasmids encoding high expression promoters (Figure 2.2A). In addition, the
fusion proteins were detected using an anti-GFP antibody ruling out antibody
binding differences between subtypes.
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Figure 2.2 Nef proteins from group M reference strains differ in CD4
downregulation.
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(A) Schematic of pN1 Nef-EGFP plasmids that express Nef-EGFP fusion
proteins from HIV-1 group M subtype reference strains driven by a CMV
promotor. (B) CD4+ HeLa cells were transfected with plasmids expressing EGFP
or various Nef-EGFP fusion proteins and stained for cell surface CD4 24 hours
post-transfection. Cell surface CD4 was measured by flow cytometry. A
representative histogram is shown. (C) CD4 downregulation was quantified and
calculated relative to NL4.3 (green) (n≥5, p<0.05). (D) CD4+ HeLa cells were
transfected with plasmids expressing EGFP or various Nef-EGFP fusion proteins
and lysed at 24 hours post-transfection. Lysed cells were analyzed for Nef-EGFP
and actin protein expression by western blot.

2.3.3

Group M subtypes also differ in their ability to downregulate
MHC-I.

We next investigated Nef-mediated downregulation of MHC-I utilizing a modified
viral vector system to infect the CD4+ T-cell line, Jurkat E6.1. Multiple HIV-1
proteins, Nef, Env and Vpu, modulate cell surface levels of CD4, whereas
differences in cell surface MHC-I levels are predominantly determined by the
actions of Nef upon infection (15). As a result, we were able to use an infection
model to investigate MHC-I downregulation (Figure 2.3A), rather than the
transfection model used to test CD4 downregulation (Figure 2.2A). Accordingly,
HIV-1 group M Nef reference sequences (Figure 2.1) were inserted into an
NL4.3-based replication incompetent HIV-1 lentiviral vector that expresses EGFP
(Figure 2.2A) and can be pseudotyped with the envelope protein from vesicular
stomatitis virus (31). This system allows for us to better recapitulate an HIV-1
infected cell while measuring MHC-I levels.
To test Nef-mediated MHC-I downregulation, Jurkat E6.1 cells were infected with
pseudoviruses expressing Nef from various subtypes for 48 hours and then
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analyzed for cell surface levels of MHC-I by flow cytometry. In contrast to CD4,
Nef proteins from different subtypes displayed more variability in their ability to
downregulate MHC-I (Figure 2.3B, C). As observed, for CD4 downregulation, Nef
from subtypes C, G and H showed a significantly decreased ability to
downregulate MHC-I. However, unlike with CD4 downregulation, subtype A2 and
F1 also had a decreased ability to downregulate MHC-I (Figure 2.3C). Analysis of
MHC-I downregulation efficiencies revealed that subtypes A2, C, F1, G and H all
had significantly decreased downregulation efficiency compared to the laboratory
adapted subtype B strain NL4.3. It should be noted that subtypes A2 and F1 still
maintained roughly 80% of NL4.3 activity, while subtypes C and G had below
25% of NL4.3 activity and subtype H had just over 50% (Figure 2.3C).
We once again explored Nef expression at the protein level as a possible cause
for the observed differences in MHC-I downregulation across the tested
subtypes. As expected, we were able to detect robust protein expression for Nef
NL4.3 while no Nef protein was detected upon infection of Jurkat E6.1 cells with
a virus that fails to express Nef (Figure 2.3D; NL4.3 and dNef, respectively).
Moreover, bands corresponding to Nef were also detectable from Jurkat E6.1 T
cells infected with viruses encoding Nef from subtypes A1, A2, B, D, F1 and F2,
whereas subtype C, G, H and K infections resulted in little to no detection of Nef
protein expression (Figure 2.2D). In contrast with the Nef-EGFP fusion proteins
analyzed for CD4 downregulation (figure 2.3D), a polyclonal anti-Nef antibody
was used to detect Nef protein expression. Moreover, to control for any possible
differences in infection rates between viruses encoding the various Nef proteins
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we also measured EGFP proteins levels by western blot. EGFP is expressed
from the virus, but from a differentially spliced mRNA, providing an independent
marker of infection rates. Accordingly, we did not observe any striking differences
in GFP protein expression across subtypes (Figure 2.3D), suggesting all cells
were infected at similar rates and differences in Nef levels were intrinsic to the
protein.
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Figure 2.3 Nef proteins from group M reference strains also differ in MHC-I
downregulation.
(A) Schematic of pNL4-3 ΔGag/Pol EGFP proviral vector that was used as a
template to generate pseudovirus expressing group M subtype reference strains.
(B) Jurkat E6.1 T cells were infected with pseudovirus expressing Nef proteins
from various group M subtype reference strains. At 48 hours post-infection, cells
were stained for cell surface MHC-I and analyzed by flow cytometry. A
representative histogram with an IgG isotype control is shown. (C) MHC-I
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downregulation was quantified and calculated relative to NL4.3 (green) (n≥5,
p<0.05). (D) Jurkat E6.1 T cells were infected with pseudoviruses expressing Nef
proteins from various group M subtype reference strains. At 48 hours postinfection, cells were lysed and analyzed for Nef, GFP and actin protein
expression by western blot.

2.3.4

Nef from Subtype C, G and H reference strains demonstrate
abnormal expression and subcellular localization.

Nef proteins from reference strains representing group M subtypes C, G, and H
consistently showed decreased ability to downregulate CD4 and MHC-I, which
appeared to be due to decreased steady-state levels of Nef (Figures 2.2 and
2.3). To further explore the cause of these observed differences, we next
measured levels of HIV-1 Nef mRNA transcripts from pseudovirus infected cells.
Jurkat E6.1 T cells infected with HIV-1 pseudovirus encoding Nef from NL4.3 or
subtype B, C, G or H reference strains were harvested 48 hours post-infection
and bulk mRNA was collected from cell lysates. Upon qRT-PCR analysis, NL4.3
and subtypes B, C, G and H all showed equivalent mRNA levels, suggesting
differences in protein expression occur post-transcription (Figure 2.4A).
To gain a better understanding of what was leading to the decreased function
and expression of Nef proteins from subtypes C, G and H, we investigated the
subtype reference strains for their subcellular localization. Indeed, the proper
subcellular localization of HIV-1 Nef is essential for its function (46), while
aberrant localization of Nef to one of various subcellular locales used to degrade
proteins may provide insight to the cause of decreased Nef protein expression.
Due to its interaction with the cargo sorting proteins PACS-1 and -2, HIV-1 Nef is
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known to display a paranuclear distribution when expressed in cells, co-localizing
with the trans-Golgi network (TGN) (19, 47). To determine if Nef proteins from
group M subtype reference strains differed in their subcellular localization we
visualized, by fluorescence microscopy, CD4+ HeLa cells transfected with NefEGFP fusion proteins and co-stained for the trans-Golgi marker TGN46 (Figure
2.4B) (48). Interestingly, Nef from subtype G and H displayed a distinct
subcellular distribution when compared to the other Nef proteins analyzed
(Figure 2.4B; NL4.3, subtype B, C and G shown). Nef from subtype G and H
were more evenly distributed throughout transfected cells in a somewhat
reticulated pattern (Figure 2.4B). Nef from the subtype C reference strain, the
other low expressing Nef protein we identified, appeared to display a more typical
paranuclear subcellular distribution, albeit at a decreased fluorescence intensity
(Figure 2.4B).
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Figure 2.4 Abnormal cellular distribution of Nef proteins from subytpe C, G
and H reference strains.
(A) Jurkat E6.1 T cells were uninfected (UI) or infected with lentiviral vectors
encoding Nef from the laboratory strain NL4.3 or Nef from the subtype reference
strains B, C, G or H. At 48 hours post-infection, mRNA was isolated from the
cells and used for quantitative reverse transcriptase PCR (qRT-PCR). Levels of
Nef specific mRNA are shown relative to levels of HIV-1 Env specific mRNA
(p<0.05, n=2). (B) CD4+ HeLa cells were transfected with various Nef-EGFP
fusion plasmids. Cells were fixed in 4% PFA, immunostained for TGN46, and
imaged on a Leica DMI6000 widefield microscope on the 100X objective; scale
bar = 10µm, green=Nef-EGFP, red=TGN46. (C) Images were deconvolved and
co-localization analysis was completed using the Pearson’s Correlation with the
Image J plugin.
These visual observations were supported by quantification using Pearson’s
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correlation coefficient, a measure of the co-localization between two proteins
(32). Indeed, Nef proteins from group M subtypes co-localized with TGN46 to
varying degrees, ranging from a Pearson’s correlation of 0.60 for NL4.3 Nef to
0.11 for Nef from the subtype H reference strain (Figure 2.4C). Only Nef proteins
from subtypes F1 and F2 displayed a TGN46 co-localization not significantly
lower than NL4.3, but strikingly subtype G and H had the lowest Pearson’s
correlation, 0.15 and 0.11, respectively (Figure 2.4C). Notably, subtypes G and H
had Pearson’s correlations significantly lower than the next lowest subtype, A1;
Pearson’s correlation of 0.26, suggesting subtype G and H displayed an
abnormal subcellular distribution relative to the HIV-1 group M reference strains
that we analyzed (Figure 2.4B, C). As expected, Nef from subtype C
demonstrated moderate co-localization with TGN46 (Figure 2.4B, C; Pearson’s
correlation of 0.36), not significantly different than the functional Nef proteins
from subtype A2 and K reference strains.

2.3.5

Low expressing Nef subtype C, G and H do not undergo
proteasomal degradation.

Due to the decreased protein levels we observed for Nef proteins from subtype
C, G and H reference strains (Figure 2.2 and 2.3), we hypothesized that these
proteins may be being targeted for degradation by cellular cytosolic processes
that mediate the degradation of proteins (49). To test this hypothesis, we first
used the proteasomal inhibitor MG132 to potentially rescue Nef proteins from
subtype C, G and H and delineate if these proteins are degraded via the
proteasomal pathway. Thus, Jurkat E6.1 T cells were infected with viruses
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encoding Nef from NL4.3 or subtype C and treated with 10 µM of MG132 for 0, 2,
4, or 8 hours immediately prior to collection and lysis at 48 hours post-infection.
Lysed cells were then assayed for Nef expression by western blot (Figure 2.5).
Inhibition of the proteasomal degradation pathway did not increase detectable
levels of Nef from the subtype C reference strain, with the most prominent band
corresponding to Nef occurring in the absence of MG132 (Figure 2.5A; 0 hours).
Alternatively, Jurkat E6.1 T cells were infected with viruses encoding Nef from
NL4.3 or subtype G or H and treated with varying concentrations of MG132 for 6
hours immediately prior to collection and lysis at 48 hours post-infection.
Intracellular content of the lysed cells was then analyzed by western blot. As with
previous experiments (Figure 2.2 and 2.3), we were unable to detect robust
protein expression for Nef proteins from subtype G and H, whereas Nef from
NL4.3 was readily detectable (Figure 2.5B, C). Upon treatment with 0, 5, 10 or 20
µM of MG132, there was no observable change in protein levels of any of the Nef
proteins investigated (Figure 2.5B, C). Taken together, these findings suggest
that the decreased levels of Nef from subtype C, G and H reference strains are
not due to degradation of these viral proteins by the proteasome.
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Figure 2.5 Subtype C, G and H expression is not rescued by proteasomal
inhibition.
(A) Uninfected (UI) or Jurkat E6.1 T cells infected with pseudoviruses encoding
Nef from subtype B or C reference strains were treated with 10 µM of the
proteasomal inhibitor MG132 for 0, 2, 4, or 8 hours prior to collection and lysis at
48 hours post-infection. Cell lysates were analyzed for Nef, GFP and actin
protein expression by western blot. (B) Jurkat E6.1 T cells infected were infected
with pseudovirus encoding Nef from NL4.3 or subtype G (B) or H (C) reference
strains. At 42 hours post-infection, infected cells were treated with 0, 5, 10 or 20
µM of the proteasomal inhibitor MG132 for 6 hours prior to collection and lysis at
48 hours post-infection. Cell lysates were analyzed for Nef, GFP and actin
protein expression by western blot.

2.3.6

Low expressing Nef subtype C, G and H are not targeted to
a lysosomal or multivesicular bodies compartment.

In addition to degradation by the proteasome, decreased expression of cytosolic
proteins can be due to their uptake into the endosomal network within cells (50).
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Proteins can be internalized and removed from cells either via degradation in
lysosomal compartments or secreted in exosomes via a CD63 dependent
mechanism (50). To investigate these potential routes of protein removal as the
cause of decreased Nef expression, we imaged CD4+ HeLa cells transfected with
Nef-EGFP fusion proteins from HIV-1 subtype B, C, G and H reference strains.
Transfected cells were then co-stained with lysosomal-associated membrane
protein 1 (LAMP-1) or CD63, markers of the lysosome (51) and exosome (52)
pathways, respectively. As previously observed, Nef proteins from subtype G and
H displayed a distinct subcellular distribution (Figure 2.4B), however, these
proteins did not appear to be localized to either LAMP-1 or CD63 positive
compartments (Figure 2.6A, C). When LAMP-1 co-localization was quantified, all
subtypes had a Pearson’s correlation less than 0.22 (Figure 2.6B). Nef from
subtype B and C had increased co-localization relative to subtype G and H, but
their low absolute co-localization values suggest they only had a weak colocalization with the lysomsomal compartment (Figure 2.6B). Quantification of
Nef/CD63 co-localization supported the fluorescence microscopy, with subtypes
G and H having low Pearson’s correlations of 0.10 and 0.16, respectively.
Subtype C had an elevated Pearson’s correlation of 0.42. This increased colocalization was also seen for subtype B (Figure 2.6C, D; Pearson’s correlation of
0.36), making the exosomal pathway an unlikely explanation of its low protein
expression.
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Figure 2.6 Nef subtype C, G, and H are not preferentially removed via the
endosomal network.
(A) CD4+ HeLa cells were transfected with various plasmids encoding Nef-EGFP
fusion

proteins

from

different

HIV-1

subtype

reference

strains,

and

immunostained for LAMP-1. Cells were fixed in 4% paraformaldehyde and
imaged on a Leica DMI6000 B widefield microscope on the 100× objective; scale
bar = 10 µm, green=Nef-EGFP, red=LAMP-1. (B) Images were deconvolved and
co-localization analysis was completed using the Pearson’s correlation with the
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Image J plugin. (C) CD4+ HeLa cells were transfected with various plasmids
encoding Nef-EGFP fusion proteins from different HIV-1 subtype reference
strains, and immunostained for CD63. Cells were fixed in 4% PFA and imaged
on a Leica DMI6000 B widefield microscope on the 100× objective; scale bar =
10 µm, green = Nef-EGFP, red = CD63. (D) Images were deconvolved and colocalization analysis was completed using the Pearson’s correlation with the
Image J plugin.

2.3.7

Nef subtype G and H display increased mitochondrial colocalization.

As investigation of the canonical proteasomal and lysosomal degradation
pathways could not explain the decreased expression and distinct subcellular
localization of Nef from subtype G and H reference strains, we next investigated
alternate subcellular locales. Nef is a cytosolic protein that is membrane bound
(46), we therefore investigated other membrane-delineated compartments in the
cell. We first investigated the localization of Nef proteins from subtypes B, C, G
and H with the endoplasmic reticulum (ER), as this membrane bound organelle
can be a site of protein degradation via the endoplasmic-reticulum-associateddegradation pathway (ERAD). To label the ER, we constructed a red fluorescent
protein (RFP) that was modified to include the ER target sequence KDEL, RFPKDEL. Proteins that contain the KDEL target sequence are retained in the
endoplasmic reticulum due to recognition by the KDEL receptor (53). CD4+ HeLa
cells were co-transfected with Nef-EGFP fusion proteins and RFP-KDEL and
then imaged by fluorescence microscopy. Interestingly, Nef from subtype C did
appear to co-localize with RFP-KDEL (Figure 2.7A), but this finding was not
supported when multiple independent experiments were quantified. Indeed, there
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was minimal co-localization as measured using Pearson’s correlation. Nef
proteins from subtype B, C, G and H all displayed similar co-localization as the
cytosolic EGFP, which was used as a negative control (Figure 2.7B). This is in
contrast to an EGFP protein that was modified with a KDEL target sequence,
which we used as our positive control, and showed near ubiquitous colocalization with RFP-KDEL, as seen with a Pearson’s correlation of 0.95 (Figure
2.7B). Overall, these findings do not support the ER as the subcellular
destination of low expressing Nef proteins from subtypes C, G and H.
The final subcellular compartment that we investigated was the mitochondria.
Although, there has not been any reports of HIV-1 Nef localizing to this organelle,
the reticulated nature of the distribution of Nef from subtype G and H (Figure 2.4
and 2.6) was reminiscent of fluorescence imaging of the mitochondria (54). In
order to label the mitochondria we used the mitochondrial potential-dependent
fluorescent dye, MitoTracker® Deep Red FM. CD4+ HeLa cells were transfected
with Nef-EGFP fusion proteins from subtype B, C, G and H and prior to fixation
were incubated with 100 nM of MitoTracker® Deep Red FM for 30 minutes.
Strikingly, there was strong co-localization of all Nef proteins with MitoTracker®
(Figure 2.7C, D), however, it is important to note that even cells transfected with
unfused EGFP displayed moderate co-localization with MitoTracker® (Figure
2.7D). We believe this was due to the diffuse nature of the MitoTracker® dye,
which was particularly evident in the perinuclear region of cells (Figure 2.7C). To
determine if the strong co-localization of Nef with MitoTracker® was maintained
outside these heavily labeled regions, we selected peripheral areas of
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transfected cells and reanalyzed them for Nef/MitoTracker® co-localization.
Interestingly, when only these peripheral regions were considered, the degree of
co-localization of Nef proteins from subtype B and C reference strains with
MitoTracker® decreased to levels not significantly different than cells transfected
with EGFP alone (Figure 2.7D). However, the strong co-localization of Nef
proteins from subtype G and H with MitoTracker® was maintained, with both
subtypes having a Pearson’s correlation of 0.71 (Figure 2.7D). These findings
support our early observations that Nef proteins from subtype G and H reference
strains display a unique subcellular distribution (Figure 2.4B, C), even when
compared to the other low expressing subtype C reference strain (Figure 2.7D).
They also raise the possibility that these Nef proteins are preferentially localized
to mitochondrial dense regions of the cells, an as of yet unreported finding for
HIV-1 Nef.
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Figure 2.7 Increased co-localization of Nef proteins from subtype G and H
with mitochondria.
(A) CD4+ HeLa cells were co-transfected with various Nef-EGFP fusion plasmids
encoding Nef from different HIV-1 subtype reference strains, and KDEL-RFP.
Cells were fixed in 4% PFA and imaged on a Leica DMI6000 B widefield
microscope on the 100× objective; scale bar = 10 µm. (B) Images were
deconvolved and co-localization analysis was completed using the Pearson’s
correlation with the Image J plugin. Green bar = positive control, Red bar =
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negative control. (C) CD4+ HeLa cells were transfected with various Nef-EGFP
fusion plasmids encoding Nef from different HIV-1 subtypes. Cells were stained
with 100 nM MitoTracker® DeepRed for 15 min, then fixed in 4% PFA, and
imaged on a Leica DMI6000 widefield microscope on the 100× objective; scale
bar = 10 µm, green=Nef-EGFP, red=mitochondria, boxes represent an example
of the area considered in peripheral co-localization analysis. (D) Total (dark blue
or red) or peripheral (light blue or red) colocalization of Nef-EGFP and
MitoTracker® Deep Red. Images were deconvolved and co-localization analysis
was completed using the Pearson’s correlation with the Image J plugin.

2.3.8

Differences in Subtype C expression and function are due to
variations in amino acid sequence.

Unable to identify the route of degradation for the low expressing Nef proteins
from subtype C, G and H reference strains, we focused subsequent
investigations on elucidating the genetic determinants of the low expressing
subtype C. Our studies contrasted the low expressing subtype C reference strain
C.BR92025 with the high expressing subtype B reference strain B.JRFL, as it
displayed the greatest functionality in our earlier tests (Figure 2.2 and 2.3) and
displayed typical subcellular distribution in our previous investigations (Figure
2.4). Before altering the protein sequences of Nef B.JRFL and Nef C.BR92025,
we first wanted to verify that the differences in protein expression were not due to
differences in codon-usage between these two Nef proteins. To do so, we
synthesized a Nef B.JRFL protein that contained all possible synonymous
mutations found in Nef C.BR92025, termed Nef Silent B, ensuring that the only
differences between Nef C.BR92025 and Nef Silent B were the non-synonymous
mutations that resulted in amino acid changes (Figure 2.8A). The same process
was performed to synthesize a Nef Silent C, which contained all the synonymous
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mutations found in Nef B.JRFL (Figure 2.8A).
These synthesized protein sequences were inserted into the proviral vectors
described earlier (Figure 2.3A), which were then used to generate HIV-1
pseudoviruses expressing Nef Silent C or Nef Silent B. To test these proteins for
functionality, Jurkat E6.1 T cells were infected with pseudovirus and stained for
cell surface MHC-I at 48 hours post-infection. Surprisingly, when analyzed for
MHC-I downregulation by flow cytometry, Nef Silent B demonstrated increased
efficiency relative to Nef B.JRFL, whereas Nef Silent C was less efficient than
Nef C.BR92025 at downregulating MHC-I (Figure 2.8). Indeed, cells infected with
pseudovirus encoding Nef Silent C had more MHC-I on their cell surface than
cells infected with pseudovirus that does not produce Nef (Figure 2.8B; Silent C
and dNef, respectively). Furthermore, to determine if different codon usage
between Nef C.BR92025 and Nef B.JRFL impacted protein expression,
pseudovirus infected Jurkat E6.1 cells were lysed and analyzed by western blot.
In line with the functional data above (Figure 2.8B), there were no obvious
differences in the expression of Nef B.JRFL and Nef Silent B or Nef C.BR92025
and Nef Silent C (Figure 2.8C). These results suggest that the decreased
function and expression of Nef C.BR92025 is not due to codon-usage, but rather
due to differences in the amino acid sequence.
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Figure 2.8 Decreased expression and function of Nef C.BR92025 is due to
differences in amino acid sequence.
(A) Schematic of Nef B.JRFL (Silent B) or Nef C.BR92025 (Silent C) nucleotide
sequences that were synthesized to mimicked the codon usage Nef C.BR92025
or Nef B.JRFL, respectively. Nef constructs were inserted into proviral vectors to
produce pseudovirus. (B) Jurkat E6.1 T cells were infected with the pseudovirus
lacking Nef expression (dNef; red) or expressing the indicated Nef construct and
stained for surface MHC-I at 48 hours post-infection. MHC-I downregulation was
measured by flow cytometry and calculated relative to NL4.3 (green). (n≥3,
p<0.05) (C) Jurkat E6.1 T cells were infected with pseudovirus expressing the
indicated Nef constructs and lysed at 48 hours post-infection. Lysates were
analyzed for Nef, GFP and actin expression by western blot.
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2.3.9

Subtype C impairments are due to genetic differences in two
alpha helices.

To locate the region of the subtype C protein that is responsible for the
differences in function and expression, we constructed a series of chimeric
proteins. The C-terminus of Nef B.JRFL was replaced with increasingly larger
segments of Nef C.BR92025 and the same procedure was repeated for replacing
the C-terminus of Nef C.BR92025 with increasingly larger segments of B.JRFL
(Figure 2.9A; BC 3-1 and CB 3-1, respectively). The sequences for these
chimeric proteins were inserted into the proviral vectors described earlier (Figure
2.3A), which were then used to generate pseudovirus that express various
chimeric Nef proteins.
To test Nef function, Jurkat E6.1 T cells were infected with pseudoviruses
expressing Nef B.JRFL, Nef C.BR92025 or the various chimeric Nef proteins and
stained for surface MHC-I at 48 hours post-infection. MHC-I downregulation was
analyzed by flow cytometry. When the C-terminal 90 amino acids of B.JRFL were
replaced with the corresponding C-terminal 90 amino acids of C.BR92025
(Figure 2.9A; BC 3) there was no detectable change in MHC-I downregulation.
Strikingly, when the next 50 amino acids of Nef B.JRFL (NL4.3 positions 116-67)
were replaced with the corresponding 50 amino acids of Nef C.BR92025 (Figure
2.9A; BC 2), there was a significant decrease in MHC-I downregulation to less
than 50% of NL4.3 (Figure 2.9B). When the next 43 amino acids of Nef B.JRFL
(NL4.3 position 24-67) were replaced with those of Nef C.BR92025 (Figure 2.9A;
BC 1), there was no additional decrease in MHC-I downregulation. It is important
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to note that the function of these chimeric proteins never fell to the level of the full
length Nef C.BR2025, suggesting that the final N-terminal 24 amino acids that
were not replaced in our chimeric proteins also played a role in determining
MHC-I downregulation (Figure 2.9A, B). In addition to MHC-I downregulation, we
also measured expression of these chimeric proteins by western blot of lysates
from Jurkat E6.1 T cells infected with the pseudoviruses used above. Strikingly,
the same segments of Nef C.BR92025 that decreased MHC-I downregulation
(Figure 2.9A, B) resulted in nearly undetectable levels of protein (Figure 2.9C).
These findings further suggest that the functional impairment seen in Nef
C.BR92025 is linked to defects in protein expression.
Importantly, when the same chimeric experiments were performed with segments
of Nef C.BR92025 being replaced with Nef B.JRFL (Figure 2.9A; CB 3-1), there
was an increase in MHC-I downregulation and protein expression when the
central region Nef B.JRFL (NL4.3 positions 116-67) was introduced into Nef
C.BR92025 (Figure 2.9B, C). These Nef C.BR92025 chimeric experiments
corroborate the findings from our Nef B.JRFL chimeric experiments and support
this region as a major determinant of Nef function and expression. In line with the
Nef B.JRFL chimeric experiments, the chimeric protein with only 24 N-terminal
amino acids from Nef C.BR92025 (Figure 2.9A; CB 1) did not show a complete
rescue of function equivalent to Nef B.JRFL (Figure 2.9B). This suggests that this
N-terminal region is also important for Nef function, however, these N-terminal
amino acids do not appear to be required to rescue expression of Nef
C.BR92025 (Figure 2.9C).
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Figure 2.9 Decreased function and expression of Nef C.BR92025 is
determined by an N-terminal and central region.
(A) Schematic of chimeric proteins of Nef B.JRFL with increasing C-terminal
portions of Nef C.BR92025 (BC 3-1) or vice versa (CB 3-1). Nef constructs were
inserted into proviral vectors to produce pseudovirus. (B) Jurkat E6.1 T cells
were infected with the pseudovirus lacking Nef expression (dNef; red) or
expressing the indicated Nef construct and stained for surface MHC-I at 48 hours
post-infection. MHC-I downregulation was measured by flow cytometry and
calculated relative to NL4.3 (green) (n≥3, p<0.05). (C) Jurkat E6.1 T cells were
infected with pseudovirus expressing the indicated Nef constructs and lysed at
48 hours post-infection. Lysates were analyzed for Nef, GFP and actin
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expression by western blot.
To confirm the importance of the central region (NL4.3 positions 67-116) and the
N-terminal region (NL4.3 positions 1-24) in determining the decreased
expression and function of Nef C.BR92025 we completed additional chimeric
experiments. Chimeric proteins were constructed to introduce region 67-116 of
Nef C.BR92025 into Nef B.JRFL (Figure 2.10A; Nef BCB). The introduction of
these 49 amino acids significantly decreased the ability of Nef BCB to
downregulate MHC-I in Jurkat E6.1 T cells infected with pseudovirus expressing
this chimera (Figure 2.10B). This 49 amino acid region was also introduced into
the BC 1 chimeric protein used in the previous chimeric experiment to construct a
Nef B.JRFL protein that contained amino acids 1-24 and 67-116 of Nef
C.BR92025 (Figure 2.10A; CBCB). Strikingly, this Nef CBCB chimera showed a
further decrease in its ability to downregulate MHC-I in Jurkat E6.1 T cells
infected with pseudovirus expressing this new chimeric (Figure 2.10B).
Additionally, both Nef BCB and Nef CBCB chimeric proteins showed decreased
expression via western blot in infected cells, however, these proteins were still
detectable (Figure 2.10C).
Similar chimeric proteins were constructed by inserting amino acids 1-24 and/or
67-116 of Nef B.JRFL into a Nef C.BR92025 backbone (Figure 2.10A; CBC and
BCBC). When either region was introduced on its own (Figure 2.10A; CBC or CB
1), the resulting Nef proteins functioned at about 50% of Nef NL4.3, whereas
when both regions were introduced (Figure 2.10A; BCBC) the resulting Nef
protein downregulated MHC-I as efficiently as Nef B.JRFL (Figure 2.10B). In both
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chimeras that contained amino acids 67-116 from Nef B.JRFL (Figure 2.10A;
CBC and BCBC), there was a marked increase in protein expression as detected
by western blot of pseudovirus infected Jurkat E6.1 T cells (Figure 2.10C).
However, amino acids 1-24 did not appear to increase protein expression (Figure
2.10C), highlighting the importance of the central region (amino acids 67-116) in
the expression of Nef.
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Figure 2.10 Amino acids 1-24 and 67-116 contain the amino acid
determinants of altered function and expression of Nef C.BR92025
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(A) Schematic of chimeric proteins of Nef B.JRFL with amino acids 67-116
(BCB), 1-24 (CB 1) or both (CBCB) of Nef C.BR92025. Schematic of chimeric
proteins of Nef C.BR92025 with amino acids 67-116 (CBC), 1-24 (BC 1) or both
(BCBC) of Nef B.JRFL. Nef constructs were inserted into proviral vectors to
produce pseudovirus. (B) Jurkat E6.1 T cells were infected with the pseudovirus
lacking Nef expression (dNef; red) or expressing the indicated Nef construct and
stained for surface MHC-I at 48 hours post-infection. MHC-I downregulation was
measured by flow cytometry and calculated relative to NL4.3 (green) (n≥3,
p<0.05). (C) Jurkat E6.1 T cells were infected with pseudovirus expressing the
indicated Nef constructs and lysed at 48 hours post-infection. Lysates were
analyzed for Nef, GFP and actin expression by western blot.

2.3.10

Point mutations in C.BR92025 are located in highly
conserved regions in HIV-1 Nef.

Having identified the N-terminal 24 amino acids and central region 67-116 as
containing the determinants of decreased function and expression of Nef
C.BR92025, we next analyzed the amino acid sequence of these regions. Nef
protein sequence alignments revealed point mutations in Nef C.BR92025 at
positions 13 (W13R), 84 (A84V) and 92 (E92K) that were absent in the laboratory
adapted subtype B strain NL4.3 (Figure 2.11A) and in all other subtype reference
strains analyzed (Figure 2.1). To determine the prevalence of these point
mutations across prominent HIV-1 group M subtypes, we constructed amino acid
sequence logos of Nef for regions spanning residues 13, 84 and 92 from
subtypes A1, B, C and D (Figure 2.11). These subtypes were selected due to
their high global prevalence compared to other Group M subtypes (6). Sequence
logos were constructed by selecting up to 10 sequences from each country that
had Nef sequences available in the NIH Los Alamos HIV database (55). These
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sequence logos revealed a high level of conservation of W13, A84, and K92 in
other subtype C Nef sequences (Figure 2.11A) and across other prominent HIV-1
subtypes (Figure 2.11B). When 4553 full-length Nef protein sequences from the
NIH Los Alamos HIV database were queried W13, and A84 occurred at >99%
frequency and K92 occurred at a frequency of 92.75%. However, the frequency
for a basic residue at position 92 (K92 or R92) was 99.52%.

!"
NL4.3

MGGKWSKSSVIGWPAVRERMRRAEPAADGVGAVSRDLEKHGAITSSNTAANNAACAWLEA 60

Consensus_C MGGKWSKSSIVGWPAVRERIRRTEPAAEGVGAASQDLDKHGALTSSNTATNNADCAWLEA 60
C.BR92025
MGNKWSKCSTVGRPAIRERMRR-APAAEGVGPASQDSDKYGALTSSSTPANNADCAWLEA 59
** ****.* :* **:***:** ***:*** .*:* :*:**:***.* :*** ******

NL4.3

QE-EEEVGFPVTPQVPLRPMTYKAAVDLSHFLKEKGGLEGLIHSQRRQDILDLWIYHTQG 119

Consensus_C QEEEEEVGFPVRPQVPLRPMTYKAAFDLSFFLKEKGGLEGLIYSKKRQEILDLWVYHTQG 120
C.BR92025
QQEEEEVGFPVRPQVPLRPMTYKAVVDLSFFLEEKGGLEGLIYSKKRQDILDLWVYNTQG 119
*: ******** ************..***.**:*********:*::**:*****:*.***
NL4.3

YFPDWQNYTPGPGVRYPLTFGWCYKLVPVEPDKVEEANKGENTSLLHPVSLHGMDDPERE 179

Consensus_C YFPDWQNYTPGPGVRYPLTFGWCFKLVPVDPREVEEANEGENNCLLHPMSQHGMEDEDRE 180
C.BR92025
YFPDWQNYTPGPGVRFPLTFGWCFKLVPVDPREVEEANTGENNSLLHPMSLHGMEDSHRE 179
***************:*******:*****:* :***** ***..****:* ***:* .**
NL4.3

VLEWRFDSRLAFHHVARELHPEYFKNC* 206

Consensus_C VLKWKFDSHLARRHMARELHPEYYKDC* 207
C.BR92025
VLQWKFDSLLARRHMARELHPEYYKDC* 206
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Figure 2.11 Rare point mutations identified in the Nef protein of subtype C
reference strain C.BR92025.
(A) Clustal Omega was used to align protein amino acid sequences of Nef from
the laboratory strain NL4.3, a subtype C consensus sequence from the NIH AIDS
Los Alamos Database and the subtype C reference strain C.BR92025. Inset
boxes show sequence logos with the size of the one letter amino acid code
proportional to the frequency at which that amino acid is found at a given
position. Black arrows indicate rare point mutations found in the subtype C
reference strain C.BR92025. (B) Sequence logos from globally prevalent HIV-1
subtypes A1, B and D. Black arrows indicate Nef amino positions 13, 84, and 92.
“*” indicates identical residues, “:” indicates conserved residues, “.” indicates
semiconserved residues. Residues in blue are acidic amino acids, residues in
pink are basic amino acids, residues in red are uncharged non-polar amino acids
and those in green are uncharged polar amino acids.

2.3.11

Decreased expression and function of Nef C.BR92025 is
specific to this HIV-1 reference strain.

Due to the rare nature of the W13R, A84V and K92E mutations identified in Nef
C.BR92025 we wanted to see if the decreased function and expression we
observed (Figure 2.2 and 2.3) was unique to this reference strain. To do so, we
replicated our assays of Nef-mediated CD4 (Figure 2.2) and MHC-I (Figure 2.3)
downregulation, but this time included a subtype C consensus Nef sequence
obtained from the NIH Los Alamos HIV database (sequence can be seen in
Figure 2.11A). As before, we analyzed CD4 downregulation in CD4+ HeLa cells
transfected with plasmids encoding Nef-EGFP fusion proteins with Nef from
NL4.3, consensus C, C.BR92025 or B.JRFL. As mentioned above, these
constructs allowed us to analyze CD4 downregulation independent of HIV-1 Env
and Vpu, which can also downregulate CD4 (24). In accordance with our initial
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test of CD4 downregulation (Figure 2.2), CD4+ HeLa cells transfected with Nef
C.BR92025-EGFP showed a significant decrease in CD4 downregulation relative
to NL4.3 (Figure 2.12A). However, we now demonstrate that this decrease in
function is specific to this subtype C reference strain as Nef Consensus C-EGFP
displayed equivalent CD4 downregulation relative to NL4.3 (Figure 2.12A). As
before, CD4 was efficiently downregulated from CD4+ HeLa cells transfected with
Nef B.JRFL-EGFP (Figure 2.12A). Furthermore, when transfected cells were
analyzed for protein expression by western blot, we once again observed
reduced Nef protein levels in cells expressing Nef C.BR92025-EGFP, but not in
cells transfected with Nef Consensus C-EGFP (Figure 2.12B). These findings
suggest that the impaired function and expression of Nef C.BR92025 is specific
to this reference strain.
We next investigated Nef-mediated CD4 downregulation in a T cell line to verify
that the impairment of Nef C.BR29025 in this key function occurs in the
physiological host cells of HIV-1. In order to delineate the effects of HIV-1 Vpu,
we inserted the various Nef proteins into NL4.3-based lentiviral vectors that
lacked expression of Vpu (dVpu). Jurkat E6.1 T cells infected with pseudovirus
made from these vectors demonstrated a similar pattern of CD4 downregulation
to that in CD4+ HeLa cells, with Nef C.BR92025 unable to effectively
downregulate CD4 (Figure 2.12C). Strikingly, this impairment in CD4
downregulation is much more evident when Nef C.BR92025 is expressed in the
absence of NL4.3 Vpu, suggesting Vpu partially masks this defect in Nef
C.BR9025 function. As with the results from CD4+ HeLa cells (Figure 2.12A),
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CD4 was efficiently downregulated from the cell surface of Jurkat E6.1 T cells
infected with pseudovirus expressing Nef Consensus C and Nef B.JRFL in the
presence or absence of Vpu (Figure 2.12C). This once again highlights the
functional impairment of Nef C.BR92025 in contrast to a subtype C consensus
Nef.
To test Nef-mediated MHC-I downregulation we used the NL4.3-based,
replication incompetent lentiviral vectors described earlier (Figure 2.3A). As
observed prior (Figure 2.3), Nef C.BR92025 demonstrated impaired MHC-I
downregulation in pseudovirus infected Jurkat E6.1 T cells, barely above the
levels of a lentiviral vector lacking the Nef protein (dNef), which served as our
negative control (Figure 2.12D). Jurkat E6.1 T cells infected with lentiviral vectors
expressing consensus C Nef showed levels of MHC-I downregulation equivalent
to NL4.3 and Nef B.JRFL (Figure 2.12D) further demonstrating the observed
defects in Nef C.BR92025 function are specific to this reference strain. Indeed,
when pseudovirus infected Jurkat E6.1 T cells were analyzed for Nef expression
by western blot, consensus C Nef was readily detectable, whereas we were once
again unable to detect a strong band corresponding to Nef C.BR92025 (Figure
2.12E). To independently confirm the reduced expression of Nef C.BR92025, we
constructed alternative vectors that encoded Nef C.BR92025 and Nef B.JRFL
fused to EGFP. When Jurkat E6.1 T cells infected with these vectors were
analyzed by flow cytometry, those expressing Nef C.BR92025 had a clear
reduction in EGFP fluorescence, indicative of reduced Nef-EGFP protein levels
(Figure 2.12F).
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Figure 2.12 Impaired function and expression of Nef C.BR92025 is unique
to this reference strain.
(A) CD4+ HeLa cells were transfected with plasmids encoding EGFP fusion
proteins from the laboratory strain NL4.3, Consensus C Nef, or Nef from the
reference strains B.JRFL or C.BR92025 as well as a non-fused EGFP as a
negative control. Cell surface levels of CD4 were measured using flow cytometry
with an APC conjugated anti-CD4 antibody 24 hours post-transfection.
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Downregulation efficiency relative to NL4.3 was calculated using mean
fluorescence intensity (p<0.05, n=3). (B) Cell lysates from transfected CD4+
HeLa cells were collected and lysed 24 hours post-infection. Lysates were
analyzed for fusion protein expression by western blot using an anti-GFP
antibody. (C) Jurkat E6.1 T cells were infected using lentiviral vectors either
expressing NL4.3 Vpu or not (dVpu) in addition to expressing Nef from the
laboratory strain NL4.3, lacking Nef expression (dNef), Consensus C Nef, or Nef
from the reference strains B.JRFL or C.BR92025. Cell surface levels of CD4
were measured using flow cytometry with an APC conjugated anti-CD4 antibody
48 hours post-infection. Downregulation efficiency relative to NL4.3 was
calculated using mean fluorescence intensity (p<0.05, n=3). (D) Jurkat E6.1 T
cells were infected with lentiviral vectors expressing Nef from the laboratory
strain NL4.3, lacking Nef expression (dNef), Consensus C Nef, or Nef from the
reference strains B.JRFL or C.BR92025. Cell surface levels of MHC-I were
measured by flow cytometry 48 hours post-infection with a pan-specific antiMHC-I primary antibody (W6/32) and an Alexa Fluor® 647 conjugated secondary
antibody. Downregulation efficiency relative to NL4.3 calculated using mean
fluorescence intensity (p<0.05, n=4). (E) Uninfected Jurkat E6.1 cells (UI) or cells
infected with the lentiviral vectors described above expressing non-fusion Nef
proteins were collected and lysed 48 hours post-infection. Lysates were analyzed
for Nef, EGFP and actin protein levels by western blot. (F) Jurkat E6.1 cells were
infected with lentiviral vectors encoding EGFP fused to the Nef proteins from the
reference strains B.JRFL and C.BR92025. A representative histogram from three
independent experiments is shown

2.3.12

C.BR2025 undergoes increased protein turnover.

As we were previously unable to demonstrate Nef C.BR92025 being
preferentially targeted for a cellular degradation pathway (Figure 2.5 and 2.6) we
posited that Nef C.BR92025 was undergoing accelerated degradation relative to
Nef NL4.3 and Nef B.JRFL. In order to investigate the rate of Nef protein turnover
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we performed a pulse-chase experiment with Jurkat E6.1 cells infected with
lentiviral vectors expressing the high-expressing Nef B.JRFL or the lowexpressing

Nef

C.BR92025.

Infected

cells

were

labeled

with

35

S-

Methionine/Cysteine for 30 min (pulse) and then chased in unlabeled media for
up to 240 min. Subsequently, Nef protein was purified by immunoprecipitation
using anti-Nef coated agarose beads and Nef protein levels were analyzed by
autoradiography. Interestingly, the amount of Nef C.BR92025 protein remaining
after a 240 min chase period was significantly lower than Nef B.JRFL (Figure
2.13A). The data from the pulse-chase experiments were fitted with a one-phase
decay non-linear regression, whose slope was used to calculate the half-life of
the Nef proteins (Figure 2.13B). The regression analysis revealed that Nef
C.BR92025 was removed from infected cells almost 4 times faster than Nef
B.JRFL (half-life of 2.2 hours vs. 8.0 hours).
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Figure 2.13 Nef C.BR92025 undergoes increased protein turnover.
(A) Jurkat E6.1 T cells were infected with lentiviral vectors encoding Nef from the
reference strains B.JRFL or C.BR92025. At 48 hours post-infection a

35

S pulse-

chase was performed. Cells were lysed and immunoprecipitated using an anti-
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Nef antibody. Immunoprecipitated proteins were separated by SDS-PAGE and
imaged by autoradiography. A representative image from three independent
experiments is shown. (B) The intensities of bands corresponding to
immunoprecipitated Nef were determined using ImageQuant 5.2 software and
used to calculate the amount of protein remaining relative to time point 0. Onephase non-linear regression was used to calculate protein half-life. Dotted black
line represents 50% of the initial protein remaining (p<0.05, n=3).

2.3.13

Rare point mutations in Nef C.BR92025 affect protein
expression and decreased function.

To determine the role rare point mutations identified in Nef C.BR92025 play in
the observed decrease in function and protein expression, we carried out a
mutational analysis of Nef C.BR92025. Introduction of single point mutations in
Nef C.BR92025 that revert the amino acids at positions 13, 84, and 92 to the
conserved residues normally found in Nef (R13W, V84A and K92E) each
resulted in significant, but incomplete rescue of Nef-mediated MHC-I
downregulation in pseudovirus infected Jurkat E6.1 T cells (Figure 2.14A). In
addition to MHC-I downregulation, we analyzed the mutants for Nef expression
by western blot. Interestingly, reversion of position 84 from a valine, as found in
C.BR92025, to the conserved alanine was sufficient to rescue expression of Nef
C.BR92025 despite not fully restoring Nef function (Figure 2.14B). To fully
restore the function of Nef C.BR92025 to the levels of Nef NL4.3, a combination
of mutations at position 13 and either position 84 (CR13W V84A) or 92 (CR13W E92K)
were required (Figure 2.14A).
In addition to the effects of these rare point mutations on the function of Nef
C.BR92025, we were also interested in determining if mutations at residues 13,
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84 and 92 were sufficient to disrupt function and expression of our high
expressing subtype B reference strain, Nef B.JRFL. To achieve this we
performed a reciprocal mutational analysis, where we mutated residues 13, 84
and 92 to the amino acids found in Nef C.BR92025, W13R, A84V, and K92E,
respectively. Similar to our results with Nef C.BR92025, introduction of single
point mutations at positions 13 and 84 only partially disrupted the function of Nef
B.JRFL in pseudovirus infected E6.1 T cells, however, mutation at position 92 did
not affect function in Nef B.JRFL (Figure 2.14C). Interestingly, a single point
mutation at position 84 from alanine to valine was sufficient to markedly decrease
the amount of Nef protein detected by western blot (Figure 2.14D; BA84V),
mirroring the results from our mutational analysis of Nef C.BR92025 (Figure
2.14B; CV84A). A combination of mutations at positions 13 and 84 were required
to fully disrupt expression and function of Nef B.JRFL (Figure 2.14C, D; BW13R
A84V).

A combination of mutations at position 13 and 92 only partially disrupted

expression and function (Figure 2.14C, D; BW13R K92E), which is in agreement with
our results that showed the single K92E mutation in Nef B.JRFL did not impair
function or expression (Figure 2.14C, D; BK92E). These results suggest a critical
role of residues W13 and A84 (and to a lesser extent E92) in the function of the
HIV-1 Nef protein, with residue A84 being responsible for controlling protein
expression (Figure 2.14E).
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Figure 2.14 Residues 13, 84 and 92 are important for expression and
function of HIV-1 Nef.
(A) Jurkat E6.1 T cells were infected using lentiviral vectors expressing Nef from
the laboratory strain NL4.3, lacking Nef expression (dNef), Nef from the
reference strain C.BR92025 as well as various C.BR92025 mutants. Cell surface
levels of MHC-I were measured by flow cytometry 48 hours post-infection with a
pan-specific anti-MHC-I primary antibody (W6/32) and an Alexa Fluor® 647
conjugated secondary antibody. Downregulation efficiency relative to NL4.3 was
calculated using mean fluorescence intensity (p<0.05, n=4). (B) Cell lysates from
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Jurkat E6.1 T cells infected with the lentiviral vectors described above were
collected and lysed 48 hours post-infection. Lysates were analyzed for Nef,
EGFP and actin protein levels by western blot. (C) and (D) The same
experiments described in (A) and (B) were conducted using lentiviral vectors
expressing Nef from the reference strain B.JRFL as well as various B.JRFL
mutants. (E) A summary of results from experiments with lentiviral vectors
harboring combination mutants in C.BR92025 (CR13W
A84V K92E)

2.3.14

V84A)

and B.JRFL (BW13R

from (A) and (C), respectively.

A point mutation at residue 84 results in a rapid decrease in
Nef C.BR92025 protein levels.

Our mutational analysis suggests that proper and sustained expression of the
HIV-1 Nef protein requires an alanine at position 84. In order to support these
findings we conducted additional pulse-chase experiments in Jurkat E6.1 T cells
using lentiviral vectors encoding Nef B.JRFL, Nef C.BR92025 or those Nef
proteins harboring point mutations at position 84. As described above, Nef
C.BR92025 protein levels decrease at a faster rate than Nef B.JRFL (Figure
2.13). Mutation of the valine at position 84 in Nef C.BR92025 to an alanine
rescues the protein from rapid removal, more than doubling its half-life (Figure
2.15A, B; 2.2 hours to 4.6 hours). Similarly, mutation of the alanine at position 84
in Nef B.JRFL to a valine is sufficient to dramatically increase the rate at which
the protein is removed from cells, shortening its half-life to almost a quarter of the
wild-type Nef B.JRFL (Figure 2.15A, B; 8.0 hours to 2.1 hours). The importance
of residue 84 is further highlighted by the complete disruption of MHC-I
downregulation through the introduction of a large bulky tryptophan residue into
the otherwise highly functional Nef B.JRFL (Figure 2.15C). These findings
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support the importance of residue 84 of HIV-1 Nef, suggesting that mutating Nef
A84 away from the highly conserved alanine is sufficient to disrupt expression of
HIV-1 Nef.
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Figure 2.15 Alanine at position 84 in HIV-1 Nef is critical for sustained
expression.
(A) Jurkat E6.1 T cells were infected with lentiviral vectors encoding Nef from the
reference strains B.JRFL or C.BR92025 as well as mutants at position 84
(B.JRFLA84V and C.BR92025V84A). At 48 hours post-infection a
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S pulse-chase

was performed. Cells were lysed and immunoprecipitated using an anti-Nef
antibody. Immunoprecipitated proteins were separated by SDS-PAGE and
imaged by autoradiography. A representative image of three independent
experiments is shown. (B) The intensities of bands corresponding to
immunoprecipitated Nef were determined using ImageQuant 5.2 software and
used to calculate the amount of protein remaining relative to time point 0. Onephase non-linear regression was used to calculate protein half-life. Dotted black
line represents 50% of the initial protein remaining (p<0.05, n=3). (C) Jurkat E6.1

127

T cells were infected using lentiviral vectors expressing Nef from the laboratory
strain NL4.3, lacking Nef expression (dNef), Nef from the reference strains
B.JRFL or C.BR92025 as well as B.JRFL mutants at residue 84 (BA84V and
BA84W). Cell surface levels of MHC-I were measured by flow cytometry 48 hours
post-infection with a pan-specific anti-MHC-I primary antibody (W6/32) and an
Alexa Fluor® 647 conjugated secondary antibody. Downregulation efficiency
relative to NL4.3 calculated using mean fluorescence intensity (p<0.05, n=4).

2.4 Discussion
In the early years of the HIV/AIDS epidemic, the viral isolates used for research
studies were predominantly from group M subtype B due to the very high
prevalence of subtype B in North America and Western Europe, where much of
the early research was taking place (7, 8). As the extensive genetic diversity of
HIV-1 became apparent, there was a need to develop a panel of full-length
reference strains for the various HIV-1 subtypes (36, 56). These reference strains
were selected based on availability of full-length molecular clones and no
obvious history of recombination. As such, they were thought to be pure subtype
strains and could serve as representative of the various group M subtypes.
Despite the existence of these panels, there still remains very little information on
the function of HIV-1 proteins from group M subtypes that have lower global
prevalence.
We aimed to determine if the genetic variability inherent in HIV-1 impacted the
function of Nef, an HIV-1 accessory protein that plays a major role in
pathogenesis (57). Our functional analysis revealed three reference strains,
C.BR92025, G.FI93HH8793 and H.BE93VI997 that had decreased levels of
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expression and consequently displayed significantly impaired function, as
measured by CD4 (Figure 2.2) and MHC-I (Figure 2.3) downregulation efficiency.
This decreased expression was confirmed to be at the protein level (Figure 2.4)
and was not reversible by chemical inhibition of the proteasome (Figure 2.5).
As HIV-1 Nef exerts its function through establishing a network for protein:protein
interactions with host proteins throughout infected cells, proper subcellular
localization of this accessory protein is vital (58). Indeed, when the N-terminal
myristoylation site on Nef, which targets it to lipid membranes, is mutated, Nef is
rendered essentially useless (59). Therefore, we investigated the subcellular
localization of the low expressing reference strains to determine if we could
identify the source of their functional and expression impairment. Strikingly, Nef
proteins from subtype G and H reference strains displayed a unique subcellular
distribution that was markedly different from all other Nef proteins analyzed
(Figure 2.4). Upon further investigation, these atypically distributed Nef proteins
appeared to co-localize with mitochondria (Figure 2.7). To the best of our
knowledge, there have been no previous reports of HIV-1 Nef interacting with
mitochondria, however viral proteins from human cytomegalovirus and hepatitis
C have been shown to localize to mitochondrial membranes (60). Interestingly, it
has been documented that mitochondria are able to respond to external stresses,
such as viral infection, and initiate mitophagy (self degradation of mitochondria
through autophagy) (61). This process could explain the decreased levels of Nef
from subtype G and H, but this is just speculation, with many more investigations
needed to support such a mechanism. Indeed, the increased co-localization with
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mitochondria of Nef from subtype G and H reference strains was only observed
when isolating the periphery of transfected cells for image quantification (Figure
2.7C, D). Furthermore, mitophagy results in degradation via the lysosome, which
we were unable to detect in our assays. A more objective method would be
needed to confirm this unique finding.
Our further investigations focused on the other low expressing reference strain
C.BR92025. The reference strain C.BR29025 was isolated from a 23-year-old
male hemophilic patient from Brazil in 1992 and later deposited into the NIH Los
Alamos HIV database (62). Upon phylogenic analysis, the full-length C.BR92025
clustered with other subtype C reference strains, suggesting that it was not
dramatically different from other subtype C viruses (56, 62, 63). These reference
strains were selected to allow for intersubtype comparison of HIV-1 proteins,
specifically the lesser-studied regulatory proteins; however, they were selected
based on availability of full-length sequences without verification that all proteins
functioned properly (56).
The clinical progression of this patient is not well documented, but at the time of
sampling he had active viral replication with detectable viral titers and p24 levels
(62). In addition, C.BR92025 has been used as a reference strain and is
replication-competent in vitro (64, 65). However, given the importance of HIV-1
Nef for disease progression, decreased expression of this key accessory protein
should result in decreased viral replication. Indeed, when C.BR92025 has been
used as a reference strain, it has demonstrated decreased fitness compared to
the laboratory strain HIV-1 BaL (65). Interestingly, in competition assays to
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determine viral fitness, C.BR92025 was outcompeted by viral isolates from longterm survivors (65). These findings demonstrate that C.BR92025 has decreased
replicative capacity, but the authors did not explore these differences further, so it
is not possible to attribute defects in replication directly to Nef. Analysis of Nef
sequences from a separate cohort comparing elite controllers to chronic
progressors showed no increased prevalence of mutations at residues 13, 84 or
92 between the two groups (66). However, as this cohort was limited to 45
viruses from each group, a much larger database is needed to make definitive
conclusions on the role of these mutations in disease progression.
Given the high mutation rate of HIV-1 and the strong immunogenicity of the Nef
protein (67), highly conserved residues suggest functional and/or structural
importance. As a result, we were intrigued to discover the subtype C reference
strain C.BR92025 contained three rare residues at positions 13, 84 and 92
(NL4.3 numbering), which we identified through extensive chimeric protein
analysis (Figure 2.9 and 2.10). Across every group M subtype found in the NIH
Los Alamos HIV Database, these residues exist almost exclusively as a
tryptophan (W13), alanine, (A84) and a basic amino acid (K/R92), whereas in the
subtype C reference strain C.BR92025, these residues are an arginine (R13),
valine (V84) and glutamic acid (E92) (Figure 2.11). To determine if the functional
impairment of Nef C.BR92025 was unique to this reference strain, we once again
focused on Nef-mediated MHC-I and CD4 downregulation, two well-documented
Nef functions (16-20). The impairments in both MHC-I and CD4 downregulation
were not found in a consensus subtype C protein (Figure 2.11A, D), nor Nef
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NL4.3 and a Nef protein the subtype B reference strain B.JRFL, as documented
earlier (Figure 2.2 and 2.3). Furthermore, decreased protein expression was not
seen in cells infected or transfected with Nef from consensus subtype C (Figure
2.11B, E). These findings further support the hypothesis that the rare point
mutations identified in Nef C.BR92025 were the source of its decreased function
and expression. This was of interest because the affected residues lie outside
the well-described motifs in Nef known to be required for proper receptor
downregulation. Of the three residues, only W13 has been implicated in MHC-I
downregulation (35). The importance of CD4 downregulation for HIV-1 replication
is highlighted by the redundant functions of the viral proteins Nef, Vpu and Env,
all of which can decrease cell surface levels of CD4 in infected cells (15, 24).
This functional redundancy may have been enough to compensate for the
defects in Nef that we have identified and allow this strain to establish an initial
infection despite its decreased replication efficiency (65).
Minimal literature exists on naturally occurring residues altering expression of
HIV-1 Nef. Therefore we decided to explore the low expressing Nef C.BR92025
further. Pulse chase analysis revealed that Nef C.BR92025 has a half-life that is
little over a quarter of the high expressing Nef B.JRFL (2.2 hours vs. 8.0 hours)
(Figure 2.13). This rapid rate of protein turnover explains why Nef C.BR92025 is
barely detectable by western blot despite mRNA levels equal to Nef B.JRFL
(Figure 2.4). Interestingly, at the 0 min chase time point, the intensity of the band
corresponding to Nef C.BR92025 exceeds that of Nef B.JRFL. This increased
intensity may be due to the presence of two additional sulfur containing
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methionine residues in Nef C.BR92025 relative to Nef B.JRFL, allowing for
increased incorporation of [35S]. Regardless, this time point should capture all
newly synthesized protein produced during the 30 min pulse, with no time for
protein turnover, suggesting that Nef C.BR92025 is being continually produced at
a high level, but is removed from cells very efficiently. This efficient removal of
Nef from infected cells results in increased surface levels of MHC-I and CD4.
To confirm the role of the rare point mutations in the observed decreases in Nef
function and protein levels we conducted a mutational study in both subtype B
and C reference strains B.JRFL and C.BR92025, respectively. Although our
findings were not completely complementary between the high expressing Nef
B.JRFL and the low expressing Nef C.BR92025, both sets of experiments found
an important role for W13 and A84 for expression and function of HIV-1 Nef.
Specifically, W13 appears to be required for efficient MHC-I downregulation as a
W13R mutation significantly reduces MHC-I downregulation efficiency of Nef
B.JRFL, whereas a R13W mutation rescues the MHC-I downregulation efficiency
of Nef C.BR92025. It is important to note that the role of W13 appears to be
independent of protein expression levels as these mutations do not alter
detection of the respective proteins by western blot (Figure 2.14B, D). However,
an A84V mutation was sufficient to markedly decrease Nef protein levels in the
high expressing Nef B.JRFL, while a V84A mutation was sufficient to restore Nef
to detectable levels in the low expressing Nef C.BR92025. These changes in
protein levels were accompanied by corresponding changes in MHC-I
downregulation, suggesting altered protein levels played a role in the impairment

133

in Nef function. The role of the third rare point mutation, E92, is less clear. Our
mutational studies in Nef C.BR92025 suggest an important role for K92 in
function and expression of Nef as the restorative E92K mutation partially rescues
function and expression of Nef C.BR92025. However, in the context of Nef
B.JRFL, the K92E mutation does not significantly impact function and
expression.
Our findings that W13 plays an important role in MHC-I downregulation are in
agreement with a previous structural study of Nef in complex with MHC-I and AP1 (35). This model suggests an intramolecular interaction of W13, located in the
N-terminal alpha helix, with a hydrophobic pocket in the core of Nef (Figure
2.16A). This docking of the N-terminal helix is thought to be required for proper
positioning of Nef at membranes allowing for the formation of the Nef, MHC-I and
AP-1 complex. This was supported by a W13A mutation that disrupted MHC-I
downregulation and the ability of Nef to pull-down AP-1 in vitro (35). The
presence of the charged arginine residue at positions 13 in Nef C.BR92025
would presumably disrupt this intramolecular interaction (Figure 2.16A),
explaining the observed decrease in MHC-I downregulation.
To our knowledge, this is the first report of a role for A84 in proper expression of
HIV-1 Nef and therefore we wondered if the altered rate of protein turnover we
observed were attributable to this residue. Pulse-chase analysis of cells infected
with lentiviral vectors encoding Nef B.JRFL, C.BR92025 and their corresponding
mutants at position 84 revealed that these single amino acid mutations were
sufficient to alter the rate of protein turnover. When an A84V mutation was
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introduced into Nef B.JRFL, its pulse-chase profile shifted to resemble Nef
C.BR92025, whereas a V84A mutation introduced into Nef C.BR92025 shifted its
pulse-chase profile to resemble Nef B.JRFL (Figure 2.15A, B).
These findings were particularly interesting as alanine and valine are quite similar
in structure, with their side chains differing by just two methyl groups. Analysis of
previously reported structural models of HIV-1 Nef indicate residue 84 is located
within alpha helix-2 and is orientated towards the protein core (Figure 2.16B)
(35). As such the increased size of the valine side chain may cause
intramolecular steric hindrances that could affect Nef C.BR92025 structure. This
hypothesis is supported by a tryptophan mutant (A84W), which introduces a
large bulky residue and more severely disrupted Nef receptor downregulation
(Figure 2.15C). Accumulated Nef C.BR92025 could be targeted for removal from
the cell by the various protein degradation pathways (49, 68), resulting in the
observed increase in protein turnover.
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Figure 2.16 Potential intramolecular interactions of Nef W13 and A84.
Structural model of HIV-1 Nef (PDB ID: 4EN2). (A) The N-terminal alpha helix of
HIV-1 Nef is depicted as a cartoon structure in green with the side chain of W13
shown in orange. The remaining Nef structure is shown using surface
representation with electrostatic potentials depicted in red (negative charge) and
blue (positive charge). Zoomed in image showing W13 (top right) and W13R
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mutant (bottom right). (B) Nef alpha helix-2 is depicted as a cartoon structure in
green with the side chain of A84 shown in orange. The remaining Nef structure is
shown using surface representation with electrostatic potentials depicted in red
(negative charge) and blue (positive charge). Zoomed in image showing A84 (top
right) and A84V mutant (bottom right). (C) The amino acid sequence of NL4.3
Nef is shown with the N-terminal alpha helix and alpha helix-2 depicted using the
colors described in (A) and (B).
The conflicting results from the mutational studies in regard to residue 92
preclude conclusions on its role in Nef function. The findings from our Nef
B.JRFL mutational studies that residue 92 did not affect MHC-I downregulation is
in agreement with a recent report that mutation of the KEK94 motif failed to
disrupt MHC-I downregulation (69). In addition, an earlier study demonstrated
that K92 was dispensable for Nef-mediated CD4 downregulation (70), further
suggesting a limited role in Nef function.
Interestingly, there are a number of MHC-I epitopes that span residue 84,
suggesting strong immune pressure against consensus protein sequences in that
region (67, 71-73). Despite increased immune pressure, the presence of an
alanine at position 84 appears to be under positive selection, further supporting
its importance in function and/or expression of Nef (71, 72). This study adds to
other protein-wide screens of polymorphisms to assess genetic robustness of
HIV-1 proteins such as integrase (74) and capsid (75). Identification of highly
conserved residues that appear to have strict structural constraints may be useful
for the development of T cell based vaccines that include Nef as a target for CTL
responses.
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In conclusion, we have identified a subtype C reference strain deposited in the
NIH Los Alamos HIV Database that contains three point mutations at otherwise
highly conserved residues in HIV-1 Nef. We have shown that the presence of
these point mutations is responsible for decreased function and expression of the
viral protein. Of note, an alanine at residue 84 located in Nef alpha helix-2
appears to be essential for proper expression of HIV-1 Nef. The importance of
residue 84 in Nef biology provides an additional molecular target for disrupting
Nef function, an anti-HIV-1 approach that has gained interest in both cure and
treatment fields (76, 77).
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Chapter 3

3

Elucidating the mechanistic details of SERINC5
antagonism by HIV-1 Nef

3.1 Introduction
In order for HIV-1 to successfully replicate in host cells, it must not only
overcome the adaptive immune response, but also a collection of anti-viral host
proteins known as restriction factors (1, 2). Examples of restriction factors include
apolipoprotein

B

mRNA-editing

enzyme

catalytic

polypeptide-like

3G

(APOBEC3G) and bone marrow stromal cell antigen 2 (BST2), also termed
tetherin. APOBEC3G is a cytidine deaminase that is packaged into HIV-1 virions
and results in cytidine to uracil mutations in newly reverse transcribed viral DNA,
rendering the encoded HIV-1 proteins non-functional (3, 4). By binding to the
HIV-1 RNA genome, APOBEC3G also inhibits the binding of reverse
transcriptase, decreasing the subsequent production of viral DNA (5). Tetherin is
a cell surface protein that has an N-terminal transmembrane domain and a Cterminal glycosylphosphatidylinositol (GPI) membrane anchor. In HIV-1 infected
cells, the N-terminus of tetherin is embedded in the cellular lipid bilayer, while the
C-terminus is anchored in the lipid bilayer of budding virions through the GPI
domain. By simultaneously anchoring itself in both the host cell and virion,
tetherin acts to tether budding virions to the infected cell, preventing their release
and limiting the intercellular spread of HIV-1 (6). HIV-1 is able to replicate in the
presence of these restriction factors due to the activity of the viral accessory
proteins Vif and Vpu. Indeed, Vif counteracts the anti-HIV-1 activity of
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APOBEC3G by inducing ubiquitination and subsequent proteasomal degradation
of APOBEC3G, preventing its packaging in virions (4). Similar to Vif, Vpu targets
tetherin for degradation by inducing its ubiquitination. Furthermore, Vpu hijacks
the trafficking of tetherin, rerouting it from the cell surface to the trans-Golgi
network (TGN). Both degradation and rerouting of tetherin deplete the amount of
this restriction factor on the cell surface, allowing budding virions to be released
and increasing the spread of HIV-1 (6).
The anti-restriction factor activity of Vif and Vpu highlights the ability of HIV-1 to
utilize the functional flexibility of its accessory proteins to evolve mechanisms to
overcome host cell barriers to replication. The lentiviral accessory protein Nef is
known to counteract host restriction factors in the closely related simian
immunodeficiency virus (SIV), but HIV-1 Nef had not been shown to counteract a
host restriction factor until very recently (7).
Nef has long been known to increase the infectivity of HIV-1 virions in vivo, but
the mechanism used by Nef to achieve this increased infectivity has eluded
researchers for decades (8, 9). However, the recent discovery of the restriction
factor serine incorporator 5 (SERINC5) and its reported antagonism by Nef has
established the key player involved in this novel Nef function. Indeed, when cells
are infected with HIV-1 that is mutated such that it does not express Nef,
SERINC5 is located at the cell surface and incorporated into the viral membrane
during the viral budding process. Through an as of yet undetermined mechanism,
virion-resident SERINC5 molecules interfere with the fusion of virions with host
cells and the subsequent release of viral contents into the cytoplasm. By
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downregulating SERINC5 from the cell surface, Nef limits the incorporation of
SERINC5 in HIV-1 virions, increasing their infectivity and the spread of HIV-1 in
infected patients (10, 11).
Prior to the identification of SERINC5 as a novel HIV-1 restriction factor there
was limited research on the physiological role of SERINC5. SERINC5, also
referred to as C5orf12, is a multipass transmembrane protein with 10
transmembrane domains (12). Studies of the rat orthologue of SERINC5 have
implicated this protein in the biosynthesis of the serine containing lipids
phosphatidylserine and sphingolipids. SERINC5 may act as a scaffold protein at
the plasma membrane, allowing for the assembly of lipid synthesizing protein
complexes (13).
Following the identification of SERINC5 as an HIV-1 restriction factor, there have
been studies into the evolution of SERINC5 antagonism by Nef (14, 15), the
mechanism of SERINC5 viral restriction (16-20) and the mechanism by which
Nef antagonizes SERINC5 (21, 22). These studies have increased our
understanding of the implications of this function of Nef, however, there remains
multiple aspects of this interaction that remain unknown. Mutational studies have
implicated the trafficking protein AP-2 in the downregulation of SERINC5 (10, 11,
16), however the direct interaction motifs involved in Nef-mediated SERINC5
downregulation have not been fully described. Most studies have focused on the
impact of these mutations on HIV-1 infectivity rather than investigating the
Nef:SERINC5 interaction directly. Indeed, only recently was it demonstrated that
Nef forms a complex with SERINC5 in cells (22). Additionally, domain-swapping
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studies have shown that the fourth intracellular loop in SERINC5 is required for
its anti-infectivity effects, however, it is not known if this intracellular loop is
involved in a Nef:SERINC5 interaction (21).
In addition to elucidating details of Nef-mediated SERINC5 downregulation,
these recent studies have also created some confusion. Of particular interest is
the ultimate fate of downregulated SERINC5 in infected cells. There is
compelling evidence suggesting that SERINC5 downregulation is mechanistically
similar to Nef-mediated CD4 downregulation with both Nef functions involving an
AP-2

mediated

trafficking

pathway

(10,

14,

16).

Nef-mediated

CD4

downregulation relies on interactions with AP-2 and the beta subunit of the
coatomer COPI to traffic CD4 to lysosomes for degradation (23). Initial studies
demonstrating

the

requirement

for

AP-2

in

Nef-mediated

SERINC5

downregulation would suggest a similar fate to CD4. However, earlier studies
concluded that SERINC5 is not degraded following its downregulation and
instead cell surface levels of SERINC5 are decreased while total cellular levels
remain unchanged (10, 11, 16). This is contrary to the recent findings of Shi, J. et
al., who investigated the trafficking pathway that SERINC5 undertakes following
its

downregulation

and

demonstrated

sorting

of

SERINC5

into

the

aforementioned degradative lysosomal compartments (22).
Furthermore, these initial studies have largely focused on laboratory strains of
HIV-1 Nef or have used well described reference sequences. This approach is
valuable to establish the breadth of this Nef function and potential differences
between HIV-1 subtypes. This has allowed researchers to demonstrate that

148

SERINC5 downregulation is a conserved function of Nef and may play a role in
the interspecies spread of SIVs (14). However, these previous findings do not
provide

a

clear

picture

of

the

variability

of

Nef-mediated

SERINC5

downregulation and the importance of this function in the pathogenicity of Nef.
HIV-1 Nef has evolved to be a highly multifunctional protein, capable of
mediating numerous protein-protein interactions. The recent discovery of
SERINC5 is just the latest example of how Nef modifies the cellular architecture
of infected cells to best suit HIV-1 replication. The significant role Nef plays in
HIV-1 disease progression necessitates a comprehensive understanding of the
interactions mediated by Nef and their consequences. Herein, we have utilized
the biochemical technique bimolecular fluorescence complementation (BiFC) to
confirm the interaction of HIV-1 Nef with the restriction factor SERINC5 and used
mutational analysis to identify genetic determinants of this interaction in both
proteins. We also used BiFC to outline a detailed trafficking pathway used by Nef
to downregulate SERINC5 and support the findings that SERINC5 is ultimately
sorted into a degradative compartment. Finally, we analyzed the downregulation
of SERINC5 by 15 patient derived nef sequences and demonstrate that
SERINC5 downregulation is highly variable and more sensitive than CD4
downregulation to differences in Nef expression. These findings enhance our
understanding of how Nef is able to antagonize the restriction factor SERINC5,
allowing for optimal HIV-1 infectivity.

149

3.2 Methods
3.2.1

Cell Culture

CD4+ HeLa cells (ATCC, Manassas, VA) were grown in complete DMEM
containing 10% FBS (Wisent, Quebec, Canada), 100 U/ml penicillin and 100
µg/ml streptomycin (Hyclone, Logan, UT). All cells were grown at 37°C in the
presence of 5% CO2 and sub-cultured in accordance with supplier’s
recommendations.

3.2.2

Expression vectors

The pBJ5 plasmid encoding SERINC5 was kindly provided by Dr. Heinrich
Gottlinger (University of Massachusetts Medical School, Boston, MA). An XbaI
site within SERINC5 was used to insert an internal hemagglutinin (HA) epitope
tag between residues 290-291 (SERINC5 int.HA), as described previously (10).
N- and C-terminal deletion mutants were constructed using primers that
introduced a XhoI restriction enzyme (RE) site and an upstream start codon or a
NotI site and an early stop codon, respectively. Mutants were inserted into a
XhoI/NotI digested pBJ5 vector.
BiFC vectors were constructed by inserting Nef NL4.3 or the various Nef mutants
into a pVC-N1 plasmid (24). Inserts were PCR amplified with primers encoding
EcoRI and AgeI restriction enzyme (RE) sites and inserted into an EcoRI/AgeI
digested pVC-N1 vector. SERINC5-VN WT or the various SERINC5-VN mutants
were constructed in a similar fashion, but inserted into a XhoI/NotI digested pVNN1 vector.
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Nef-EGFP fusion plasmids were generated by inserting patient-derived Nef
sequences into the pEGFP-N1 (Takara, Mountain View, CA) expression plasmid.
pEGFP-N1 was digested with EcoRI and BamHI and Nef coding sequences were
introduced using isolate specific primers that added an EcoRI and BamHI site
with no stop codon to the 5’ and 3’ ends of Nef, respectively. The SERINC5-GFP
fusion plasmid was constructed using the same methods as above, but with
SERINC5 specific primers.
Sequencing was performed at the Robarts Research Institute Genomics Center
to confirm all constructs.

3.2.3

Bimolecular Fluorescence Complementation (BiFC)

For BiFC studies, CD4+ HeLa cells were seeded onto coverslips. Twenty-four
hours later, cells were transfected with VN and/or VC containing plasmids at
equal molar ratios with PolyJet transfection reagent (FroggaBio, Toronto,
Canada). Twenty-four hours post-transfection, cells were incubated for one hour
at room temperature to allow for fluorophore maturation (24). This maturation
period is needed to allow for the chemical reactions required to form the cyclic
fluorophore from the two non-fluorescent VN and VC fragments (25). Once
matured, cells were fixed in 4% PFA and prepared for immunofluorescence or
flow cytometry.

3.2.4

Immunofluorescence

The staining protocol used for immunofluorescence has been described
elsewhere (26). Briefly, all cells used in BiFC or localization studies were fixed
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24 hours post-transfection by washing twice with PBS, incubating for 20 minutes
in 4% PFA and subsequently washing three times in PBS. Intracellular
compartments were stained by first permeabilizing cells (5% BSA in PBS and
0.2% Triton X-100) for 1 hour and subsequently incubating with the appropriate
antibodies diluted in blocking buffer for 2 hours (anti-Rab5, Cell Signaling; 1:200,
anti-Rab7,

Cell

Signaling;

1:100,

anti-LAMP-1,

Developmental

Studies

Hybridoma Bank; 1:200, anti-TGN46, Sigma Aldrich; 1:200, anti-CD63,
Developmental Studies Hybridoma Bank; 1:200, anti-HA, Thermo Fisher
Scientific; 1:400). Cells were washed three times in blocking buffer and incubated
with a secondary antibody diluted in blocking buffer (donkey anti-rabbit Alexa
Fluor® 647 or donkey anti-mouse Alexa Fluor® 647 (1:1000; Jackson
ImmunoResearch, West Grove, PA)) for 2 hours at room temperature. Finally,
cells were washed three times in PBS (3 minutes each) and mounted onto glass
slides

using

Fluoromount-G

or

DAPI-Fluoromount-G

(Southern

Biotech,

Birmingham, AL).
Once stained, cells were observed using a Leica DMI6000 B with 63× or 100×
objectives using the FITC, Cy3, Cy5 and DAPI filter settings and imaged with a
Hamamatsu Photometrics Delta Evolve camera. Images were deconvolved using
the

Advanced

Fluorescence

Deconvolution

(Leica,

Wetzlar,

Germany)

application on the Leica Application Suite software. Co-localization analysis was
conducted using Pearson’s Correlation from the Image J plugin JACoP, as
described previously (27).
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3.2.5

Flow Cytometry

For BiFC experiments, CD4+ HeLa cells were prepared for flow cytometry
following fluorophore maturation (24). Cells were washed twice with PBS and
trypsinized for 3-5 minutes at 37°C and 5% CO2. Cells were then washed twice in
PBS and fixed in 2% PFA for 15 minutes at 4 degrees. Cells were finally washed
twice with PBS and read using the GFP channel on a BD FACSCanto II flow
cytometer. Data was analyzed using FlowJo software (version 9.6.4; TreeStar,
Ashland, OR) and the BiFC signal was determined by measuring the mean
fluorescence intensity (MFI) of GFP.
For receptor downregulation studies, CD4+ HeLa cells were transfected with NefEGFP and/or SERINC5 int.HA plasmids according to the manufacture’s
instructions. Twenty-four hours post-transfection cells were washed twice with
PBS and trypsinized for 3-5 minutes at 37°C and 5% CO2. Cells were then
washed twice in PBS and fixed in 2% PFA for 15 minutes at 4 degrees. Following
fixation, cells were washed twice with PBS and incubated with the appropriate
fluorophore-conjugated antibody (APC-conjugated mouse anti-human CD4,
1:250, clone OKT4, BioLegend, San Diego, CA; Alexa Fluor® 647 mouse antiHA.11, 1:250, BioLegend, San Diego, CA) while rocking at room temperature for
1 hour. Cells were washed twice with PBS and read using the GFP and APC
channels on the BD FACSCanto II flow cytometer. Data was analyzed using
FlowJo software (version 9.6.4; TreeStar, Ashland, OR).
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3.2.6

Western Blots

Transfected CD4+ HeLa cells were collected at 24 hours by lysis in SDS-PAGE
sample buffer (0.062 M Tris pH 6.8, 5% 2-mercaptoethanol, 10% glycerol, 2%
SDS). Cells were lysed at 4°C while rotating for 20 min before insoluble cellular
debris was removed by centrifugation at 20 000 ×g for 20 min. Lysates were
sonicated at 30% max power (Sonic Dismembrator Model 300, Thermo Fisher
Scientific, Waltham, MA) and proteins were separated on 12% SDS-PAGE gels
and subsequently transferred to nitrocellulose membranes. Membranes were
blocked in 5% non-fat skimmed milk (Bioshop, Burlington, Ontario, Canada) in
TBS containing 0.1% Triton X-100 for 45 min, then incubated overnight at 4°C
with various primary antibodies: rabbit anti-Nef polyclonal antibody (1:2500;
catalog number 2949, NIH AIDS Research and Reference Reagent Program,
USA), rabbit anti-GFP polyclonal antibody (1:3000, Clontech, Takara), rabbit antiSERINC5 polyclonal antibody (1:1000, Abcam PLC, Cambridge, UK, mouse antiHA monoclonal antibody (1:2500, Thermo Fisher Scientific, Waltham, MA), or
mouse anti-β-actin monoclonal IgG (1:3000, Thermo Fisher Scientific, Waltham,
MA). Membranes were washed 3 times in TBS containing 0.1% Triton X-100
and incubated for 2 hours at room temperature with the appropriate speciesspecific HRP-conjugated antibodies (1:3000, Thermo Fisher Scientific, Waltham,
MA). Blots were developed using ECL substrates (Millipore Inc., Billerica, MA)
and a C-DiGit chemiluminescence western blot scanner (LI-COR Biosciences,
Lincoln, NE).
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3.2.7

Patient Cohort Information

Patient-derived Nef proteins were isolated from PBMCs collected from treatmentnaïve, HIV-1 infected women from Zimbabwe or Uganda. The details of this
cohort have been described previously (28-30). Briefly, women from Zimbabwe
or Uganda were enrolled in a study looking at the effects of hormonal
contraception on HIV-1 acquisition. Participants were eligible if they were
between the ages of 18 and 35, HIV-negative, sexually active, not pregnant, and
had no history of injection drug use or blood transfusion in the past 3 months
(30). Participants were ineligible if they had a hysterectomy or used an
intrauterine device or had an abortion in the last 30 days (30). Women were
monitored and those who contracted HIV-1 were enrolled in the Hormonal
Contraception and HIV-1 Genital Shedding and Disease Progression among
Women with Primary HIV Infection study. HIV-1 infected women were followed
longitudinally, with CD4 cell counts and viral load measurements taken
approximately every 3 months. For this study, patients were selected if they had
samples taken within 150 days post sero-conversion to avoid isolating
sequences from women with extensive quasispecies. Patient nef sequences
were isolated with a nested-PCR protocol using primers that bind upstream of nef
in the env open reading frame and downstream of nef in the HIV-1 3’ LTR (Table
3.1). Sequences were obtained from 45 patients, 15 of those sequences were
successfully cloned into expression vectors. Sequences denoted with a four digit
isolate number were from HIV-1 infected women from Zimbabwe and represent
HIV-1 group M subtype C. Sequences denoted with a hyphenated isolate number
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were from HIV-1 infected women from Uganda and represent HIV-1 group M
subtype A. Subtyping was performed based on protease (PR), reverse
transcriptase (RT) and env sequences, as described previously (31). Access to
this cohort was kindly provided by Dr. Eric Arts (University of Western Ontario,
London, ON). All human ethics protocols have been approved by Case Western
University and/or Western University (Project title – In vitro analysis of HIV fitness
and evolution in newly HIV infected women; Project ID – 105737).
Table 3.1 Primers used for patient-derived nef sequencing.
Primer

PCR Round Direction

Sequence

JD-352

I

Sense

AGGAAGCACTATGGGCGC

JD-617

I

Sense

GCTGACGGTACAGGCCA

JD-616

I

Sense

TTCCTTGGGTTCTTGGGA

JD-355

I

Anti-Sense

GCACTCAAGGCAAGCTTTAT

JD-354

I

Anti-Sense

GAGGCTTAAGCAGTGGGTTC

JD-310

II

Sense

AGCTACCACCGCTTGAGAGAC

JD-618

II

Sense

GAAGAAGGTGGAGAGAGAG

JD-619

II

Sense

TGTGGAACTTCTGGGAC

JD-621

II

Anti-Sense

CCAGGCTCAGATCTGGTC

JD-620

II

Anti-Sense

ACCAGAGAGACCCAGTACA

3.2.8

Sequence alignments

Clustal Omega was used to generate amino acid sequence alignments of Nef
NL4.3 and Nef 2130 (32, 33).
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3.2.9

Statistical analysis

Statistical analysis was conducted using GraphPad Prism software (GraphPad
Software, Inc., La Jolla, CA). All results were analyzed by one-way analysis of
variance except the correlation of receptor downregulation and Nef expression
(Figure 3.7D), which was analyzed by linear regression.

3.3 Results
3.3.1

Cellular interaction of SERINC5 and Nef requires a diacidic
motif in Nef.

Initially, we sought to explore the mechanistic details of Nef-mediated SERINC5
downregulation. To do so, we first wanted to demonstrate a Nef:SERINC5
interaction

in

cells

using

the

technique

of

bimolecular

fluorescence

complementation (BiFC). BiFC employs a split fluorophore to visualize the close
association of two proteins. The N- and C-terminal portions of the Venus
fluorophore, VN and VC, respectively, are fused to two proteins of interest, which
are then co-expressed. If the two proteins of interest come within 20 angstroms
the split fluorophore is able to reconstitute and can be detected by fluorescence
microscopy or flow cytometry (25). Accordingly, we constructed plasmids
encoding the fusion proteins SERINC5-VN (S5-VN in Figure 3.1) and Nef-VC
and co-transfected them in CD4+ HeLa cells. Cells were imaged after a 24 hour
incubation and a 1 hour reconstitution at room temperature. Strikingly, there was
a strong fluorescent signal in cells co-expressing both protein fragments
suggesting that Nef and SERINC5 are in close proximity within cells (Figure
3.1A, B).
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We next sought to determine what motifs in HIV-1 Nef were involved in the
Nef:SERINC5 interaction. Previous reports had implicated the Nef dileucine motif
at position 164/165 (LL165) and the diacidic motif at positions 174/175 (DD175) as
important for Nef-mediated SERINC5 downregulation (16), but it remained
unknown if these motifs were involved in a Nef:SERINC5 interaction. To test this,
we co-transfected CD4+ HeLa cells with SERINC5-VN and Nef-VC proteins that
were mutated at either the dileucine motif (Nef-VC LL/AA165) or at the diacidic
motif (Nef-VC DD/GA175) and visualized for potential reconstitution of the Venus
fluorophore using fluorescence microscopy. When compared to cells expressing
wild-type Nef (Nef-VC WT), cells expressing Nef-VC LL/AA165 or Nef-VC
DD/GA175 showed a significant decrease in BiFC signal, however, the effect of
the Nef LL/AA165 mutation was less severe and highly variable when compared to
the Nef DD/GA175 mutation (Figure 3.1A, B). These findings suggest that the
Nef:SERINC5 interaction is dependent on the aspartic acid residues at positions
174 and 175 and to a lesser extent on the leucine residues at positions 164 and
165.
In order to corroborate the BiFC readout using an alternative method, we also
measured the BiFC signal between Nef and SERINC5 by flow cytometry.
Accordingly, we co-expressed Nef-VC WT, LL/AA165 or DD/GA175 and SERINC5VN fusion proteins and measured the BiFC signal on the GFP channel.
Importantly, when the fusion proteins were expressed on their own, there was no
detectable fluorescence (Figure 3.1C, D). As in our fluorescence microscopy
experiments (Figure 3.1A, B), robust fluorescence was detected upon the co-
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expression of Nef-VC WT and SERINC5-VN (Figure 3.1C, D). However, when
Nef was mutated at the diacidic motif, Nef-VC DD/GA175, there was a significant
decrease in the Nef:SERINC5 BiFC signal (Figure 3.1C, D). Interestingly, when
measured by flow cytometry, the Nef-VC LL/AA175 mutant did not disrupt the
Nef:SERINC5 BiFC signal (Figure 3.1C, D). These findings support the role of
the Nef diacidic motif, Nef DD175, in the Nef:SERINC5 interaction, but suggest
that the Nef LL165 motif does not play a major role in mediating the Nef:SERINC5
interaction.
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(A) CD4+ HeLa cells were co-transfected with SERINC5-VN and one of Nef-VC
WT, Nef-VC LL/AA165, or Nef-VC DD/GA175. Twenty-four hours post-transfection
cells were imaged on the FITC channel. Imaged cells were manually outlined to
aid visualization. (B) The mean fluorescence intensity (MFI) of the BiFC signal
was measured using ImageJ software and quantified relative to the signal from
SERINC5-VN/Nef-VC WT co-transfected cells. (n≥31, **** p<0.0001) (C) CD4+
HeLa cells were co-transfected as in (A) and then prepared for flow cytometry
and read using the GFP channel. A representative histogram is shown. (D) GFP
MFI, representing BiFC signal, was quantified from 3 independent experiments.
(*** p<0.001)

3.3.2

SERINC5 with intracellular loop four deletion maintains a
BiFC fluorescent signal with Nef.

Upon identifying the diacidic motif of Nef (Nef DD175) as important for the
Nef:SERINC5 interaction (Figure 3.1), we next mapped the regions of SERINC5
that were required for this interaction. Since SERINC5 has only recently begun to
be studied, there is limited information available on amino acid motifs involved in
its function. As a result, instead of introducing point mutations in SERINC5, we
made larger deletions of regions we suspected may be involved in its interaction
with Nef (Figure 3.2A). SERINC5 is a multi-pass transmembrane protein with 10
transmembrane domains. We used topology predicting software (TMHMM Server
v. 2.0, DTU Bioinformatics) to identify potential regions in SERINC5 with which
Nef could interact (34, 35). We focused on the 3 largest intracellular regions as
they would be the putative interaction domains with the cytosolic Nef protein.
These intracellular SERINC5 domains are: the N-terminal and C-terminal tails as
well as the fourth and largest intracellular loop. An 8 amino acid section of the Nterminal tail, SERINC5 int.HA d24-32, was targeted for deletion as it preserved a
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predicted signal peptide sequence in the N-terminal 23 amino acids required for
sorting SERINC5 to the cell surface. A large portion of the fourth intracellular
loop, SERINC5 int.HA d339-384, was also deleted to try and maximise the
likelihood of including any potential binding motifs. In addition, two C-terminal
deletions were made resulting in SERINC5 int.HA 1-449 and SERINC5 int.HA 1451 (Figure 3.2A). These two separate C-terminal deletions were made as
transmembrane predicting software differed in their estimation of where the final
transmembrane segment of SERINC5 became intracellular. All mutated
SERINC5 proteins were designed with an internal HA epitope tag to facilitate
subsequent experiments (Figure 3.2A).
We first determined if our engineered SERINC5 deletions or truncations affected
SERINC5 protein expression. Plasmids encoding the SERINC5 int.HA (referred
to as S5 WT in Figure 3.2) and the various SERINC5 mutants (S5 d24-32, d339384, 1-449 and 1-451 in Figure 3.2) were transfected in CD4+ HeLa cells and
stained with an Alexa Fluor® 647 conjugated anti-HA antibody to detect cell
surface SERINC5 protein levels. Transfected and stained cells were analyzed by
fluorescent microscopy and MFI of Alexa Fluor® 647 was quantified for each
condition (Figure 3.2B, C). When compared to non-transfected cells, all truncated
proteins could be visualized suggesting the truncated proteins were expressed.
However, when compared to wild-type, SERINC5 int.HA d24-32, 1-449 and 1451 had a decreased Alexa Fluor® 647 MFI, suggesting these deletions may
interfere with trafficking of SERINC5 (Figure 3.2A, B). In addition to testing cell
surface levels of the SERINC5 mutants by microscopy, we utilized western
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blotting to detect total expression of the mutants in transfected cells. CD4+ HeLa
cells were transfected as above, and lysates were collected at 24 hours. The
various SERINC5 proteins were detected using both an anti-HA and antiSERINC5 antibody (Figure 3.2F). The only commercially available antibody
against SERINC5 was raised against an epitope contained in the d339-384
deletion, thus SERINC5 int.HA d339-384 was only detectable using the anti-HA
antibody. Interestingly, all truncated SERINC5 proteins were readily detectable
by western blot. Indeed, staining with the anti-HA antibody produced a similar
pattern to that observed with fluorescent microscopy (Figure 3.2A, B), but
staining with anti-SERINC5 resulted in the detection of strong signals for the Cterminal deletion mutants SERINC5 int.HA 1-449 and 1-451 (Figure 3.2F).
Together, these findings suggest that the SERINC5 deletions did not completely
disrupt the folding or stability of SERINC5, but impaired cell surface levels of all
but the SERINC5 variant with the deletion of the fourth intracellular loop
(SERINC5 int.HA d339-384).
In order to determine if the SERINC5 deletion mutants had an impact on the
Nef:SERINC5 interaction, we next used these SERINC5 mutations (Figure 3.2A)
in BiFC experiments. Accordingly, the SERINC5 mutants were fused to the Nterminal portion of the Venus fluorophore to make them compatible with Nef-VC
for BiFC experiments. CD4+ HeLa cells were co-transfected with Nef-VC and
SERINC5 int.HA-VN (S5-VN WT in Figure 3.2) or the various SERINC5 int.HAVN deletion mutants (S5-VN d24-32, d339-384, 1-449 and 1-451 in Figure 3.2)
and analyzed by fluorescence microscopy to determine the BiFC MFI. As with
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our previous BiFC experiments, we were only able to detect a fluorescent signal
when both Nef-VC and SERINC5 int.HA-VN were co-transfected and not when
unfused VN and VC fragments were co-transfected (Figure 3.2C, D). A BiFC
signal was also detectable for all mutants, but only SERINC5 int.HA-VN,
SERINC5 int.HA-VN d339-384 and SERINC5 int.HA-VN 1-449 had a BiFC signal
significantly increased from the negative control, VC:VN (Figure 3.2D). Whereas
Nef-VC:SERINC5 int.HA-VN 1-449 had a BiFC signal significantly less than NefVC:SERINC5 int.HA-VN, the deletion of the fourth intracellular loop (SERINC5
int.HA-VN d339-384), did not decrease the BiFC signal (Figure 3.2D). NefVC:SERINC5 int.HA-VN d339-384 showed a strong fluorescent signal not
significantly different than Nef-VC:SERINC5 int.HA-VN, suggesting that upon
deletion of this intracellular region Nef-VC and SERINC5 int.HA-VN d339-384 are
still able to reconstitute an active fluorophore. The remaining mutants did have
decreased BiFC signals when co-transfected with Nef-VC, but when compared
relative to their total expression (Figure 3.2C), these mutants did not appear to
further disrupt the Nef:SERINC5 interaction.
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Figure 3.2 Characterizing SERINC5 deletion mutants for expression and
BiFC potential.
(A) Schematic of SERINC5 int.HA (S5 WT) deletion mutants showing regions
deleted (red boxes) and location of HA epitope tag. (B) CD4+ HeLa cells were
transfected with the indicated SERINC5 (S5) constructs and at 24 hours posttransfection were surface stained with an anti-HA antibody conjugated to Alexa
Fluor® 647. Scale bar represents 20 µm. (C) CD4+ HeLa cells were cotransfected with Nef-VC and a VN-tagged version of the indicated SERINC5
constructs (S5-VN). At 24 hours post-transfection cells were imaged for BiFC.
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Scale bar represents 20 µm. (D) ImageJ software was used to quantify surface
Alexa Fluor® 647 MFI of cells from (B), (n≥17). (E) The MFI of the BiFC signal
from (C) was measured using ImageJ software, (n≥14, * are compared to VC:VN,
* p<0.05, **** p<0.0001). (F) CD4+ HeLa cells were transfected with the
SERINC5 constructs shown in (A) and collected and lysed at 24 hours posttransfection. Proteins were detected by western blot using an anti-SERINC5,
anti-HA or anti-actin antibody. (Note: the epitope that is detected by antiSERINC5 is deleted in SERINC5 int.HA d339-384 (S5 d339-384))

3.3.3

SERINC5 lacking intracellular loop 4 is susceptible to
NefNL4.3-mediated downregulation.

Our findings that deletion of the fourth intracellular loop (SERINC5 int.HA d339384) did not disrupt the Nef:SERINC5 BiFC signal (Figure 3.2C, D) was
surprising given that this region had recently been implicated in the anti-infectivity
activity of SERINC5 (21). However, that study did not explore the interaction
between Nef and SERINC5. Given that the Nef-VC:SERINC int.HA-VN d339-384
interaction gave a robust BiFC signal (Figure 3.2), we next wanted to determine if
Nef could remove this mutant SERINC5 from the cell surface. Before measuring
Nef-mediated SERINC5 downregulation efficiency, we first wanted to determine if
the deletions introduced into SERINC5 impaired its ability to reach the cell
surface. CD4+ HeLa cells were transfected with SERINC5 int.HA, d24-32, d339384, 1-449 or 1-451 (S5 WT, d24-32, d339-384, 1-449 or 1-451 in Figure 3.3),
stained with anti-HA Alexa Fluor® 647 and then cell surface levels were
quantified by flow cytometry. We observed that compared to SERINC5 int.HA,
when cells were transfected with SERINC5 int.HA d24-32 and 1-449, very few
cells expressed these mutant SERINC5 variants on their surface. This is in
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contrast to SERINC5 int.HA d339-384 and 1-451, which both had a similar size
of SERINC5 positive population compared to SERINC5 int.HA (Figure 3.3A, B).
We also were able to measure the density of SERINC5 on the surface of cells by
measuring Alexa Fluor® 647 MFI. Whereas the d24-32 and 1-449 deletions
decreased the number of cells expressing SERINC5 on their surface, none of the
SERINC5 deletions completely abrogated the MFI of SERINC5 on the cell
surface. However, SERINC5 int.HA d24-32 and 1-451 had significantly
decreased cell surface SERINC5, suggesting that these mutations may affect the
ability of SERINC5 to reach the cell surface (Figure 3.3A, B).
For our analysis of Nef-mediated SERINC5 downregulation we focused on
SERINC5 int.HA d339-384 and 1-451, as the other two deletion mutants had
minimal SERINC5 positive populations. Accordingly, CD4+ HeLa cells were cotransfected with EGFP or Nef-EGFP and SERINC5 int.HA, d339-384 or 1-451
and stained with anti-HA Alexa Fluor® 647. Cells were analyzed using flow
cytometry by first gating on GFP positive cells and then measuring Alexa Fluor®
647 MFI (SERINC5 expression) (Figure 3.3C). The fold decrease in SERINC5
downregulation was calculated by taking the ratio of Alexa Fluor® 647 MFI in
cells transfected with EGFP and SERINC5 int.HA, d339-384 or 1-451 compared
to cells transfected with Nef-EGFP and SERINC5 int.HA, d339-384 or 1-451.
Surprisingly, deletion of the fourth intracellular loop (S5 d339-384) or the Cterminal deletion in 1-451 (S5 1-451) did not impair the ability of NefNL4.3 to
downregulate SERINC5 (Figure 3.3D). These findings suggest that SERINC5
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with an intracellular loop 4 deletion is still susceptible to NefNL4.3-mediated
downregulation.
B.
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Figure 3.3 SERINC5 with deletion of intracellular loop 4 is susceptible to
NefNL4.3-mediated downregulation.
(A) Cell surface expression of SERINC5 deletion mutants. CD4+ HeLa cells were
transfected with the indicated SERINC5 constructs and stained with Alexa Fluor®
647 anti-HA 24 hours post-transfection. Cells were analyzed by flow cytometry
and gated based on a non-transfected control. (B) Cell surface expression of
SERINC5 deletion mutants were quantified based on either the % of SERINC5
positive cells (teal) or the Alexa Fluor® 647 MFI of SERINC5 positive cells (red).
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(C) SERINC5 downregulation was measured in CD4+ HeLa cells transfected with
SERINC5 int.HA WT, SERINC5 int.HA d339-384 or SERINC5 int.HA 1-451 and
EGFP or Nef-EGFP. Cells were gated based on non-transfected cells and cells
transfected with EGFP alone. (D) Fold decrease in cell surface SERINC5
expression was quantified based on 3 independent experiments. Fold decreases
were calculated by taking the ratio of Alexa Fluor® 647 MFI in Nef-EGFP vs.
EGFP co-transfected cells

3.3.4

HIV-1 Nef traffics SERINC5 to LAMP-1 and CD63 positive
compartments.

After demonstrating that Nef and SERINC5 interact in cells, and defining the
genetic determinants of this interaction, we next wanted to elucidate where in the
cell Nef was trafficking SERINC5 in order to determine the functional significance
of this interaction. To do this, we once again employed the technique of BiFC,
this time in conjunction with counter staining for various intracellular
compartments. We first focused on the endosomal trafficking pathway that can
be visualized by staining for the trafficking proteins Rab5 and Rab7. Rab5 and
Rab7 mark early and late endosomes, respectively, and represent a common
pathway used by Nef to traffic cellular proteins, most notably MHC-I and CD4,
away from the cell surface (26, 36). To define how Nef alters the subcellular
localization of SERINC5 we first transfected CD4+ HeLa cells with SERINC5EGFP (S5-EGFP in Figure 3.4) alone to observe where SERINC5 localized in the
absence of Nef (Figure 3.4A). We then compared this subcellular distribution with
that of the Nef:SERINC5 BiFC signal in CD4+ HeLa cells co-transfected with NefVC and SERINC5-VN (S5-VN in Figure 3.4B). Neither SERINC5-EGFP or the
Nef:SERINC5 signal showed a strong co-localization with the early endosomal
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marker Rab5, both with Pearson’s correlation below 0.3 (Figure 3.4C; 0.27 v.
0.29). There was a slightly increased co-localization with the late endosomal
marker Rab7, with the Nef:SERINC5 BiFC signal co-localizing significantly more
than SERINC5-EGFP, however, both had Pearson’s correlation less than 0.5
(Figure 3.4C; 0.39 v. 0.46). These findings suggest that Nef:SERINC5 complexes
have increased trafficking to late endosomal compartments, but that this
localization does not represent grossly abnormal trafficking of SERINC5 (Figure
3.4D). The presence of SERINC5-EGFP and the Nef:SERINC5 BiFC complex in
late endosomes is not surprising given that endocytosed cargo often traffics
through the late endosome to its final destination.
The next compartment we investigated was that of multivesicular bodies (MVBs).
It is well documented that Nef expression leads to the accumulation of MVBs and
that Nef traffics cargo, such as CD4, through MVBs en route to lysosomes (23,
37, 38). MVBs contain intraluminal vesicles, the contents of which are degraded
by fusion of MVBs with lysosomes or released extracellularly as exosomes when
MVBs fuse with the plasma membrane (39). Indeed, the routing of Nef within
MVBs is essential for the release of Nef in exosomes . MVBs can be labelled with
antibodies against the membrane protein CD63, a heavily glycosylated
tetraspanin protein that is enriched in MVBs and used as a marker for exosomes
(39). Strikingly, SERINC5-EGFP displayed little co-localization with CD63
positive compartments, with a Pearson’s correlation of 0.21, but the
Nef:SERINC5 BiFC complex showed a significantly increased co-localization,
0.52, with the marker for MVBs (Figure 4C). This discrepancy suggests that Nef
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alters the physiologic subcellular distribution of SERINC5 by trafficking it to a
CD63 positive compartment (Figure 3.4D).
In order to determine where SERINC5 is ultimately trafficked inside cells, we
explored two terminal trafficking compartments. The TGN, where Nef sequesters
MHC-I following its downregulation (26, 40), can be labelled using TGN46, which
recognizes an integral trans-Golgi membrane protein. Similar to the late
endosomes, we observed that there was co-localization of both SERINC5-EGFP
and Nef:SERINC5 BiFC with the TGN, but significantly more SERINC5-GFP
localized to the TGN (Figure 3.4C; 0.52 v. 0.41). The other terminal trafficking
compartment we explored was the lysosome, which can be labelled using
antibodies that target lysosomal-associated membrane protein-1 (LAMP-1) (41).
Nef is known to target internalized CD4 to lysosomes, resulting in its degradation
(23). Interestingly, we saw a distinct difference in the co-localization patterns of
SERINC5-EGFP and the Nef:SERINC5 BiFC complex (Figure 3.4A, B). As with
the MVBs, we observed that SERINC5-EGFP did not co-localize strongly with
LAMP-1, whereas the Nef:SERINC5 BiFC complex had a significantly increased
co-localization with the lysosomal marker (Figure 3.4C; 0.19 v. 0.59). Taken
together, our findings suggest HIV-1 Nef is able to hijack normal SERINC5
trafficking and ultimately shuttle this restriction factor to a degradative
compartment, via MVBs (Figure 3.4D).
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Figure 3.4 HIV-1 Nef reroutes SERINC5 to CD63 and LAMP-1 positive
compartments.
(A) CD4+ HeLa cells were transfected with SERINC5-EGFP (S5-EGFP) and at
24 hours post-transfection were permeablized and stained for markers of
subcellular compartments. Representative images are shown. Scale bar
represents 20 µm. (B) CD4+ HeLa cells were co-transfected with Nef-VC and
SERINC5-VN (S5-VN) and at 24 hours post-transfection were permeablized and
stained for markers of subcellular compartments. Representative images are
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shown. Merged images from cells transfected with VC and VN not attached to
target proteins are included to show specificity of BiFC signal. Scale bar
represents 20 µm. (C) Quantification of co-localization between subcellular
markers and SERINC5-EGFP (green) or Nef:SERINC5 BiFC (red). Colocalization was determined using Pearson’s Correlation of at least 30 cells for
each condition. (* p<0.05, ** p<0.01, **** p<0.0001) (D) Schematic showing the
BiFC interaction of Nef and SERINC5 and the trafficking route taken by
SERINC5 in the presence or absence of Nef.

3.3.5

Altered trafficking of SERINC5 requires the Nef diacidic and
dileucine motifs.

To confirm the altered trafficking of SERINC5 and investigate the Nef motifs
involved, we next conducted BiFC experiments using Nef proteins mutated at the
dileucine (Nef-VC LL/AA165) or diacidic motifs (Nef-VC DD/GA175). We focused
on how these mutants affected the trafficking of SERINC5 to CD63 and LAMP-1
positive compartments, as these were the prominent differences observed
between SERINC5-EGFP and Nef:SERINC5 (Figure 3.4) and these motifs are
important in the Nef:SERINC5 interaction (Figure 3.1). CD4+ HeLa cells were cotransfected with SERINC5-VN and Nef-VC WT, LL/AA165 or DD/GA175 and then
counter stained with antibodies against CD63 or LAMP-1 (Figure 3.5A, C). As
anticipated due to its role in the Nef:SERINC5 interaction, mutation of the diacidic
motif significantly decreased the ability of Nef to shuttle SERINC5 to CD63 and
LAMP-1 positive vesicles (Figure 3.5B, D; p<0.0001). Interestingly, despite
inconclusive findings on its role in the Nef:SERINC5 interaction (Figure 3.1),
mutation of the dileucine motif decreased the ability of Nef to shuttle SERINC5 to
the same extent as mutation of the diacidic motif (Figure 3.5B; p=0.24, Figure
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5D; p=0.68). These findings suggest that the although the Nef LL165 motif plays a
minor role in the Nef:SERINC5 interaction, this motif, along with Nef DD175, is
required for the diversion of SERINC5 to MVBs and lysosomes.
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Figure 3.5 Diacidic and dileucine motifs in Nef are required for altered
trafficking of SERINC5.
CD4+ HeLa cells were transfected with SERINC5-VN and Nef-VC LL/AA165 or
Nef-VC DD/GA175. Twenty-four hours post-transfection cells were stained for
CD63 (A) or LAMP-1 (C). Representative images are shown. Scale bars
represent 20 µm. Co-localization of the BiFC signal with CD63 (B) or LAMP-1 (D)
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was quantified based on Pearson’s Correlation for cells co-transfected with
SERINC5-VN and Nef-VC WT (green), LL/AA165 (yellow) or DD/GA175 (orange).
(n≥16 cells; **** p<0.0001)

3.3.6

Steady state levels of SERINC5 are reduced upon Nef
expression.

Given that Nef is shuttling SERINC5 through MVBs to lysosomes (Figure 3.4),
we hypothesized that the levels of SERINC5 in Nef expressing cells would be
decreased. To test this, we analyzed SERINC5 protein levels in CD4+ HeLa cells
co-transfected with SERINC5 int.HA (S5 in Figure 3.6) and EGFP, Nef-EGFP or
Nef-EGFP DD/GA175. SERINC5 int.HA was readily detectable in cells cotransfected with SERINC5 int.HA and EGFP, however, when SERINC5 int.HA
was expressed with Nef-EGFP there was a marked decrease in SERINC5 int.HA
levels by western blot (Figure 3.6). Interestingly, when SERINC5 int.HA was cotransfected with Nef mutated at its diacidic motif, Nef-EGFP DD/GA175, we no
longer observed a decrease in SERINC5 int.HA levels. These findings support
the trafficking of SERINC5 to MVBs and subsequent trafficking to a degradative
compartment or release through extracellular vesicles. Furthermore, these
findings also support the role of the diacidic motif in the downregulation and
decrease of cellular SERINC5 levels.
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Figure 3.6 HIV-1 Nef decreases SERINC5 protein levels.
CD4+ HeLa cells were either transfected individually with SERINC5 int.HA (S5),
EGFP, Nef-EGFP or Nef-EGFP DD/GA175, or co-transfected with SERINC5
int.HA (S5) and EGFP, Nef-EGFP or Nef-EGFP DD/GA175. At 24 hours posttransfection cells were lysed and analyzed for SERINC5 expression by western
blot using an anti-SERINC5 antibody.

3.3.7

SERINC5 downregulation is highly variable among patient
derived Nef isolates.

Nef appears to use a similar mechanistic pathway to downregulate CD4 and
SERINC5 (11, 42, 43). It is well documented that CD4 downregulation is highly
conserved among HIV-1 Nef proteins (44). Therefore, we were interested if
SERINC5 downregulation displayed this same level of conservation. To do so,
we used 15 Nef patient isolates from a cohort of treatment-naïve, HIV-1 infected
women from Uganda and Zimbabwe. Sequences from Uganda were HIV-1 group
M subtype A, whereas those from Zimbabwe were HIV-1 group M subtype C.
These women were enrolled in a study to determine the effect of hormonal
contraception on HIV-1 transmission. Participants were routinely tested for HIV-1
infection by serology and once they sero-converted they had CD4 cell counts and
viral loads measured throughout their follow-up (28-30). nef sequences were
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isolated from purified PBMCs by PCR and cloned into an mammalian expression
vector to generate EGFP fusion proteins for flow cytometry analysis. To test the
functionality of these patient Nef isolates, CD4+ HeLa cells were transfected with
the various Nef-EGFP plasmids, stained with an anti-CD4 antibody and CD4
downregulation

was

measured

by

flow

cytometry.

As

expected,

CD4

downregulation was conserved among the HIV-1 Nef proteins (Figure 3.7A). All
isolates except 2130 showed significantly enhanced CD4 downregulation
efficiency compared to our negative control, cells transfected with EGFP alone,
but not significantly different than our positive control, cells transfected with Nef
NL4.3-EGFP. In addition to analyzing Nef function, these EGFP-fused Nef
proteins enabled the examination of protein expression by measuring the EGFP
MFI levels in transfected cells. Unlike CD4 downregulation, we observed a high
level of variability in regards to Nef expression among isolates. With isolates
showing significantly increased or decreased EGFP MFI compared to Nef NL4.3EGFP (Figure 3.7A). These results suggest that the Nef isolates retrieved from
this cohort are functionally active, despite varying expression levels. The
variability in Nef expression was confirmed by western blot of CD4+ HeLa cells
transfected with the Nef-EGFP fusion proteins (Figure 3.7B).
After establishing the functionality of the Nef isolates, we next investigated the
ability of these proteins to downregulate SERINC5. CD4+ HeLa cells were cotransfected with SERINC5 int.HA and the various Nef isolates, stained with an
anti-HA antibody conjugated to Alexa Fluor® 647 and SERINC5 downregulation
was determined by flow cytometry. Interestingly, in contrast to CD4
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downregulation, SERINC5 downregulation varied greatly among Nef isolates
(Figure 3.7C). As with the above experiments, we observed a wide range of Nef
expression as measured by EGFP MFI. Unlike CD4, these differences in protein
expression greatly influenced

SERINC5 downregulation, with more highly

expressed Nef proteins tending to downregulate SERINC5 to a larger degree
(Figure 3.7D). However, there were a number of isolates including 2005, 2391
and 2634 that displayed high Nef expression by EGFP MFI, but presented
minimal SERINC5 downregulation. Of note, as with CD4 downregulation, Nef
isolate 2130 failed to downregulate SERINC5 any more than cells transfected
with EGFP alone. Interestingly, when comparing 14 Nef isolates, we observed a
significant positive correlation between isolate expression and SERINC5
downregulation, but not with CD4 downregulation (Figure 3.7D). This correlation
was seen when Nef 2130 was removed due to mutations that disrupted its
expression (Figure 3.8). These results demonstrate that Nef-mediated SERINC5
downregulation is more variable than CD4 downregulation among HIV-1 infected
individuals and is more sensitive to differences in Nef expression.
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Figure 3.7 SERINC5 downregulation is highly variable among patient
derived Nef proteins.
Nef protein sequences were isolated from a cohort of treatment-naïve, HIV-1
infected women. (A) CD4+ HeLa cells were transfected with EGFP or one of the
indicated Nef-EGFP fusion proteins. At 24 hours post-transfection EGFP positive
cells were analyzed for CD4 expression by flow cytometry using an APC antiCD4 antibody. FlowJo software was used to quantify fold decrease in surface
CD4 levels (purple) and Nef expression (green) based on EGFP MFI from 3
independent experiments. (B) CD4+ HeLa cells were tansfected as in (A) and at
24 four hours post-transfection analyzed for Nef-EGFP fusion protein and
GAPDH expression using an anti-GFP antibody. (C) CD4+ HeLa cells were cotransfected with SERINC5 int.HA and EGFP or one of the indicated Nef-EGFP
fusion proteins. At 24 hours post-transfection EGFP positive cells were analyzed
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for surface SERINC5 int.HA expression by flow cytometry using an anti-HA
antibody conjugated to Alexa Fluor® 647 . FlowJo software was used to quantify
fold decrease in surface SERINC5 levels (purple) and Nef expression (green)
based on EGFP MFI from 3 independent experiments. (D) The correlation
between receptor downregulation and Nef expression for CD4 (green) and
SERINC5 (red) was determined using Prism software. (* refers to a slope
significantly not zero, * p<0.05). Note: isolate 2130 was removed from the
analysis for (D) due to the identification of mutations that disrupt its expression.

3.3.8

Functionally impaired Nef isolate 2130 was retrieved from a
slow-progressor.

As noted above, Nef isolate 2130 was unable to downregulate CD4 and
SERINC5 (Figure 3.7A, B). In addition, based on GFP MFI, Nef isolate 2130 was
very weakly expressed (Figure 3.7A, B). To explore possible mechanisms for
these abnormalities we analyzed the amino acid sequence of 2130. Interestingly,
we found that Nef isolate 2130 uses a non-canonical isoleucine as a start codon,
and contains two premature stop codons at NL4.3 position 113 and 141 (Figure
3.8A). Together, these mutations explain why Nef isolate 2130 was undetectable
by western blot (Figure 3.7C) and not functional (Figure 3.7A, B). After identifying
these mutations we next investigated their impact on the disease progression of
the patient this isolate was recovered from. To do so, we analyzed the CD4 cell
counts and viral load measurements from this patient as well as 44 other patients
from the cohort. Strikingly, the patient from which isolate 2130 was retrieved had
high CD4 cell counts and low viral loads that were sustained for close to 5 years
after sero-conversion (Figure 3.8B, C). These findings add to the documented
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phenomena of individuals infected with Nef-defective viruses experiencing
delayed disease progression.
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Figure 3.8 Non-functional Nef 2130 isolated from a patient with delayed HIV1 disease progression.
(A) Clustal Omega was used to compile an amino acid sequence alignment of
Nef 2130 and Nef NL4.3. Nucleotide polymorphisms of note are outlined in black
boxes. Red residues are uncharged non-polar, green are uncharged polar, pink
residues are basic, blue residues are acidic, • indicates stop codon; * below
residues indicates identical residues, : indicates conserved residues. Scatter plot
showing CD4 cell counts (B) or viral load (C) vs. days post-infection for 45
patients from which Nef sequences were retrieved.
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3.4 Discussion
Initial studies demonstrating the anti-infectivity role of SERINC5 and its
antagonism by HIV-1 Nef clearly showed the ability of Nef to limit the
incorporation of SERINC5 into budding virions (10, 11). However, these studies
focused primarily on the infectivity of the resulting viruses, rather than on the
mechanistic details of how Nef downregulates SERINC5. We used bimolecular
fluorescence complementation (BiFC) to demonstrate that HIV-1 Nef interacts
with SERINC5 in cells (Figure 3.1A). This is in agreement with a recent report
from Shi, J. et al (22), but in contrast to that study, we demonstrated that
mutation of the diacidic motif at Nef positions 174/175 (Nef DD/GA175)
significantly decreases the ability of Nef and SERINC5 to interact. This diacidic
motif has been shown to be required for the Nef-mediated antagonism of
SERINC5, as mutations of the two aspartic acid residues results in similar virion
infectivity as cells infected with Nef deleted viruses (16). Surprisingly, mutation of
the Nef dileucine motif, Nef LL165, which has also been shown to be required for
SERINC5 antagonism, did not conclusively decrease the Nef:SERINC5 BiFC
signal. There was a significant, but highly variable decrease when measured by
fluorescent microscopy, but no significant change when measured by flow
cytometry (Figure 3.1). Nef DD175 is a motif required for the interaction of Nef with
subunit H of the vacuolar ATPase, which acts as a connector protein between
Nef and AP-2 (45). Additionally, structural studies have demonstrated that Nef
DD175 stabilizes the central loop region of Nef (149-179), which interacts directly
with the α-σ2 ‘hemicomplex’ of AP-2 (46). The Nef dileucine motif is the primary
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motif responsible for the Nef:AP-2 interaction and binds directly to the α-σ2
‘hemicomplex’ (14, 47, 48). Our findings suggest that the interaction of Nef with
subunit H of the vacuolar ATPase is required for the initial interaction of Nef and
SERINC5, but that this interaction can occur in the absence of the Nef:AP-2
interaction.
We next explored what regions of SERINC5 may be involved in the
Nef:SERINC5 interaction (Figure 3.2). As there is limited knowledge on the
structure and function of SERINC5 we constructed a series of deletion mutants
that targeted different intracellular regions of SERINC5 (Figure 3.2A). Deletions
that targeted the N- or C-terminal tails of SERINC5 impaired the proper cell
surface expression of SERINC5 and not surprisingly also disrupted the
Nef:SERINC5 BiFC interaction. However, deletion of intracellular loop 4 of
SERINC5 did not affect the cell surface expression of SERINC5 or the strength
of the BiFC signal (Figure 3.2B, C, D). Western blotting showed that all deletion
mutants were expressed, but that the N- and C-terminal deletions decreased
expression more than deletion of intracellular loop 4 of SERINC5 (Figure 3.2E).
These findings are intriguing in light of a recent study that used domain swapping
experiments to show that intracellular loop 4 is responsible for the anti-infectivity
activity of SERINC5 (21). This suggests that the structural determinants for the
Nef:SERINC5 interaction may be distinct from those required for the anti-viral
affects of SERINC5. Further supporting this distinction was the fact that deletion
of intracellular loop 4 did not impair the trafficking of SERINC5 to the cell surface
or the ability of NefNL4.3 to downregulate SERINC5 from the cell surface. This
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raises the possibility that additional smaller intracellular loops in SERINC5
contribute to the interaction with Nef, akin to the distinct functional roles of
intracellular domains of G-coupled protein receptors (49). However, additional
studies will be required to determine if our intracellular loop deletion impacts the
anti-infectivity activity of SERINC5.
We also employed BiFC to elucidate the molecular pathway used by Nef to
remove SERINC5 from the cell surface (Figure 3.3). Our data suggests that the
Nef:SERINC5 complex is trafficked through early and late endosomes to a
lysosomal compartment, via MVBs (Figure 3.3D). This is in contrast to SERINC5
expressed in the absence of Nef, which is localized predominantly at the TGN.
The molecular pathway we demonstrated by BiFC is the same pathway used by
Nef to downregulate and degrade CD4 (23). Even prior to the discovery of
SERINC5, there have been a number of studies that suggest the pro-infectivity of
HIV-1 Nef is related to its ability to hijack the clathrin-dependent endocytic
machinery (45, 50, 51). This function has been well documented as the means
by which Nef downregulates CD4, suggesting SERINC5 antagonism is
mechanistically similar to CD4 downregulation.
The mechanistic similarities between CD4 and SERINC5 downregulation are
further supported by BiFC experiments that demonstrate the requirement of the
dileucine (Nef LL165) and diacidic (Nef DD175) motifs in Nef for transport of
SERINC5 to CD63 positive MVBs and LAMP-1 positive lysosomes (Figure 3.5).
The trafficking defect observed with the diacidic motif mutation is in agreement
with our earlier findings that this mutation disrupts the interaction of Nef and
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SERINC5. The disrupted trafficking of SERINC5 in the presence of Nef LL/AA165
supports the involvement of AP-2 in SERINC5 downregulation, even if this motif
is not essential for the interaction of Nef and SERINC5. AP-2 has been widely
implicated in SERINC5 downregulation by mutational and gene knock-out
experiments (10, 14, 16), but here we visually demonstrate the altered trafficking
of SERINC5 when the motifs involved in the Nef:AP-2 interaction are mutated.
The localization of the Nef:SERINC5 complex to a lysosomal compartment
suggests that Nef is mediating the degradation of SERINC5. We demonstrate
through western blot that SERINC5 levels are decreased upon expression of Nef
and that this decrease in SERINC5 expression is rescued by mutation of the
diacidic motif in Nef (Nef DD/GA175). This is in agreement with a recent report
showing that chemical blockade of lysosomal acidification increased the levels of
SERINC5 in cells (22), but in contrast with earlier reports that suggested Nef
does not affect steady state levels of SERINC5 (16). Given the similar endocytic
pathway used by Nef to downregulate CD4 and SERINC5 shown here, and
elsewhere, one would suspect a similar degradative fate of these two targets of
HIV-1 Nef. Further studies investigating the kinetics of SERINC5 protein turnover
in the presence or absence of Nef could provide more conclusive evidence of the
fate of SERINC5. Unfortunately, the multiple transmembrane domains within
SERINC5 increases the difficulty of many of the biochemical assays of protein
turnover.
We also demonstrated that the ability of patient-derived Nef proteins to
downregulate SERINC5 is highly variable (Figure 3.7). This is in contrast to Nef-
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mediated CD4 downregulation, which is conserved across various Nef proteins
(44). Interestingly, we show that there is a significant correlation between Nef
protein expression and SERINC5 downregulation, but not CD4 downregulation.
This suggests that SERINC5 downregulation is more sensitive to differences in
Nef protein expression, potentially due to differences in the affinity of Nef for CD4
versus SERINC5. Alternatively, there may be as of yet underdetermined motifs in
HIV-1 Nef that influence SERINC5, but not CD4 downregulation. One of the
characteristics of Nef-mediated SERINC5 downregulation that has recently
emerged is the variable nature of SERINC5 antagonism by Nef (10, 11, 14). The
first reports of SERINC5 antagonism by Nef demonstrated that the lab adapted
strain NefSF2 and the primary isolates Nef97ZA012 and Nef93BR020 potently inhibited
SERINC5 incorporation into HIV-1 virions, whereas the primary isolates
Nef94UG114 and Nef90CF056 either weakly inhibited or failed to inhibit SERINC5
incorporation (10). SERINC5 was initially discovered based on screening assays
that utilized the laboratory strain NefNL4.3, however this strain shows a relatively
mild inhibition of SERINC5 (10, 11). Indeed, in our study we observed that
NefNL4.3 resulted in anywhere from a 1.1 (Figure 3.7) to 1.5 (Figure 3.3) fold
decrease in cell surface levels of SERINC5. This mild inhibition is in contrast to
some of the patient-derived Nef proteins that we studied, such as the 7.9 fold
decrease in cell surface SERINC5 levels seen by Nef 2410 (Figure 3.7). Given
this variability, it raises the possibility that differences in SERINC5 antagonism
may influence HIV-1 spread and pathogenesis. This is supported by a study
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showing the prevalence of SIV in various primate species correlates with the
ability of their respective Nef proteins to antagonize SERINC5 (14).
Finally, while investigating SERINC5 downregulation from patient-derived Nef
proteins we identified a non-functional Nef protein that contained a non-canonical
start codon and 2 premature stop codons (Figure 3.8). When the patient data
from which this protein was isolated from was analyzed, we observed elevated
CD4 levels and sustained low viral loads for close to 5 years post-infection. This
finding adds to the large body of evidence demonstrating the role of Nef in
disease progression.
In this report we demonstrate that Nef and SERINC5 interact within cells and
begin to outline the amino acid motifs in each protein that are required for this
interaction. In addition, we have used BiFC to visualize the molecular pathway
used by Nef to downregulate SERINC5, supporting the prevailing hypothesis that
Nef uses a similar mechanism to downregulate both CD4 and SERINC5. Finally,
we provide further support for the highly variable nature of Nef-mediated
SERINC5 downregulation by investigating this function in patient-derived Nef
proteins.
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Chapter 4

4

Overview, discussion and future directions

4.1 Discussion
4.1.1

General Discussion

As HIV-1 Nef lacks enzymatic or structural activity, it must carry out its functions
by interacting with a large network of host proteins (1). Nef harbours a number of
protein-interacting motifs throughout its 206 amino acid sequence that it utilizes
to modify the intracellular architecture of HIV-1-infected cells to favour viral
replication (2). These modifications include, but are not limited to, the
downregulation of cell surface proteins that in one way or another interfere with
HIV-1 replication. Nef-mediated downregulation of the HIV-1 entry receptor CD4
(3) and the adaptive immune surveillance molecule MHC-1 (4) are well
established and extensively characterised in the current literature. However, the
recent discovery of the host restriction factor SERINC5 (5, 6) and its antagonism
by HIV-1 Nef highlights the fact that even after more than three decades of HIV-1
research, we still do not have a complete understanding of this devastating
pathogen. Indeed, one of the areas of HIV-1 research that still requires
elucidation is the impact of the genetic flexibility of HIV-1 on the molecular
mechanisms of the virus.

4.1.2

Summary of findings

In chapter 2 of this dissertation, HIV-1 group M subtypes were investigated for
how they differ in the key Nef functions of CD4 and MHC-I downregulation. This
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investigation led to the identification of three Nef proteins from subtype C, G and
H reference strains that displayed atypical function and expression (Figure 2.2
and 2.3). Furthermore, fluorescence imaging of Nef proteins from subtype G and
H demonstrated that these proteins were abnormally distributed (Figure 2.4),
potentially localizing to mitochondria (Figure 2.7). A more in-depth analysis of Nef
from the subtype C reference strain C.BR92025 led to the discovery of a key
alanine residue at amino acid position 84, that when mutated, accelerated the
rate of Nef protein turnover (Figure 2.15) (7).
In chapter 3, the molecular mechanisms of how Nef antagonizes SERINC5 were
investigated. HIV-1 Nef was shown to interact with SERINC5 as revealed by
BiFC (Figure 3.1). This powerful imaging technique was then used to map the
interaction motifs on Nef and SERINC5 and to elucidate how Nef removed
SERINC5 from the cell membrane. These studies identified Nef LL165 and Nef
DD175 as essential for the rerouting of SERINC5 to a lysosomal and/or
multivesicular body compartment (Figure 3.4 and 3.5), supporting the hypothesis
that Nef utilizes a similar mechanism to downregulate CD4 and SERINC5. Nef
DD175 was also shown to be required for the Nef:SERINC5 interaction (Figure
3.1) and the Nef-dependent decrease of cellular SERINC5 protein levels (Figure
3.6). Finally, analysis of SERINC5 downregulation by a number of patient-derived
Nef proteins demonstrated that this recently identified function of Nef is highly
variable, and more sensitive to changes in Nef expression than CD4
downregulation (Figure 3.7).
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4.1.3

Genetic diversity and Nef function

Our initial interest in investigating the impact of HIV-1 genetic diversity on Nef
function stems from the key role Nef plays in HIV-1 pathogenesis (8) and the
observed differences in disease progression between HIV-1 group M subtypes
(9-11). We hypothesized that if group M subtypes differed in Nef-mediated
receptor downregulation, that may explain some of the differences in disease
progression between subtypes. Indeed, transgenic mouse models that express
HIV-1 Nef in CD4+ cells and develop an AIDS-like phenotype (12), have been
used to demonstrate decreased pathogenicity of Nef proteins unable to
downregulate CD4 (13). The same animal model was used to show that the
Nef:SFK interaction, which is required for MHC-I downregulation, is also required
for Nef pathogenicity (14). In addition, analysis of Nef proteins from cohorts of
HIV-1 infected individuals has repeatedly shown a correlation between impaired
receptor downregulation and disease progression (15-18). However, these cohort
analyses predominantly focus on differences in Nef function within a specific
subtype, rather than between subtypes.
The largest and most conclusive study looking at Nef function between subtypes
only investigated HIV-1 group M subtypes A, B, C, and D (19), leaving the less
prevalent subtypes that are found almost exclusively in central and west Africa
understudied. Indeed, there exists very little literature characterizing the function
of HIV-1 proteins from subtypes F1, F2, G, H, J and K. This is not all that
surprising given that when the Los Alamos National Library HIV database is
queried, there are only 86 complete HIV-1 genome sequences available for
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subtype G, compared to 3104 for subtype B alone (20). That is a 36-fold
difference despite that fact that globally subtype B is only responsible for twice as
many infections as subtype G (21).
Admittedly, given current estimates, subtypes F, H, J and K are relatively rare,
but they still account for over a quarter of a million infections globally (21).
Regardless, their relatively low prevalence does not preclude the study of these
subtypes from revealing novel and potential useful information about the
molecular details of HIV-1 infection. Indeed, our analysis of Nef proteins from
subtype G and H reference strains suggests these proteins have impaired
function and expression (Figure 2.2 and 2.3) that may be related to their unique
subcellular distribution to mitochondria (Figure 2.7). Additional studies need to be
done to determine what is leading to this altered localization and if cells
expressing these Nef proteins undergo changes in oxidative phosphorylation.
Furthermore, a more extensive analysis of Nef function in low prevalence group
M subtypes is required to determine if the findings from the subtype G and H
reference strains used here occurs elsewhere.
Interestingly, when, as mentioned above, subtypes A, B, C and D were analyzed
for Nef-mediated receptor downregulation, the authors of that study also noted
variations in Nef expression between subtypes (19). On average, Nef proteins
from subtype C infected individuals displayed decreased expression relative to
subtypes A, B and D. Differences in Nef expression has also been noted in other
studies, and some have hypothesized that these differences arise due to immune
escape mutations that come at a fitness cost (17). Conventionally, it is assumed
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that there is rapid and abundant Nef production from the first mRNA transcripts
made during HIV-1 infection (2). Given the heterogeneous nature of HIV-1, it
would not be surprising if some proportion of viruses did not follow this
convention. Considering the key role Nef plays in HIV-1 pathogenesis (8) and the
influence early viremic control has on disease progression (22), these variations
in Nef expression may have profound effects on the clinical course of HIV-1.
Therefore, understanding the molecular determinants of variations in Nef
expression, and how they may be influenced, holds great value. Our identification
of an alanine residue at position 84 as critical for optimal Nef expression
highlights how susceptible Nef can be to amino acid variation, even with its
significant genetic flexibility (Figure 2.15). If regions such as this can be targeted,
either through induced immune responses, or through chemical interference, it
could add another therapeutic option to the arsenal against HIV-1.
We used mammalian expression plasmids (Figure 2.2A) or replicationincompetent viruses (Figure 2.3A) throughout our studies, and as such, there
was little to no opportunity for viruses encoding Nef with a mutation at position 84
to revert back to an alanine or for compensatory mutations to occur that could
restore expression of the protein. Longer term studies passaging live virus could
determine if Nef C.BR92025 is able to revert to a more functional form.
Furthermore, in our infection model we expressed Nef C.BR92025 in the context
of the a laboratory adapted subtype B virus, NL4.3. Thus, there is a possibility
that Nef C.BR92025 expressed from its parental viral genome may function
differently. However, the equal mRNA transcript levels (Figure 2.4A) and
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impairment in a transfection model (Figure 2.2 and 2.12) make that unlikely in our
opinion.

4.1.4

SERINC5 antagonism by HIV-1 Nef

The past two decades have seen the discovery of a number of host proteins that
act to restrict HIV-1 infection (23). In order to successfully infect and replicate
within cells, HIV-1 accessory proteins are able to antagonize these host
restriction factors. In addition to expanding our understanding of the intricacies of
HIV-1 infection, the discovery of these virus-host interactions present novel
therapeutic targets. If the accessory proteins that antagonize host restriction
factors can be inhibited, the immune system may be able to more effectively
control HIV-1. In addition, restriction factors have piqued interest as therapeutic
targets as they do not mutate as freely as viral proteins, one of the major barriers
of many current treatment strategies (24). Regardless of the approach taken, a
complete understanding of the mechanistic details of these virus-host
interactions is required if they are to be exploited for therapeutic use.
While much of the present research on Nef antagonism of SERINC5 has focused
on infectivity as a readout, we chose to measure SERINC5 downregulation
(Figure 3.3 and 3.7) and subcellular trafficking (Figure 3.4 and 3.5) to try and
elucidate mechanistically how Nef counteracts SERINC5. Our use of BiFC
allowed us to demonstrate that Nef and SERINC5 interact within cells (Figure
3.1), a finding that was only recently reported during the preparation of this work
(25). This finding is significant as it supports a directed targeting of SERINC5 by
Nef, rather than SERINC5 downregulation being a by-product of global
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alterations in endocytic trafficking in the presence of Nef. The Nef:SERINC5
interaction is just one of many that the viral accessory protein is able to mediate,
and demonstrates how targeting key cellular pathways is an efficient method of
viral adaptation (1). HIV-1 Nef hijacks the host adaptor protein 2 (AP-2) to insert
itself in the endocytic network, thereby dramatically altering the cellular
environment. The interaction with AP-2 is essential for Nef to mediate the
clathrin-dependent downregulation of CD4, allowing for its subsequent shuttling
through the endosomal network to a lysosomal compartment, where it is
degraded (26). Our mutational analysis and subcellular tracking of internalized
SERINC5 support the hypothesis that the Nef:AP-2 interaction is also key to Nef,
ultimately targeting SERINC5 for lysosomal degradation.
We also demonstrated that SERINC5 downregulation is variable among patientderived Nef proteins, in contrast to CD4 downregulation, which is highly
conserved (Figure 3.7). Interestingly, SERINC5 was more sensitive than CD4 to
differences in Nef protein expression. Given the mechanistic similarities between
SERINC5 and CD4 downregulation, these differences are intriguing and may
suggest that SERINC5 downregulation is distinct from that of CD4, in an as of yet
undetermined manner. Furthermore, whatever differences that exist between
Nef-mediated SERINC5 and CD4 downregulation may not face as strong of an
evolutionary selection pressure as there is growing evidence that HIV-1 Env also
plays a critical role in SERINC5 antagonism (27, 28). Virions containing
SERINC5-resistant Env proteins do not display impaired infectivity, even in the
absence of Nef. Therefore, there may be a functional interplay between HIV-1
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Nef and Env, where SERINC5-sensitive Env proteins require a more functional
Nef protein. This relationship still needs to be borne out in larger studies of Nef
and Env proteins.
In future studies we would like to investigate if the variability in SERINC5
antagonism by HIV-1 Nef plays a role in disease progression. With the cohort
available to use, we are in a good position to investigate this. Indeed, this had
been our original intention, however, inefficient retrieval of Nef isolates from
patient PBMCs limited the statistical power with which we could analyze the
effect of SERINC5 downregulation on disease progression. Interestingly, disease
progression within this cohort has been previously shown to differ between
infecting subtype (9). If enough Nef proteins can be retrieved, a thorough
investigation of CD4, MHC-I and SERINC5 downregulation could determine if
differences in Nef function between subtypes plays a role in disease progression.

4.1.5

Exploring Nef:host protein interactions

The study of viruses and how they interact with host cells has been a fruitful area
of research for those wishing to better understand basic cell biology. The minimal
coding capacity of most viral genomes necessitates they evolve highly
multifunctional proteins. These multifunctional proteins, of which HIV-1 Nef is an
example, can serve as tools for probing the inner workings of cells. Indeed, the
search for how Nef is able to increase HIV-1 infectivity instigated the study of the
novel host restriction factor SERINC5 (5, 6). The physiological role of SERINC5
is still to be fully determined, but its antagonism by HIV-1 Nef will surely expedite
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our understanding of this host protein, both in the context of HIV-1 infection and
in healthy cells.
In our future work we hope to use this approach to investigate other key host
proteins that Nef hijacks during HIV-1 infection. As a first step we have
performed a mass spectrometry analysis to characterize the interactome of the
cargo sorting proteins PACS-1 and -2 (Appendix 1). Nef interacts with these host
proteins to downregulate MHC-I (29, 30), and in the same vein as the similarities
in CD4 and SERINC5 downregulation, we hypothesize that this interaction may
result in other alterations in infected cells. Using the methods outlined in this
dissertation, we hope to elucidate and describe novel Nef:host interactions that
can illustrate more about the function of his key HIV-1 protein and the cells it
inhabits.

4.1.6

Concluding remarks

HIV-1 has long been at the forefront of biomedical research and we now know a
great deal about how and why this virus has reached pandemic proportions.
However, we have been continually humbled by our inability to prevent or cure
individuals of their infections. Perhaps there still remain key aspects of HIV-1 and
how it interacts with host cells that we do not fully understand. We have explored
the mechanistic details of HIV-1 Nef functions and how this pathogenic protein is
impacted by the genetic diversity that characterizes HIV-1. We hope that by
aiding in our basic understanding of this virus, we have strengthened the
knowledge base from which new and exciting discoveries can emerge.
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Appendix
Appendix 1 PACS-1 and PACS-2 interactome
Appendix 1.1
Proper cell homeostasis is dependent on the compartmentalization of molecules
to discrete subcellular locales. This spatial separation was paramount to the
emergence of multicellular organisms composed of genetically identical cells
serving distinct functions. To achieve this, eukaryotic cells have evolved a
network of trafficking proteins that function to target proteins to specific regions
within the cell (1). One such family of proteins is the Phosphofurin Acidic Cluster
Sorting or PACS proteins. As their name suggests, PACS proteins were
identified through the investigation of how the proprotein convertase furin was
trafficked throughout cells (2, 3). Also contained in their name is the mechanism
used by PACS proteins to sort their target proteins. Indeed, PACS proteins
primarily bind to cargo proteins that contain stretches of acidic amino acids and
connect these proteins with the endomembrane trafficking machinery (4). The
binding of PACS proteins to cargo proteins can be regulated by the
phophorylation status of serine residues located in proxmity to acidic clusters
which are often modulated by cellular kinases and phosphatases such as casein
kinase 2 (CK2) and protein phosphatase 2A (PP2A), respectively (reviewed in
(5)).
The human genome encodes two PACS proteins, PACS-1 and PACS-2, that
share 54% homology and both primarily function through binding of acidic
clusters on cargo proteins (6). However, whereas PACS-1 links cargo proteins to
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the endomembrane network by forming a ternary complex with adaptor proteins
1 and 3 (AP-1 and -3) (4), PACS-2 forms a ternary complex with the vesicle
coatmer COPI (6).
The essential role PACS proteins play in maintaining cellular homeostasis is
beginning to emerge and is highlighted by various siRNA knockdown
experiments (reviewed in (7)). Knockdown of PACS-1 demonstrates its
importance in cellular events such as the TGN localization of furin (2), while
knockdown of PACS-2 has revealed, amongst other functions, a role in TNF
(tumour necrosis factor)-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis (8). Moreover, recent studies have implicated point mutations in both
PACS-1 (9) and PACS-2 (10) in neurodevelopmental diseases. Interestingly,
these mutations lie within the Furin Binding Region (FBR) of PACS-1 or PACS-2.
The FBR is specifically implicated in PACS interactions with cargo proteins (2).
Given the important and multifunctional role PACS proteins play in organizing
cellular architecture, it is not surprising that a number of viruses have evolved
mechanisms to hijack these sorting proteins to assist in their replication
(reviewed in (11)). For example, as described elsewhere in this thesis, the HIV-1
accessory protein Nef contains an acidic cluster that allows it to interact with
PACS-1 and -2 and usurp their roles in membrane trafficking to downregulate
MHC-I (12, 13).
The relationship between HIV-1 Nef and the PACS proteins led us to investigate
other potential virus:host interactions that Nef may be able to establish through
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its hijacking of the PACS proteins. To do so, we aimed to study the interactome
of PACS-1 and PACS-2 upon their overexpression. Accordingly, CD4+ HeLa cells
were transfected with pN1 PACS-1-FLAG and pN1 PACS-2-FLAG plasmids and
immunoprecipitated with an anti-DYKDDDDK antibody, which recognizes FLAG,
after lysis at 24 hours post-transfection. Proteins were separated on a 12% gel
by SDS-PAGE and silver stained using the Pierce® Silver Stain for Mass
Spectrometry kit (Appendix 1.1.1A and 1.1.2A). The gel was subsequently
analyzed by liquid chromatography mass spectrometry at the Southern Alberta
Mass Spectrometry Centre at the University of Calgary. Peptide hits from the
liquid chromatography mass spectrometry analysis were compiled by the
Southern Alberta Mass Spectrometry Centre and investigated for enriched
biological processes using highest confidence interaction scores on STRING
v10.5 (14).
Numerous interaction networks were overrepresented in the mass spectrometry
results compared to what would be expected from a random collection of proteins
(Appendix 1.1.1B and 1.1.2B). Of note, proteins involved in establishing protein
localization and response to viruses were enriched in the mass spectrometry
results. Proteins involved in establishing protein localization include the nuclear
transport proteins importin 5, 7, 8 and 9, (IPO5, 7, 8 and 9), which were
immunoprecipitated with PACS-1 and -2 (Appendix 1.1.1D and 1.1.2C) or
numerous members of adaptor protein family 14-3-3 (YWHAB, YWHAE,
YWHAH, YWHAG and YWHAZ), which were immunoprecipitated exclusively by
PACS-2

(Appendix

1.1.2C).

Encouragingly,

more

specific

biochemical
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experiments have previously shown that PACS-2, but not PACS-1 interacts with
members of the 14-3-3 family (8), supporting the findings from the mass
spectrometry analysis. The proteins involved in responding to viruses included
interferon induced proteins (HERC5, IFIT1, 2, and 3) or innate immune
molecules that sense viral nucleic acids (DDX58 and OASL) (Appendix 1.1.1E
and Appendix 1.1.2D).
Our preliminary analysis provides a framework for future investigations of PACS1 and -2 interactions that may be co-opted by HIV-1 Nef to aid in viral replication.
Indeed, we are in the process of validating a number of these hits and
determining if these interactions are altered in the presence of Nef. These
studies will hopefully increase our understanding of the multifunctional nature of
HIV-1 Nef and how it exerts its pathogenic effects.
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Appendix 1.1. 1 Mass spectrometry analysis of the PACS-1 interactome.
(A) CD4+ HeLa cells were left untransfected (NT) or transfected with pN1-PACS1-FLAG or pN1-PACS-2-FLAG. Cell lysates were immunoprecipitated with antiDYKDDDDK agarose beads and washed 5 times in PBS. Immunoprecipitated
proteins were separated by SDS-PAGE using a 12% gel. The gel was
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subsequently silver stained using the Pierce® Silver Stain for Mass Spectrometry
kit (product number 24600; Pierce Biotechnology, Rockford IL) and imaged as
shown in (A). The lane corresponding to cells transfected with pN1-PACS-1-Flag
was excised and sent for liquid chromatography mass spectrometry analysis at
the Southern Alberta Mass Spectrometry Centre at the University of Calgary.
STRING v10.5 was used generate a protein interaction map (B) and to analyze
mass spectrometry hits for enriched biological functional groups. Proteins
involved in establishing protein localization are highlighted in red and a subset of
these proteins are shown in (C) and (D). Proteins involved in response to viruses
are highlighted in green and these proteins are shown in (E).
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Appendix 1.1. 2 Mass spectrometry analysis of the PACS-2 interactome.
(A) CD4+ HeLa cells were left untransfected (NT) or transfected with pN1-PACS1-FLAG or pN1-PACS-2-FLAG. Cell lysates were immunoprecipitated with antiDYKDDDDK agarose beads and washed 5 times in PBS. Immunoprecipitated
proteins were separated by SDS-PAGE using a 12% gel. The gel was
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subsequently silver stained using the Pierce® Silver Stain for Mass Spectrometry
kit (product number 24600; Pierce Biotechnology, Rockford IL) and imaged as
shown in (A). The lane corresponding to cells transfected with pN1-PACS-2-Flag
was excised and sent for liquid chromatography mass spectrometry analysis at
the Southern Alberta Mass Spectrometry Centre at the University of Calgary.
Results of the liquid chromatography mass spectrometry analysis were compiled
by the Southern Alberta Mass Spectrometry Centre. STRING v10.5 was used
generate a protein interaction map (B) and to analyze mass spectrometry hits for
enriched biological functional groups. Proteins involved in establishing protein
localization are highlighted in red and a subset of these proteins are shown in
(C). Proteins involved in response to viruses are highlighted in green and these
proteins are shown in (D).
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